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Abstract 
Hand Foot and Mouth Disease (HFMD) is a contagious viral disease that 
commonly affects infants and children. HFMD, caused by a group of enteroviruses, 
is characterised by various symptoms such as fever, rashes, poor appetite and 
multiple ulcers in mouth. The two major etiological agents of this disease are the 
coxsackievirus A16 (CA16) and enterovirus 71 (EV71). However, unlike other 
HFMD causing enteroviruses, EV71 has been commonly associated with severe 
clinical manifestation leading to cardiopulmonary failure and death. Such clinical 
presentation is in contrast to other HFMD causing enteroviruses which are often mild 
and self-limiting. However due to a lack of understanding on EV71 pathogenesis 
there are currently no effective antiviral therapies or vaccines approved by the United 
States of America Food and Drug Administration (FDA)  to prevent HFMD.  
 
To address this gap in the literature, this study aimed to 1) establish an in vitro model 
of viral infection of human cells by using rhabdomyosarcoma (RD) cells and human 
epithelial colorectal cell line (HT29), which mimic in vivo host-pathogen interactions 
of EV71 virus infection of human cells and 2) integrate the results from investigating 
host-pathogen interaction between human colorectal cells and invading EV71 
(including miRNA and mRNA) and 3) through the examination of the effect of EV71 
replication in miRNA depleted cells.  
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Chapter One of this thesis provides a detailed literature review of the general 
background of work, explored the scientific problem being investigated and the 
overall aims of the study. Chapter Two is the first of the five result chapters where 
we established the human colorectal cells (HT29) as a viable and a more relevant in 
vitro model to study EV71 pathogenesis. Chapter Three provides an in depth 
transcriptomic analysis to elucidate the host-pathogen interaction between the 
established human colorectal cells and invading enterovirus 71. Our results suggested 
that types I, II and III interferon signalling pathways may be the key defence 
mechanism against EV71 in intestinal epithelial cells. In Chapter Four, we evaluated 
the importance of miRNAs during EV71 infection by performing a global 
knockdown of miRNAs in human epithelial colorectal cells. We have demonstrated 
that the global knockdown of miRNAs resulted in severe deficiency in EV71 
replication which suggests that EV71 utilised miRNAs during infection and in the 
absence of miRNAs, EV71 was unable to successfully mount an infection. To further 
explore the involvement of miRNA during EV71 infection, we examined the changes 
in miRNA profile during EV71 infection. We demonstrated that there are miRNAs 
changes during EV71 pathogenesis and alteration to the host antiviral pathways 
during infection.  
 
Chapter Five, reports the comparative proteomic analyses on EV71-susceptible 
and EV71-resistant cells. We demonstrated that EV71 infection may be actin 
dependent. This was consistent with existing literatures that the knockdown of genes 
that were important in actin polymerisation or the use of actin disrupting drug would 
result in decrease of EV71 replication kinetics. In Chapter Six, we evaluated if the 
droplet digital PCR was a useful tool for the detection and the absolute quantitation 
IX 
 
of EV71 viral copy number. We demonstrated that the ddPCR platform to be 
generally comparable if not better to real-time PCR platform which could be used for 
monitoring antiviral therapeutics in EV71 infected patients. 
 
Finally, Chapter Seven provides an overall discussion of the key findings of 
this project. Taken together, this thesis has provided further understanding of the 
pathogenesis of EV71. Elucidating the host-pathogen interaction and the mechanism 
that the virus uses to bypass host defence systems to establish infection will aid in the 
development of potential antiviral therapeutics for HFMD patients. 
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Chapter 1: Literature Review 
1.1 INFECTIONS OF HUMANS WITH HFMD VIRUSES 
 
Hand Foot and Mouth Disease (HFMD) is a contagious paediatric disease 
caused by a group of enteroviruses (Lui et al., 2013b, McMinn, 2002, McMinn, 
2012, Ooi et al., 2010, Patel & Bergelson, 2009, Solomon et al., 2010). HFMD was 
first reported in New Zealand in 1957 where approximately 60 individuals were 
affected (Robinson et al., 1958). This self-limiting disease is characterised by a 
variety of symptoms such as fever, rashes, poor appetite and in particular, multiple 
ulceration in the mouth of the infected individual (Huang et al., 2012, Khong et al., 
2012, Lee et al., 2009, Lin et al., 2002, McMinn et al., 2001, McMinn, 2002, Ooi et 
al., 2009). Other frequently encountered symptoms include poor appetite, vomiting 
and lethargy (Chong et al., 2003).  
  
The coxsackievirus A16 (CA16) and enterovirus 71 (EV71) are the two major 
etiological agents of this disease with the latter being associated with significant 
mortality (Wong et al., 2010, Ho et al., 2011, Huang et al., 2012). Unlike other 
enteroviruses causing HFMD, EV71 has been strongly associated with severe clinical 
manifestations leading to encephalitis, cardiopulmonary failure and death (Chu et al., 
2001, Lee et al., 2011, Lee & Chang, 2010, Lee et al., 2012, McMinn, 2012). Such 
clinical presentation is in contrast to other HFMD causing enteroviruses which are 
often mild and self-limiting (Lee et al., 2011, Lee & Chang, 2010, Lee et al., 2012, 
Lee et al., 2009, McMinn et al., 2001, Muir & van Loon, 1997, Solomon et al., 
2010).  
3 
 
1.2 CLINICAL MANIFESTATION OF EV71 INFECTIONS 
 
Clinically, EV71 pathogenesis can be distinguished into four different stages of 
symptomatic progression, including: Stage 1 (herpangina- also known as mouth 
blister), Stage 2 (central nervous system complications), Stage 3 (cardiopulmonary 
failure) and Stage 4 (convalescence) (Lee & Chang, 2010, Lee et al., 2012). In a 
large prospective study of several HFMD epidemics in Sarawak Malaysia, over a 
span of seven years, approximately 10-30% of EV71 infected patients developed 
neurological complications which were not observed in CA16  infected patients (Ooi 
et al., 2007). Key neurological complications of the EV71 infected patients includes: 
1) brainstem and/or cerebellar encephalitis (58%), 2) aseptic meningitis (36%), and 
3) brainstem encephalitis (4%) (Ooi et al., 2007).  
 
EV71-related neurological complications have been associated with clinical 
manifestations including myoclonic jerks and limb weakness, which can progress to 
seizures, altered consciousness, neurogenic pulmonary oedema and acute respiratory 
distress syndrome (ARDS) often leading to deaths (Chen et al., 2004, Huang et al., 
1999, Khong et al., 2012, McMinn et al., 2001, Ooi et al., 2009, Prager et al., 2003, 
Lu et al., 2004a). Results of studies utilising animal models to investigate this virus 
are consistent with epidemiological data where approximately 10-30% of patients 
presented with central nervous system complications (Chang et al., 2004, Khong et 
al., 2012, Ooi et al., 2010, Ooi et al., 2009, Ooi et al., 2007).  
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1.3 EPIDEMIOLOGY OF EV71 
 
EV71 was first identified in 1974 in California (USA) after it was isolated from 
the stool of a patient with central nervous system disease in 1969 (Schmidt et al., 
1974). Recent advances on molecular evolution techniques have predicted that EV71 
could have emerged in the human population as early as 1941 (Lee et al., 2012, Tee 
et al., 2010, van der Sanden et al., 2009). Large fatal outbreaks first appeared in 
Bulgaria in 1975 where there were 44 deaths and 451 patients reported to be 
presented with neurological complications (Chumakov et al., 1979). The second 
major outbreak was reported in Hungary in 1978 where there were 47 deaths and 
1550 cases of patients with neurological complications (826 aseptic meningitis, 724 
encephalitis) (Nagy et al., 1982).  
 
Two decade later, EV71 re-emerged in Malaysia (1997) and Taiwan (1998) 
with ensuing outbreaks, epidemics and pandemics occurring every two to three years 
in the Asia Pacific countries such as Australia, China, Taiwan, Japan, Korea, 
Malaysia, Vietnam, Thailand and Singapore (Schmidt et al., 1974, Chumakov et al., 
1979, McMinn et al., 2001, Huang et al., 2012). Recurrent outbreaks of HFMD 
supports the urgent need to develop a vaccine or antiviral therapies against 
enteroviruses for the treatment of HFMD patients. However due to the limited 
understanding of EV71 pathogenesis there are currently no effective antiviral 
therapies or vaccines approved by the United States of America FDA to prevent 
HFMD. 
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1.4 PICORNAVIRDAE 
 
EV71 is a positive strand RNA virus belonging to the Enterovirus genus in the 
Picornaviridae family (Lui et al., 2013b, McMinn, 2002, McMinn, 2012, Ooi et al., 
2010).  Picornaviruses are amongst the world’s oldest known viruses and are 
classified under the family Picornaviridae. As implied by the name, Picornaviruses 
are a group of very small “pico” (a unit of measurement), RNA viruses. This family 
of viruses consist of five main genera – Rhinoviruses, Enteroviruses, Aphthoviruses, 
Cardioviruses and Heptoviruses (REACH) (Lin et al., 2009a, Lin et al., 2009b). The 
most notable member of the Picornaviridae family is the poliovirus (Lee et al., 2012, 
McMinn, 2002, McMinn, 2012, Solomon et al., 2010, Wong et al., 2010, Wu et al., 
2010). With the near eradication of poliovirus (with the exception of Afghanistan, 
India, Nigeria and Russia), EV71 has emerged to be the most important neurotropic 
enterovirus (Huang et al., 2012, Lee et al., 2012, Wu et al., 2010). The human 
enteroviruses of the Enterovirus genus are among the most common human 
pathogens, infecting millions of people worldwide (Li et al., 2007, Oberste et al., 
1999a, Oberste et al., 1999b). Based on new molecular typing method based on 
homology within the RNA coding region for the capsid protein VP1, the human 
enteroviruses have been classified into 4 species: human enteroviruses A through to 
D, with more than 100 subtypes identified to date (Table 1.1) (Lee & Chang, 2010, 
Yi et al., 2011). Being a non-enveloped virus, they are stable over a wide range of 
pH from 3 to 10 and are resistant to alcohol, organic solvent and freezing procedures 
(Huang et al., 2012, Solomon et al., 2010). However, they can be readily inactivated 
by harsh methods such as chlorination, formaldehyde treatment and ultraviolet 
radiation (UV) (Huang et al., 2012, Solomon et al., 2010, Chan & Abu Bakar, 2005).  
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Table 1.1 Classification of Human Enterovirus species 
 
Human enterovirus species Serotype 
Human enterovirus A  
(HEV-A) 
Coxsackie A viruses (CAV) 2–8,10,12,14,16 
Enteroviruses (EV) 71,76,89–91 
Human enterovirus B  
(HEV-B) 
Coxsackie A viruses (CAV) 9, Coxsackie B viruses (CBV) 1–6 
Echoviruses (E) 1–7,9,11–21,24–27,29–33 
Enteroviruses (EV) 69,73–75,77–88,93,97,98,100,101,106,107 
Human enterovirus C  
(HEV-C) 
Coxsackie A viruses (CAV) 1,11,13,17,19–22,24 
Enteroviruses (EV) 95,96,99,102,104,105,109 
Polioviruses (PV) 1–3 
Human enterovirus D  
(HEV-D) 
Enteroviruses (EV) 68,70,94 
 
 
HEV, human enterovirus, EV, enterovirus, CAV, coxsackie A viruses, E, 
echoviruses 
Adopted from Solomon et al., 2010 
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1.5 GENOGROUPS OF EV71 
 
EV71 could be further classified into four distinct genogroups; A, B, C and D 
(McMinn, 2012, Ooi et al., 2010, van der Sanden et al., 2009, van der Sanden et al., 
2010, Yi et al., 2011). Viruses from the same genogroup have approximately 92% 
nucleotide sequence identity, while EV71 from different genogroups account shared 
78-83% identity (McMinn, 2012, Ooi et al., 2010). The prototype BrCr first 
described in 1974 is the only strain found in genotype A, while most other EV71 
isolates were classified under genotypes B (B1-5) or C (C1-5). Genogroup B has five 
lineages; B1 and B2 (circulating between 1970 and 1990) and B3-B5 (circulating in 
Southeast Asia since 1997) (Huang et al., 2012, McMinn, 2012). B0, a progenitor 
lineage has recently been proposed to have circulated between 1963 and 1967 (van 
der Sanden et al., 2009, van der Sanden et al., 2010) Genogroup C also has five 
lineages; C1 (dominant genogroup in Europe and America), C2 (emerged in 1995), 
C3-C5 (circulating in Southeast Asia since 1997) (Figure 1.1) (Huang et al., 2012, 
McMinn, 2012).  Finally, genogroup D is represented by a single virus strain isolated 
in India (Deshpande et al., 2003). The association between the circulating strains 
during specific endemics and their role in pathogenesis of severe clinical 
manifestation remain to be elucidated. 
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Figure 1.1 Geographic distributions of EV71 genogroups from 1960 to 2011. 
Geographic distribution of HEV71 genogroups and subgenogroups between 1960 
and 2011 From (McMinn, 2012).  
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1.6 GENOMIC AND STRUCTURAL CHARACTERISTICS OF 
ENTEROVIRUSES 
 
Enteroviruses are non-enveloped viruses approximately 30nm in diameter each 
with a capsid made up of 60 protomers consisting of four structural proteins: VP1, 
VP2, VP3 and VP4 (Lee & Chang, 2010, McMinn, 2002, McMinn, 2012, Solomon 
et al., 2010). The viral genome is composed of a single stranded, positive-polarity 
RNA molecule of around 7500 nucleotides in length (Lee et al., 2009, Lin et al., 
2009a, Singh et al., 2002, Solomon et al., 2010). It comprises a 5’ untranslated 
region (UTR), an open reading frame (ORF) encoding for around 2100 to 2200 
amino acids residues, a 3’ UTR and it terminates with a 3’ poly (A) tail of a variable 
length of 60-100 nucleotides (Bedard & Semler, 2004, Lin et al., 2009a, Lin et al., 
2009b, Ooi et al., 2010).  
 
The 5’ UTR possesses the internal ribosome entry site (IRES) which is 
important for viral RNA amplification (Bedard & Semler, 2004, McMinn, 2002, 
McMinn, 2012). The ORF polyprotein can be classified into three regions; P1, P2 
and P3, where P1 encodes for the four structural proteins; VP1, VP2, VP3 and VP4, 
while P2 and P3 encodes for seven non-structural proteins; 2A, 2B, 2C, 3A, 3B, 3C 
and 3D, that are responsible for the various stages of infection and replication in the 
host (Figure 1.2) (Brown et al., 1999, Lin et al., 2009a, Yi et al., 2011). The first 
three viral structural proteins (VP1-3) form the outside of the virus capsid, whilst 
VP4 is located exclusively on the inner surface of the capsid. The capsid protein is 
responsible for the initiation of the infection by binding to a receptor in the host 
membrane (Caggana et al., 1993, Li et al., 2011, Lin et al., 2009a, Singh et al., 2002, 
Solomon et al., 2010). Due to the capsid potentially being the virulent determinant 
10 
 
for enteroviruses, much research have been focused on the role of VP1 in viral 
pathogenesis (Caggana et al., 1993, Li et al., 2011, Lin et al., 2009a, Singh et al., 
2002, Solomon et al., 2010). 
 
 
 
 
 
 
Figure 1.2 Schematic diagram of enterovirus genome and their respective 
functions. Diagrammatic representation of the enterovirus genome is shown. The 11 
mature polypeptides are shown, together with the three main cleavage intermediates. 
The main biological functions are included for each polypeptide. UTR, untranslated 
region; IRES, internal ribosome entry site; VPg, viral protein genome-linked. 
From (Lin et al., 2009a).  
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1.7 INTRAVENOUS IMMUNOGLOBULIN TREATMENT 
 
Despite the prevalence and severity of disease in EV71 infected patients, there 
are no effective antiviral therapies or vaccines approved by the United States of 
America FDA to prevent HFMD. Treatment of HFMD infection in the hospital 
focuses on alleviating symptom such as treatment for fever, sore throat, vomiting 
and/or diarrhoea. Intravenous immunoglobulin (IVIG) is a blood product containing 
pooled immunoglobulins extracted from blood donors, which can be administrated 
intravenously to severe HFMD patients (Chang et al., 2004, Lin et al., 2002, Ooi et 
al., 2007). This is the only approved treatment for viral encephalitis routinely used 
for severe EV71 infected in patients (Chang et al., 2004, Lin et al., 2002, Ooi et al., 
2007, Wang et al., 2000, Wang et al., 2005, Wang et al., 2006).  
 
IVIG contains cytokines such as IL-1, IL-6 and interferon which play a role in 
modulating the cytokines cascade, and thus they might play a role in the therapeutic 
effect of IVIG (Wang et al., 2006). However, randomised placebo controlled clinical 
trials have yet to be performed to address the actual therapeutic effect of this 
treatment. Although retrospective analysis of several EV71 outbreaks have shown 
the benefits of  IVIG treatment, including one study in Malaysia where 95% of the 
severe EV71 infected patients survived after administration of IVIG treatment, the 
actual therapeutic mechanism of IVIG remains highly debatable and unclear (Chang 
et al., 2004, Lin et al., 2002, Ooi et al., 2007, Wang et al., 2000, Wang et al., 2005, 
Wang et al., 2006).  
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1.8 DEVELOPMENT OF VACCINE AGAINST EV71 
 
To date, a number of potential EV71 vaccine candidates, including inactivated 
whole virus, live-attenuated virus,  recombinant viral protein, virus-like particle and 
DNA vaccines, developed by different organisation are currently in animal 
preclinical trials and/or human clinical trials (Lee & Chang, 2010). The most 
straightforward strategy utilises inactivated whole virus vaccines, which have been 
found to confer good protection in animal models (Lee et al., 2012, Wu et al., 2010). 
The first described inactivated whole virus vaccine that effectively prevents 
enterovirus infection is the formaldehyde-inactivated polio vaccine developed by 
Jonas Salk in 1952 for the prevention of poliovirus infection (Aylward & Heymann, 
2005, Grassly, 2013, Hampton, 2009, Nossal, 2011, Sabin, 1981). The use of this 
vaccine since 1955 led to a drastic decrease in paralytic poliomyelitis, however, 
multiple injections are required to achieve this effect (Bek et al., 2011, Ehrenfeld et 
al., 2009).  
 
The trivalent oral poliovirus vaccine was then introduced in 1962 to replace the 
formaldehyde-inactivated polio vaccine for routine use globally (Bek et al., 2011, 
Ehrenfeld et al., 2009).  The advantage that led to this change includes the relative 
ease of oral administration, as well as the superior immunogenicity provided by 
mucosal immunisation as compared to intramuscular injection (Bek et al., 2011, 
Ehrenfeld et al., 2009). The trivalent oral poliovirus vaccine was a live-attenuated 
vaccine made from live micro-organism with their virulent properties disabled 
(Aylward & Heymann, 2005, Bek et al., 2011, Ehrenfeld et al., 2009, Halstead, 
2012, Lee & Chang, 2010, Lee et al., 2012, Nossal, 2011, Wu et al., 2001). 
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However, live vaccines are genetically unstable and in rare circumstances may revert 
to neurovirulence, resulting in vaccine associated paralytic poliomyelitis (Bek et al., 
2011, Ehrenfeld et al., 2009). Despite the shortcomings, these vaccines have aided in 
the near eradication of polioviruses from the world (Bek et al., 2011, Ehrenfeld et al., 
2009).  
 
Due to its tremendous impact on the public health and healthcare system, the 
development of a viable vaccine or antiviral treatment against EV71 has been a 
national priority in Asian countries (Lee et al., 2012). Wu and colleagues (2001) 
demonstrated that formalin-inactivated and heat inactivated strains of EV71 
demonstrated a protective efficacy of 80% against EV71 infection in mice (Wu et al., 
2001). Maternal immunisation with inactivated EV71 vaccine was also shown to 
increase the survival of suckling mice after EV71 infection (Wu et al., 2001).  In 
addition, the active immunisation of 1 day old mice with avirulent EV71 strain or 
CA16 via the oral route has prolonged survival rate of mice infected with EV71 
infections (Wu et al., 2007). Use of live attenuated strain of EV71, developed using 
genetic manipulation, has led to the limited spread of the virus (Arita et al., 2008a, 
Arita et al., 2007, Arita et al., 2008b). However, these vaccines cause certain 
neurological complications indicating the need for further work (Arita et al., 2008a, 
Arita et al., 2007, Arita et al., 2008b, Ooi et al., 2009, Ooi et al., 2007). Furthermore, 
reversion of attenuated viruses to its pathogenic form as well as the potential 
mutations that could occur are considerations before the clinical use of the vaccine 
for the treatment of EV71 infected patients can be approved. Owing to these 
technical and safety limitations, the development of live attenuated EV71 vaccine 
has not progressed significantly (McMinn, 2012). There are currently many different 
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EV71 vaccine candidates undergoing testing in various countries and using different 
formulation in these clinical trials in human (Table 1.2). 
 
 
 
 
Table 1.2 EV71 vaccine candidates in clinical trials. Adapted from (Lee et 
al., 2012). 
 
Organization Country Cell line Formulation 
Bejing Vigoo; China 
National Biotech Group 
China Vero Cell line Inactivated virus (C4) 
Sinovac China Vero Cell line Inactivated virus (C4) 
Peking Union Medical 
College 
China KMB 17 Cell line Inactivated virus (C4) 
National Health Research 
Institutes 
Taiwan Vero Cell line Inactivated virus (B4) 
Inviragen Singapore Vero Cell line Inactivated virus (B) 
 
 
 
 
 
 
15 
 
1.9 CURRENT ANTIVIRAL THERAPEUTICS AGAINST EV71 
 
In addition to the development of vaccines against HFMD, research toward 
antiviral therapies at different stages of the enterovirus replication process including 
virus attachment, uncoating, and synthesis of viral genome are currently underway 
(Li et al., 2007, Lee & Chang, 2010). The design of antiviral compounds or the 
modification of existing non-specific antiviral therapeutics inhibiting the key steps in 
viral replication may be used alone or combination for the potential treatment of 
HFMD. 
 
One example of this would be the administration of milrinone, a cyclic 
nucleotide phosphodiesterase inhibitor for the prevention of cardiopulmonary failure 
which is routinely used for the treatment of severe HFMD patients despite the mixed 
reviews on the efficacy of the treatment (Wang et al., 2005). Ribavarin, a broad 
spectrum antiviral drugs has also been used as it has been demonstrated to have a 
dose dependent inhibition against EV71 replication (Li et al., 2008). Ribavirin-
treated 12 to 15 days old mice have a greater survivability and exhibit a later onset 
and less severe paralysis compared to control (untreated) mice (Li et al., 2008).  
However, ribavirin treatment was recently shown to be ineffective in 1 day old mice 
against EV71 (Zhang et al., 2012). 
 
Another potential therapeutic approach against EV71 is the use of RNA 
interference (RNAi). Small interfering RNA (siRNA) artificially synthesised against 
the 5’ and the 3’ untranslated region were demonstrated to inhibit EV71 in a dose 
dependent manner in vitro (Deng et al., 2012, Sim et al., 2005, Tan et al., 2007a, Tan 
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et al., 2007b). Targeting conserved regions of the virus prevents the selection of 
mutants strains resulted from the sequence-specific nature of siRNA (Lu et al., 
2004b). Although the use of siRNA seems promising, the protective effect of siRNA 
treatment could only be observed in mice administrated 1 day post infection (Tan et 
al., 2007b). Delaying siRNA treatment resulted in significantly lower protective 
effect against EV71 which may not be clinically relevant in the treatment of HFMD 
patients where the incubation time is between three to seven days (Tan et al., 2007b). 
 
Despite many molecules being designed and reported to inhibit EV71 
replication in the preceding decade with the aim of eventual treatment for EV71 
infected patients, none of these gained the final approval by United States of 
America FDA for the prevention of HFMD. In most cases, the lack of compelling 
results in addition to the toxicity issues poses great limitation for their use. In 
addition, clinical application for such treatment requires little or no adverse effect as 
most HFMD patients are children requiring an extremely safe drug or therapeutic. In 
view of the increasing clinical relevance of EV71, there is an urgent need to develop 
a specific therapeutic for EV71 infected patients. Despite extensive studies on 
enterovirus infection, the exact mechanism of non-polio enterovirus (EV71) 
pathogenesis remains unclear (Lee et al., 2011). Elucidating the mechanism (s) of 
enterovirus pathogenesis may provide clues for the development of antiviral 
therapeutics against EV71.  
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1.10 EV71 PATHOGENESIS 
 
Human beings are the only known natural hosts of the human enteroviruses. 
Similar to other enteroviruses, the EV71 replication cycle is similar to a notable 
member of the family namely poliovirus (De Jesus, 2007). The virus is transmitted 
from person-to-person by direct contact of vesicular fluid or droplets from the 
infected individual or via the faeco-oral route (Nasri et al., 2007a, Nasri et al., 
2007b). Source of transmission may be direct contact with nose and throat 
discharges, saliva, fluid from blisters and stools of infected patients (Lin et al., 
2002). The digestive and respiratory tracts of humans are the common route of 
infection for enteroviruses (Wong et al., 2010, Lee et al., 2009, Liu et al., 2000, 
Brown et al., 1999). 
 
During infection, the viruses first enter the host, infect the cells in the 
gastrointestinal tract, replicate, then bypass the gut barrier and pass into the skeletal 
muscle cell before entering the bloodstream and the central nervous system via 
retrograde axonal transport (Chen et al., 2007). Muscle cells may be responsible for 
persistent infection supporting efficient virus replication (Chen et al., 2004, Chen et 
al., 2007). There are numerous factors  that may affect the severity of the disease and 
these may be both virus specific and/or host specific (Muir & van Loon, 1997). 
Secondary to the central nervous system, EV71 also affects susceptible cells in the 
reticuloendothelial system such as the liver, and spleen as well as heart, lungs, 
pancreas as well as the skin. Despite much speculation, the exact dissemination route 
of the virus from the initial site of infection to other tissues and the central nervous 
system remain elusive.  
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It was postulated that EV71 entry into susceptible cells is via specific receptors 
of which several have already been identified. The identified receptors of EV71 
include a ubiquitously expressed cellular receptor, scavenger receptor B2 (SCARB2), 
a functional receptor, human P-selectin glycoproteinligand-1, sialic-acid-linked 
glycan, dendritic cell specific intercellular adhesion molecular 3 grabbing non 
integrin (CD209) and heparin sulphate glycosaminoglycan (Gerke & Moss, 2002, 
Patel & Bergelson, 2009, Tan et al., 2013, Wong et al., 2010, Wu et al., 2010, 
Yamayoshi et al., 2012, Yamayoshi et al., 2009). Once EV71 binds to the receptors, 
it gains entry into the host cells via clathrin-mediated endocytosis which then 
releases the viral RNA into host cell cytoplasm (Buss et al., 2001, Durrbach et al., 
1996, Flanagan & Lin, 1980, Hussain et al., 2011). (Ooi et al., 2010, Ooi et al., 2009, 
Ooi et al., 2007). It was proposed that cytoskeletal system comprising of both actin 
and microtubules may be involved during clathrin-mediated endocytosis (Buss et al., 
2001, Durrbach et al., 1996, Flanagan & Lin, 1980, Gerke & Moss, 2002, Hayes et 
al., 2006, Hussain et al., 2011, Ploubidou & Way, 2001, Soldati & Schliwa, 2006, 
Yang et al., 2011). Knockdown of genes that are important in actin polymerisation 
(ARPC5, ARRB1, and WASF1) and the use of actin disrupting drug (cytochalasin B) 
have resulted in the decrease in EV71 replication kinetics in vitro (Buss et al., 2001, 
Durrbach et al., 1996, Flanagan & Lin, 1980, Gerke & Moss, 2002, Hayes et al., 
2006, Hussain et al., 2011, Ploubidou & Way, 2001, Soldati & Schliwa, 2006, Yang 
et al., 2011). 
 
After the virus has released its positive strand virion RNA into the host 
cytoplasm, the viral RNA acts as a messenger RNA that is subsequently translated 
into a large polypeptide (Bedard & Semler, 2004, Solomon et al., 2010, Wu et al., 
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2010). This polypeptide is subsequently cleaved into 11 mature structural and non-
structural proteins (Caggana et al., 1993, Solomon et al., 2010, Wu et al., 2010). 
Apoptosis or programmed cell death would then be triggered in the host cells by the 
production of EV71 2A and 3C which activates the caspases (Chi et al., 2013, Kuo et 
al., 2002, Li et al., 2002). It was also reported that EV71, in contrast does not 
stimulate apoptosis but induces the production of Mitogen-activated protein 
kinases/Extracellular signal-regulated kinases (MAPK/ERK) signalling very early 
during infection to slow down apoptosis to facilitate virus replication (Huang et al., 
2012, Wong et al., 2005).  
 
1.11 HOST PATHOGEN INTERACTION 
 
The ability of the virus to cause infection in the susceptible host directly 
correlates to the interaction between the host and pathogen. In order to survive and 
proliferate during infection, the pathogen must be able to sense, react and adapt to 
the ever-changing microenvironment inside the host. Such adaptations and the use of 
the host resources to proliferate are prerequisites for the successful colonisation of 
the host by the pathogen (Scaria et al., 2006, Ghosh et al., 2009, Roberts & Jopling, 
2010).   
 
Pathogens can be differentiated from commensal organisms by their abilities to 
subvert host cellular process and resources to their advantage. Viruses, being obligate 
intracellular parasites have developed highly sophisticated mechanisms not only to 
exploit the biosynthetic machinery for replication, but also to specifically evade the 
host immune system. This intricate host-pathogen interaction between the virus and 
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the host cells may play an important role in the establishment of the disease through 
the regulation of viral expression and subversion of host antiviral pathways (Scaria et 
al., 2006, Ghosh et al., 2009, Roberts & Jopling, 2010).  Such intricate host-pathogen 
interactions between the virus and the host cells creates a dilemma for the 
development of antiviral drugs that must target explicit viral proteins and pathway 
without killing the host cells. Hence, only a few effective antiviral drugs exist in the 
market, virus resistance and drug toxicity are significant issues for all antiviral 
therapeutics (Scaria et al., 2006, Ghosh et al., 2009, Roberts & Jopling, 2010).   
 
1.12 HOST ANTIVIRAL FACTORS AND SIGNALLING PATHWAYS 
 
Early innate and cell intrinsic response are essential to protect host cells against 
pathogens such as viruses. During viral infection the host innate immune system 
serves to limit virus infection and in turn the viruses have evolved to counteract with 
these antiviral factors to established infection (Viswanathan et al., 2010, tenOever, 
2013, Taylor & Mossman, 2013, Randall & Goodbourn, 2008, Rajsbaum & Garcia-
Sastre, 2013).  The interferon (IFN) family represents a key component of the innate 
immune response and is vital to mount a robust host response against viral infection 
(Versteeg & Garcia-Sastre, 2010, Thompson et al., 2011, Randall & Goodbourn, 
2008, Rajsbaum & Garcia-Sastre, 2013, Oudshoorn et al., 2012, de Weerd & 
Nguyen, 2012, Brennan & Bowie, 2010, Boss & Renne, 2011).  
 
The activation of IFNs begins with the recognition of pathogen-associated 
molecular patterns (PAMPs) which include Toll like receptors (TLRs), nucleotide-
binding oligomerisation domain (NOD) like receptors (NLRs), and retinoic acid-
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inducible gene I (RIG-I) like receptors (Kanarek & Ben-Neriah, 2012, Brennan & 
Bowie, 2010).  There are three classes of interferon namely type I, II and III which 
induce IFN-stimulated genes (ISGs). This family of cytokines act in an autocrine and 
paracrine manner to induce expression of transcription factors, gamma activated 
sequence and IFN-stimulated response element and this results in the induction of 
ISGs which function to slow down viral infection (Versteeg & Garcia-Sastre, 2010, 
Thompson et al., 2011, Oudshoorn et al., 2012).  ISGs slow the EV71 viral 
replication by halting transcription, translation and cell division and could even 
induce cell death (Munday et al., 2012).  These key cytokines protect the uninfected 
cells and stimulate the adaptive immune system including macrophage and dendritic 
cell (Versteeg & Garcia-Sastre, 2010, Thompson et al., 2011, Randall & Goodbourn, 
2008, Rajsbaum & Garcia-Sastre, 2013, Oudshoorn et al., 2012, de Weerd & 
Nguyen, 2012, Brennan & Bowie, 2010, Boss & Renne, 2011). 
 
1.13 MICRORNA AND TRANSCRIPTIONAL REGULATION 
 
During infection, viruses can mediate host gene expression to enhance their 
survival. Activities include altering the cellular microenvironment to allow 
successful virus replication and evasion of the host immune system (Munday et al., 
2012). Antiviral pathways such as the programmed cell death (apoptosis) could be 
activated by the host cells in an attempt to limit the infection (Munday et al., 2012). 
Viruses have developed sophisticated mechanisms to evade host-immune responses 
in order to establish infection in the hosts. These complex intertwined cellular 
processes are orchestrated by an array of molecular signalling molecules such as 
transcription factors and genes resulting in alternation to the host proteome. One of 
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the mediators for such regulation includes genes that encode for microRNA 
(miRNAs) (Sullivan & Ganem, 2005, Scaria et al., 2006). 
 
These small single-stranded RNA species (miRNAs) are of approximately 20-
24 bases in length that play a pivotal role in the post transcriptional regulation of 
gene expression (Sullivan & Ganem, 2005, Scaria et al., 2006). As such, miRNAs 
can contribute to the repertoire of host-pathogen interactions during infection by 
modulating and directing host and viral gene expression thereby, playing a pivotal 
role during infection. These small non-coding RNA were first discovered in 
Caenorhabditis elegans, but were later discovered in a wide range of organisms from 
uni to multi-cellular eukaryotes (Ghosh et al., 2009, Lau et al., 2001, Lee et al., 
1993).  
 
The biogenesis of miRNAs begins when a long primary transcript known as 
pri-miRNA is transcribed by RNA polymerase II (Ghosh et al., 2009, Roberts & 
Jopling, 2010, Scaria et al., 2006, Skalsky & Cullen, 2010, Sullivan, 2008, Sullivan 
& Ganem, 2005) (Figure 1.3). These pri-miRNAs are then processed by 
microprocessor complex which consist of RNase III enzyme Drosha and the double-
stranded-RNA-binding protein, DiGeorge Syndrome Critical Region 8 
(DGCR8/pasha) to become pre-miRNA (Ghosh et al., 2009, Gottwein & Cullen, 
2008). Pre-miRNAs are subsequently exported to the cytosol by exportin 5 where 
RNAse III-like Dicer processes these precursors to mature miRNAs (Ghosh et al., 
2009, Gottwein & Cullen, 2008). Mature miRNAs with imperfect base pairing to the 
target mRNA lead to translational repression and/or mRNA degradation by guiding 
RISC (RNA induce silencing complex) which is made up of an Argonaut protein 
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(Figure 1.3) (Ghosh et al., 2009, Gottwein & Cullen, 2008, Lee et al., 1993, Mack, 
2007, Otsuka et al., 2007, Sullivan, 2008).  
 
Recent findings have revealed complex interactions between viruses and host 
cells involving miRNA-mediated RNA silencing pathways (Han et al., 2007, Huang 
et al., 2007, Mack, 2007, Otsuka et al., 2007, Umbach & Cullen, 2009). It has been 
found that certain viruses such as such as Herpes Simplex Virus 1 and 2, encode for 
miRNAs that can regulate viral or cellular targets while some viruses are regulated 
directly or indirectly by host miRNAs (Han et al., 2007, Huang et al., 2007, Mack, 
2007, Otsuka et al., 2007, Umbach & Cullen, 2009). These miRNAs have been 
reported to block host cell apoptosis and allow the viruses to evade the immune 
system (Han et al., 2007, Huang et al., 2007, Mack, 2007, Otsuka et al., 2007, 
Umbach & Cullen, 2009). Indeed, it has become apparent that miRNAs interactions 
with the host are vital for viral survival and proliferation during pathogenesis (Scaria 
et al., 2006, Umbach & Cullen, 2009).  
 
The sophisticated means by which pathogens overcome the host barriers and 
immune system to establish, replicate, persist, exit, and infect a new host is seen as 
one of the most impressive evolutionary adaptation (Mack, 2007, Nathans et al., 
2009, Roberts & Jopling, 2010, Scaria et al., 2006, Skalsky & Cullen, 2010). 
Elucidating the mechanism of pathogenesis that the virus undertakes to bypass the 
host defence systems and establish infections would provide us with a better 
understanding of the virology of EV71 and lead to the development of potential 
antiviral therapeutics for HFMD patients. Given the importance of miRNAs in post 
transcriptional regulation of cellular responses to viral infections of host cells as well 
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as the potential contribution to the repertoire of host-pathogen interactions during 
infection by modulating host and viral gene expression, it is logical to study these 
antiviral responses.  
 
Figure 1.3 Schematic diagram of miRNA biogenesis. Schematic diagram 
of the process of miRNA biogenesis. From (Kim, 2005). 
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1.14 CONTROL OF HFMD VIRAL INFECTIONS AND THE DIAGNOSIS 
OF EV71 
 
Over the past decades, EV71 has became the cause of regular epidemics across 
the Asia-Pacific regions in countries including Australia, China, Taiwan, Japan, 
Korea, Malaysia, Vietnam, Thailand and Singapore (Schmidt et al., 1974, Chumakov 
et al., 1979, McMinn et al., 2001, Huang et al., 2012). Although there are much 
research into understanding EV71 pathogenesis and vaccine clinical trials are 
underway, with no effective vaccine or therapeutics available, the current mode of 
infection control is through public health approaches. Prevention is better than cure 
and early detection of EV71 infection potentially allows for halting transmission of 
virus via effective diagnosis and isolation of the patients (Ang et al., 2009, McMinn, 
2012, Singh et al., 2002, Solomon et al., 2010, Tan et al., 2006, Tan et al., 2008a, 
Tan et al., 2008b, Zhu et al., 2013).  
 
Epidemic control measures primarily target the interruption of viral 
transmission between individuals (Ang et al., 2009, McMinn, 2012, Solomon et al., 
2010, Yi et al., 2011). Social distancing and case isolation are transmission-reducing 
measures used to prevention HFMD infection during epidemics (Ang et al., 2009, 
McMinn, 2012, Solomon et al., 2010, Yi et al., 2011). Countries including China, 
Hong Kong, Malaysia, Singapore and Taiwan regularly practise transmission 
reducing measures such as school closure during outbreaks, although the 
effectiveness of such measures in the control of HFMD remain debatable (Ang et al., 
2009, McMinn, 2012, Solomon et al., 2010, Yi et al., 2011).  
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The diagnosis for HFMD infections is often made by the medical physician 
following physical examination of the patient and based upon the observation and 
recording of symptoms such fevers, vomit, diarrhoea, oral ulcers and body rashes 
(Ang et al., 2009, McMinn, 2012, Singh et al., 2002, Solomon et al., 2010, Tan et 
al., 2006, Tan et al., 2008a, Tan et al., 2008b, Zhu et al., 2013). However, physical 
examination is not conclusive enough to differentiate EV71 from other enterviruses 
causing HFMD (Singh et al., 2002, Tan et al., 2006, Tan et al., 2008b, Tano et al., 
2002). As such, molecular diagnostic techniques are required for the identification 
and differentiation of enterovirus-related infection (Singh et al., 2002, Tan et al., 
2006, Tan et al., 2008b, Tano et al., 2002). 
 
There are four main methodologies to diagnose and differentiate enterovirus 
infection 1) tissue culture followed by serotyping, 2) immunofluorescence assay 
(IFA), 3) enzyme linked immunosorbent assay (ELISA) and 4) nucleic acid 
amplification (Ho et al., 1999, Ooi et al., 2010, Ooi et al., 2009, Ooi et al., 2007, 
Singh et al., 2002, Solomon et al., 2010, Tan et al., 2006, Tan et al., 2008b, Tano et 
al., 2002, Wang et al., 2000). Until recently, the gold standard for identification of 
enteroviruses involved propagation by cell culture, followed by neutralization with 
specific antisera to confirm the serotype (Ho et al., 1999, Ooi et al., 2010, Ooi et al., 
2009, Ooi et al., 2007, Singh et al., 2002, Solomon et al., 2010, Tan et al., 2006, Tan 
et al., 2008b, Tano et al., 2002, Wang et al., 2000). However, this procedure is 
limited by its long turnaround time which may take a few weeks (Singh et al., 2002, 
Tan et al., 2008a, Tan et al., 2008b, Tano et al., 2002). Furthermore, some 
enteroviruses may proliferate sub-optimally in cell cultures, require several passages 
or may not be typeable (Ho et al., 1999, Wang et al., 2000).  
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Similarly using IFA, which employs the antigen-antibody complex for the 
detection of enteroviruses in cell culture prove to be unspecific and have a long 
turnaround time (Yan et al., 2001). In addition, the monoclonal antibody used was 
also reported to cross react with closely related viruses such as CA16 (Yan et al., 
2001). In the case for ELISA, although the detection for IgM in sera from EV71 
infected patients was demonstrated to be effective, cross activity with antibodies 
against other enteroviruses also resulted in false positives (Tano et al., 2002, Yan et 
al., 2001).  
 
Nucleic acid amplification using polymerase chain reaction (PCR) or real-time 
quantitative PCR is now being routinely used to detect and differentiate enterovirus 
infection (Ho et al., 1999, Ooi et al., 2010, Ooi et al., 2009, Ooi et al., 2007, Singh et 
al., 2002, Solomon et al., 2010, Tan et al., 2006, Tan et al., 2008b, Tano et al., 2002, 
Wang et al., 2000). Such molecular techniques have been shown to be more sensitive 
and have shorter turnaround time when compared to other methodologies (Singh et 
al., 2002, Tan et al., 2008a, Tan et al., 2008b, Tano et al., 2002).  Specific primers 
and probes have been designed in against various parts of the enterovirus genome to 
identify specific strains of the enterovirus (Singh et al., 2002, Tan et al., 2008a, Tan 
et al., 2008b). Over the past two decade, fluorescence based qPCR chemistry have 
revolutionised nucleic acid diagnostics and become the gold standard for quantitation 
of viral load (Henrich et al., 2012, Hayden et al., 2013). Quantitative determination 
of viral load has been used to monitor the efficiency of antiviral therapy and to 
determine changes in that therapy (Hindson et al., 2013, McDermott et al., 2013). 
Elavated viral burdens have been used as a trigger for pre-emptive treatment to 
prevent symptomatic infection (Henrich et al., 2012, Hayden et al., 2013).  
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Fast turnaround times for diagnostic techniques used to detect EV71 infections 
would likely contribute to limiting the spread and the decreased spread of the disease 
(Ang et al., 2009). Notwithstanding, earlier diagnosis would mean decreased health 
care cost by avoiding unnecessary hospitalization, antibiotics treatment, CT scans, 
magnetic resonance imaging scans and radiography of the suspected EV71 infected 
patients (Ang et al., 2009, McMinn, 2012, Singh et al., 2002, Solomon et al., 2010, 
Tan et al., 2006, Tan et al., 2008a, Tan et al., 2008b, Zhu et al., 2013). 
 
1.15 THE OVERALL OBJECTIVES OF THE STUDY 
 
The overall objective of this project was to study the mechanism (s) of EV71 
viral pathogenesis. It is hypothesised in this thesis that during EV71 infection of 
susceptible humans, host cellular miRNA and mRNA may play critical roles in 
modulating virus replication and may   indirectly correlate with viral replication. 
EV71 may have evolved means to specifically up-regulate supportive miRNA and 
down regulate limiting miRNA, thereby enhancing the host cellular environment for 
it’s replication. To address this salient question in EV71 research, this study herein 
aimed to elucidate the host-pathogen interactions between in vitro human cells and 
EV71.  
 
We aimed to do this by 1) establishing in vitro models of viral infections of 
human cells by using both a rhabdomyosarcoma (RD) cell line as well as a colorectal 
cell line which would mimic in vivo host-pathogen interactions of EV71 virus 
infection of human cells and 2) integrating the results from investigating host cellular 
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responses (including miRNA and mRNA) following viral infections and 3) 
examining the effects of EV71 replication in miRNA depleted cells.  
 
1.16 THE SPECIFIC AIMS OF THE STUDY 
 
In an attempt to address the overall project objective, this study therefore have 
five result chapters: 
 
Chapter 2-Aim 1: Characterisation of enterovirus 71 replication kinetics in 
Human colorectal cell line, HT29  
Chapter 3-Aim 2:  Elucidating the host-pathogen interaction between human 
colorectal cells and invading enterovirus 71 using transcriptomic profiling  
Chapter 4-Aim 3:  EV71 utilise host microRNAs to mediate host immune system 
enhancing survival during infection  
Chapter 5-Aim 4: Beta-actin Variant is Necessary for enterovirus 71 
Replication 
Chapter 6-Aim 5: Droplet Digital PCR as a useful tool for the quantitative 
detection of enterovirus 71. 
 
The experimental design of this study has resulted in the generation of data to 
provide us with a better understanding of the pathogenesis of EV71 and may provide 
clues for the development of antiviral therapeutics. Clearly, this study is medically 
relevant, as EV71 is an ever-increasing public health problem with frequent and 
consistent outbreaks and the potential to develop neurological complications in 
infected infants and children particularly (but not exclusively) in the South East Asia 
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regions. It is therefore crucial to understand the complex interplay between the host 
environment and the pathogen in order to determine what gives the virus its’ ability 
to survive within the host. 
 
1.17 AN ACCOUNT OF SCIENTIFIC PROGRESS LINKING TO THE 
SCIENTIFIC PAPERS 
 
The Five Chapters of results of the present study are presented as 
manuscripts/papers in this thesis that outline findings that contribute to the overall 
understanding of EV71 pathogenesis. The first result chapter of this thesis, Chapter 
Two, presents data obtained following the establishment of human colorectal cells 
(HT29) as a viable and a more relevant in vitro model to study EV71 pathogenesis. 
In Chapter Three, an in depth analysis involving transcriptomic provides data to 
elucidate the host-pathogen interaction between our established human colorectal 
cells and invading EV71. We identified key pathways that are altered during EV71 
infection of these human cells.  
 
In Chapter Four, we evaluate the importance of miRNAs during EV71 
infection by performing a global knockdown of miRNAs in human epithelial 
colorectal cells. In addition, we examine the changes in miRNA profile during EV71 
infection in order to pinpoint specific key miRNAs vital for EV71 pathogenesis. We 
demonstrated that there are miRNAs changes during EV71 pathogenesis and as a 
result the host antiviral pathways were altered during viral infections. Chapter Five, 
reports the comparative proteomic analyses on EV71-susceptible and EV71-resistant 
cells. We demonstrated that EV71 infection may be actin dependent. Finally, in 
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Chapter Six, we evaluate if the droplet digital PCR was a useful tool to detect  and 
provide an absolute quantitation of EV71 viral copy number ; a technique that may 
prove useful  to monitor the effects of antiviral therapeutics in EV71-infected 
patients. 
 
Taken together, the results presented in Chapters Two to Six of this thesis 
provide valuable insights into the host-pathogen interaction during EV71 
pathogenesis. Elucidating the mechanism(s) that the virus uses to bypass host 
defence systems and establish infections will provide us with a better understanding 
of the pathogenesis mechanism of the EV71 virus and will thus aid in the 
development of potential antiviral therapeutics for HFMD patients.  
 
This thesis is written in the format of a series of manuscripts and chapters in 
accordance with the Queensland University of Technology theses by submitted 
manuscript guidelines. Chapter 1 is a Literature Review of the topic which 
demonstrates argument to support the need for this study. Chapters Two to Six are 
manuscripts accepted for publication in peer-reviewed journals. Chapter Seven is a 
comprehensive discussion of the key findings of this project. The references for each 
paper are presented at the end of their corresponding Chapters and formatted to 
Molecular Microbiology for standardisation throughout the thesis. A complete 
bibliography of the whole thesis is provided at the end of the thesis. 
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Chapter 2: Characterisation of enterovirus 
71 replication kinetics in Human 
colorectal cell line, HT29 
Abstract 
Hand, Foot and Mouth Disease (HFMD), a contagious viral disease that 
commonly affects infants and children with blisters and flu like symptoms, is caused 
by a group of enteroviruses such as Enterovirus 71 (EV71) and coxsackievirus A16 
(CA16). However some HFMD caused by EV71 may further develop into severe 
neurological complications such as encephalitis and meningitis. The route of 
transmission was postulated that the virus transmit from one person to another 
through direct contact of vesicular fluid or droplet from the infected or via faecal-oral 
route. To this end, this study utilised a human colorectal adenocarcinoma cell line 
(HT29) with epithelioid morphology as an in vitro model for the investigation of 
EV71 replication kinetics. Using qPCR, viral RNA was first detected in HT29 cells 
as early as 12h post infection (hpi) while viral protein was first detected at 48hpi. A 
significant change in HT29 cells’ morphology was also observed after 48hpi. 
Furthermore HT29 cell viability also significantly decreased at 72hpi. Together, data 
from this study demonstrated that co-culture of HT29 with EV71 is a useful in vitro 
model to study the pathogenesis of EV71. 
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2.1 INTRODUCTION 
Hand, Foot and Mouth Disease (HFMD), a contagious viral disease that 
commonly affects infants and children, are caused by a group of enteroviruses such 
as  enterovirus 71 (EV71) and coxsackievirus A16 (CA16) (Brown et al., 1999, 
Cardosa et al., 2003, Lee et al., 2009, Prager et al., 2003). This self-limiting disease 
is characterised by fever, rashes, poor appetite and multiple ulcers in mouth (Brown 
et al., 1999, Cardosa et al., 2003, Lee et al., 2009, Prager et al., 2003).  However, 
patients infected with EV71 may further develop severe neurological complications 
such as aseptic meningitis and brainstem/cerebellar encephalitis (Lee & Chang, 
2010, Lee et al., 2009, Singh et al., 2002, Solomon et al., 2010, McMinn, 2002).  
 
EV71, a member from the Enterovirus genus of the Picornaviridae family, is a 
non-enveloped, positive sense, single stranded, RNA virus with genomic RNA of 
approximately 7400bp in length (Lee & Chang, 2010, Oberste et al., 1999a, Oberste 
et al., 1999b). EV71 was first isolated from HFMD patients with central nervous 
system disease in 1969 (Schmidt et al., 1974). Large fatal EV71 outbreaks of  HFMD  
first appeared in Bulgaria in 1975, and disease outbreaks were subsequently 
identified in Hungary in 1978 and re-emerged in Malaysia in 1997 and Taiwan in 
1998 (Chumakov et al., 1979, Nagy et al., 1982, Ho et al., 1999, Lu et al., 2002, 
Solomon et al., 2010). HFMD epidemics and pandemics have been periodically 
reported worldwide with outbreaks occurring every two to three years in countries 
including Australia, China, Taiwan, Japan, Korea, Malaysia, Vietnam, Thailand and 
Singapore (Schmidt et al., 1974, Chumakov et al., 1979, McMinn et al., 2001, 
Huang et al., 2012). The consistent presence and outbreaks of HFMD push for an 
urgent need to develop a vaccine or antiviral therapies against enteroviruses 
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(Pourianfar et al., 2012, McMinn et al., 2001, Tan et al., 2007a, Tan et al., 2007b, 
Tan et al., 2010). Currently, there are no available antiviral therapies or vaccines 
approved by the United States of America Food and Drug Administration (FDA) to 
prevent HFMD infections (Li et al., 2007).  
 
The route of transmission of EV71 was postulated to happen via direct contact 
of vesicular fluid or droplets from the infected or via faecal-oral route (Wong et al., 
2010, Lee et al., 2009, Liu et al., 2000, Brown et al., 1999). EV71 was shown to 
replicate within the gastrointestinal tract, bypass the gut barrier and infect the skeletal 
muscle cell before entering into the bloodstream and the central nervous system 
(Wong et al., 2010, Lee et al., 2009, Liu et al., 2000, Brown et al., 1999). Indeed 
various studies had shown in in vivo models such as mouse that the intestine was the 
initial site of infection for EV71 infection with the muscle cells responsible for 
persistent infection, supporting efficient virus replication (Chen et al., 2007, Chen et 
al., 2004, Khong et al., 2012). Therefore, we hypothesised that it is relevant to study 
EV71 using an in vitro model of a human gastrointestinal cell type origin during the 
initial stages of infection. 
 
In this study, we used a human colorectal adenocarcinoma cell line (HT29) 
with epithelioid morphology as an in vitro model for the investigation of EV71 
replication kinetics. To characterise the virus replication in HT29 cells, the viral VP1 
RNA and protein were monitored using qPCR and western blot respectively. In 
addition, the cell viability of HT29 to EV71 infection was monitored throughout the 
time course of 72 hours posts infection (hpi). 
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2.2 MATERIALS AND METHODS 
Cell culture and virus propagation 
Human colorectal cell line (HT29) (ATCC® catalog no. HTB-38™) was 
maintained in Roswell Park Memorial Institute medium (RPMI 1640) (PAA 
Laboratories, Austria) supplemented with 10% (v/v) Fetal Bovine Serum (FBS) 
(PAA Laboratories, Austria) and 2% penicillin–streptomycin (PAA Laboratories, 
Austria) at 37°C with 5% CO2.  The EV71 strain used in this study was isolated from 
a fatal case of HFMD during the October 2000 outbreak in Singapore, the 
Enterovirus 5865/sin/000009 strain (accession number 316321; hereby designated as 
Strain 41) from subgenogroup B4. The virus stock was prepared by propagation of 
viruses using 90% confluent HT29 cell monolayers in RPMI 1640 with 10% FBS 
and 2% penicillin–streptomycin at 37°C with 5% CO2. The virus titres were 
determined using 50% tissue culture infective dose (TCID50) per millilitre (mL) and 
the multiplicity of infection (MOI) was performed according to Reed and Muench 
method (Reed & Muench, 1938). 
 
Viral infection 
HT29 cells were seeded at a concentration of 2 × 106 cells/ml in 6-well plates 
and incubated for 24h at 37°C with 5% CO2. Cells were washed twice with 
phosphate buffered saline (PBS) and infected with EV71 at multiplicity of infection 
(MOI) of 1 or nil respectively. Following infection for 1h, the culture media were 
removed and replaced with 2 mL of fresh RPMI 1640 medium. Micrographs were 
then taken using phase contrast microscopy at different time points, after which the 
cells were trypsinised (PAA Laboratories, Austria) and harvested at 12h, 24h, 48h 
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and 72h to isolate RNA and proteins for qPCR reactions and western blots 
respectively. 
Cell viability and counts  
Cell count and viability was performed on the LunaTM Automated Cell 
Counter system (Logos Biosystem, USA) in accordance to the manufacturer’s 
instructions. Briefly, the cells were trypsinised at different time points (12h, 24h, 48h 
and 72h).  The trypsinised cells were then topped up with fresh media to a total 
volume of 1000μl media and 10μl of this cell suspension were mixed with 10μl of 
trypan blue. 10μl of this diluted cell suspension were then loaded onto the LunaTM 
counting slide for analysis.  
 
RNA isolation and cDNA synthesis 
The total cellular RNA of HT29 cells were extracted using the miRNeasy 
mini kit (Qiagen, Hilden, Germany) in accordance to the manufacturer’s instructions. 
Briefly, the cells were lysed and homogenise using the lyse solution provided 
(Qiagen, Hilden, Germany). Total RNA was harvested using the RNeasy spin 
column and washed twice before elution (Qiagen, Hilden, Germany). Harvested total 
RNA was quantitated using Nanodrop 100 spectrophotometer (ThermoScientific, 
Waltham, USA) and 1ng of the total RNA was then reverse transcripted using the 
iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, CA, USA) in accordance to 
the manufacturer’s instructions. Briefly, 1ng of the extracted RNA was mixed with 
enzyme reverse transcriptase and buffer to a volume of 20μl and subjected to thermal 
profile of 25ºC for 5m, 42ºC for 30m followed by 85ºC for 5m in accordance to the 
manufacturer’s instructions. 
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Quantitative real time polymerase chain reaction 
The EV71 specific primers targeting the conserved VP1 regions were 5′-
GCTCTATAGGAGATAGTGTGAGTAGGG-3′ and the reverse primer 5′-
ATGACTGCTCACCTGCGTGTT-3′ (Tan et al., 2008a). Primers for SCARB2 
receptors were 5′- CCAATACGTCAGACAATGCC-3′ and the reverse primer 5′-
ACCATTCTTGCAGATGCTGA-3′ were designed to span exon-exon boundaries. 
The primers for the house-keeping gene actin (β-ACT) used were 5′- 
ACCAACTGGGACGACATGGAGAAA-3′ and the reverse primer 5′-
TAGCACAGCCTGGATAGCAACGTA-3′. The quantitative real time polymerase 
chain reaction (qPCR) was performed using the iQ™ SYBR® Green Supermix (Bio-
Rad Laboratories, CA, USA) on the BioRad CFX96TM Real-Time PCR system (Bio-
Rad Laboratories, CA, USA). Briefly, 1μl of cDNA and 1 μl of the forward and the 
reverse primers were added to iQ™ SYBR® Green Supermix. The reaction mix was 
then subjected to thermal cycling profile of denaturation at 95ºC for 10m, followed 
by amplification and quantification in 40 cycles at 95ºC for 10s, 60ºC for 30s 
followed by 50ºC for 30s. At the end of amplification cycles, melting temperature 
analysis was performed by the BioRad CFX96TM Real-Time PCR system (Bio-Rad 
Laboratories, CA, USA).  
 
For absolute quantification of EV71, conventional PCR was carried out to 
amplify nt2466 to nt2669 within the VP1 region of EV71 (strain 41). The PCR 
product (204bp) was then cloned into the pGEM-T plasmid vector (Promega, 
Wisconsin, USA) and subsequently transformed into E.coli JM109 competent cells. 
RNA was synthesized in vitro from the recombinant plasmids and the concentration 
was measured spectrophotometrically at 260nm. The number of viral copies was then 
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calculated. A series of ten-fold dilutions were then prepared, yielding a series of viral 
copies ranging from 5 X 100 copies to 5 X 109 copies (Figure 2.1). Relative gene 
expression was quantified based on the formula: 2(Ct of gene−Ct of ACT). 
 
Western blot 
Total cellular protein extraction for HT29 cells and control cells were 
performed using a lysis mix in mammalian cell lysis solution – CelLytic M (Sigma-
Aldrich Pte Ltd, USA) in accordance with manufacturer’s instructions. Equal protein 
concentration (20μg) from each samples were added into SDS PAGE, 10% Mini-
PROTEAN® TGX™ (Bio-Rad Laboratories, CA, USA) and separated by 
electrophoresis. Separated proteins were transferred onto polyvinylidene diflouride 
membranes (Invitrogen, California, USA) using iBlot® Western Detection kit 
(Invitrogen, California, USA) in accordance to manufacturer instructions.  Ponceau S 
staining was performed to ensure equal level of protein present in all lanes according 
to Romero-Calvo et al (2010) (Romero-Calvo et al., 2010). Briefly, membranes were 
stained with Ponceau S (Sigma-Aldrich Pte Ltd, USA) for 1m and washed three 
times with water to remove stain. Western blot was then performed using 
WesternBreeze® Chromogenic Kit–Anti-Mouse (Invitrogen, California, USA) in 
accordance to manufacturer instructions. Briefly, the membranes were incubated 
with mouse anti EV71 antibody (AbD serotech, Oxford, UK) or anti Tubulin 
antibody (Santa Cruz Biotechnology inc, California, USA) respectively in shaker for 
an hour. The membranes were washed three times before and incubating with 
secondary antibodies (Invitrogen, California, USA) for 30m. The membranes were 
then washed three times and incubated with chromogen substrate till purple bands 
were developed in 1h. The membranes were left to air dry then placed into the 
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densitometer and scanned using the Quantity One software (Bio-Rad Laboratories, 
CA, USA). The picture was analysed using Image J (National Institutes of Health, 
USA). 
 
Statistical analysis 
All statistical analysis was performed on GraphPad Prism Version 6.0c 
(GraphPad Software, USA). Student’s t test was used to compare two groups. p 
values of < 0.05 were considered statistically significant. 
 
2.3 RESULTS 
This study aims to characterise the viral replication in an in vitro model of 
HFMD for EV71 pathogenesis study. To this end a human colorectal 
adenocarcinoma cell line (HT29) with epithelioid morphology was infected with 
EV71 over the time course of 72h. 
 
Cytopathic effects and cell viability of HT29 cells during EV71 infection 
There are no changes between control and infected cells at 12hpi, 24hpi and 
48hpi (Figure 2.2). However at 72hpi there was a statistically significant decrease of 
approximately 60% of the number of infected cells (17.6%) compared to control 
(77.5%). There are no apparent change in morphology between infected and control 
cells at 12hpi and 24hpi. However, at 48hpi and 72hpi, cells were observed to lose its 
adherence and round up, which suggest cells are under stress (Figure 2.2) with 
cytopathic effects observed. At 72hpi, in comparison with the control and infected 
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cells, there was a higher number of floating cells in the media which correlate to the 
decrease in live cells count (Figure 2.2).  
 
Viral kinetics of EV71 replication  
To further study EV71 replication kinetics in HT29 cells, the viral RNA 
expression and protein synthesis was monitored over 72h. Using established 
protocols, the kinetics of EV71 RNA synthesis in infected HT29 cells were examined 
quantitatively using qPCR at various time points (12hr, 24hr, 48hr and 72hr) (Tan et 
al., 2008b). Control cells show no viral RNA present (Figure 2.3). There was an 
expected exponential increase in viral RNA copy number of the infected cells as 
measured by qPCR. Viral RNA was first detected at 12hpi. Approximately 5 million 
virus copy number was detected at 12hpi, which then doubles at 24hpi to 
approximately 10 million virus copy number. Subsequently at 48hpi, it increased 20 
fold to a copy number of approximately 200 million virus copy number. Finally at 
72hpi, it increased 5 fold to 1000 million virus copy number. The viral copy number 
quantitated had exponential increased at every time point except 72hpi, where there 
was only a 5 fold increase in virus copy number (Figure 2.3).  
 
Viral kinetics of EV71 VP1 protein synthesis 
In addition to the detection of viral RNA, the kinetics of EV71 VP1 protein 
synthesis in infected HT29 cells was monitored using western immunoblotting blot 
with antibody specific to EV71 (Figure 2.4). Relative expression of EV71 VP1 
protein of infected and control cells were analysed using Image J and a statistically 
significant amount of virus protein were only detected at 48hpi and 72hpi.  
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Cellular receptor SCARB2 is present in both HT29 and RD cells 
Receptor binding is an essential and vital process during viral infection of the 
cells (Patel & Bergelson, 2009, Yamayoshi et al., 2012). Cellular receptor play an 
important role in the pathogenicity of viruses, particularly during the internalisation 
of virus during infection. As such we quantified the relative expression of a 
functional receptor, scavenger receptor class B, member 2 (SCARB2) based on the 
formula: 2(Ct of gene−Ct of ACT). Primers for SCARB2 and ACT were designed to span 
exon-exon boundaries to give a single PCR product of 89bp and 198bp respectively 
(Figure 2.5). HT29 was found to express SCARB2 at the expression level of 
approximately 20.2 as compared with RD cells of approximately 26.9. The presence 
of SCARB2 in HT29 further supports HT29 cells as a viable in vitro model to study 
EV71 pathogenesis. 
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Figure 2.1 Absolute quantification of EV71. A series of ten-fold dilutions 
were then prepared, yielding a series of viral copies ranging from 5 X 100 copies to 5 
X 109 copies (n=3). 
 
 
 
 
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Cell viability of HT29 cells following EV71 infection. Confluent 
HT29 cells were infected with or without EV71 (MOI of 1). (A) HT29 cells were 
harvested at different time points and cell viability assessed using vital dye trypan 
blue. (n=3, *= p values of < 0.05) (B) Micrograph of confluent HT29 cell cultures 
were taken at a magnification of 20X at different time points for 72h.  
 
64 
 
 
 
 
 
Figure 2.3 Kinetics of EV71 replication in HT29 cells. Confluent HT29 cells 
were infected with or without EV71 (MOI of 1). Total intracellular RNA was 
harvested at various time points, converted to cDNA and measured by quantitative 
real time polymerase chain reaction (qPCR) with primers specific to viral VP1. (n=3, 
*= p values of < 0.05) As observed, there was an increase in viral copy number 
through increasingly time points. 
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Figure 2.4 Kinetics of EV71 VP1 protein synthesis in HT29 cells. Confluent 
HT29 cells were infected with or without EV71 (MOI of 1). Total intracellular 
protein was harvested at various time points and measured by western blot and 
captured using Quantity One software. (n=3, *= p values of < 0.05) The results were 
then analysed using Image J. As observed, it trends the results we observed by viral 
RNA amplification. (A) Intracellular viral VP1 measured by Western blotting with 
Ponceau S staining control of membrane (B) Relative expression of viral VP1 
protein.  
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Figure 2.5 Expression SCARB2 in RD and HT29 cells. Total intracellular 
RNA was harvested from RD and HT29 cells, converted to cDNA and measured by 
quantitative real time polymerase chain reaction (qRT-PCR) with primers specific to 
SCARB2 and β-ACTB. Primers for SCARB2 and ACT (β-actin) were designed to 
span exon-exon boundaries to give a single PCR product of 89bp and 198bp 
respectively. The presence of SCARB2 in HT29 further supports HT29 cells as a 
viable in vitro model to study EV71 pathogenesis. 
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2.4 DISCUSSION 
Viral replication kinetics play an important role in the understanding of virus 
pathogenesis (Baccam et al., 2006, Chang et al., 2006, Major et al., 2004). The 
kinetics of various viruses such as hepatitis C, Nipah virus and influenza virus have 
been reported in various studies and have provided valuable information particularly 
in response to antiviral therapeutics which aid in understanding the host pathogen 
interaction (Baccam et al., 2006, Chang et al., 2006, Major et al., 2004). In 
comparison, the only information reported for EV71 virus kinetics was by Lu et al 
(2011) who demonstrated EV71 proliferation in rhabdomyosarcoma (RD) cells, of 
muscle cells origin as an in vitro model (Lu et al., 2011).  
 
In a clinical context, this may not be a good representative model during EV71 
infection of a human host. Various studies have demonstrated in animal model that 
the gastrointestinal tract, such as the intestine was the first site for EV71 proliferation 
(Chen et al., 2007, Chen et al., 2004, Khong et al., 2012). Furthermore, Khong et al 
(2012) reported that mice that were administrated with EV71 via the intraperitoneal 
route exhibited 100% mortality, as compared to mice that were administrated with 
EV71 via the oral route, with 10-30% mortality (Khong et al., 2012). Interestingly, 
the mortality rate of mice administrated with EV71 via the oral route (gastrointestinal 
tract) reported by Khong et al (2012) corresponded to the percentage of EV71 
infected human patient with central nervous system complications. This suggests the 
relevance of studying EV71 in colorectal cell line (oral route), using HT29 as an in 
vitro model (Ooi et al., 2010, Ooi et al., 2009, Ooi et al., 2007).  
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In this study, we have demonstrated that upon EV71 infection in human 
epithelial colorectal cell line (HT29), significant cell death only occurs at 72hpi. This 
was varies from the rhabdomyosarcoma (RD) cells previously reported by Lu et al 
(2011) where most cell death occurs within 24hpi. Similarly Chen et al (2007) and 
Khong et al (2012) proposed that skeletal muscle cells such as RD cells are more 
effective in supporting viral replication which allows persistent enterovirus infection 
to represent viral source of entry into the central nervous system (CNS) (Chen et al., 
2007, Khong et al., 2012). In comparison with EV71 RNA synthesis, RNA was first 
detected at 12hpi. Viral protein synthesis was only observed at a later stage during 
the infection possibly due to translation time required. Lu et al (2011) showed a 
similar trend, that viral RNA was first detected at 3hpi while viral protein was 
observed at 6hpi. We believe that such differences could be due to the fact that it 
takes three times longer for the virus to kill HT29 cells in comparison with RD cells.  
 
Receptor binding is an essential and vital process during virus infection of the 
cells (Patel & Bergelson, 2009, Tan et al., 2013, Yamayoshi et al., 2012). Cellular 
receptors, therefore, play an important role in the pathogenicity of viruses. 
Notwithstanding, viruses have been found to utilise multiple receptors for the 
facilitation of entry into susceptible cells (Patel & Bergelson, 2009, Hayes et al., 
2006, Yamayoshi et al., 2009). Thus the identification and characterisation of 
cellular receptors plays a critical role in the understanding of EV71 pathogenesis. 
Scavenger receptor class B, member 2 (SCARB2) was first reported by Yamayoshi 
et al (2009) to be a receptor for all EV71 strains and expressed in the sites of EV71 
replication in vivo (Hayes et al., 2006, Yamayoshi et al., 2009). It is composed of 478 
amino acids and belongs to the CD36 family (Yamayoshi et al., 2012). SCARB2 is 
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commonly found in abundant in the lysosomal membrane of the cell and assist in the 
internalisation of EV71 into the host cell via clathrin mediated endocytosis (Hussain 
et al., 2011, Lui et al., 2013b, Yamayoshi et al., 2012). . The presence of SCARB2 in 
HT29 further supports HT29 cells as a viable in vitro model to study EV71 
pathogenesis. 
 
Considering that different cell types have varying cellular content such as 
cytoskeleton and endoplasmic reticulum network which would potentially plays a 
role in virus replication, the virus replication kinetics may differ betwen cell types. 
Indeed, Hussain et al (2011) has demonstrated that the cytoskeletal system 
comprising of both actin and microtubules were involved endocytic kinetics (Buss et 
al., 2001, Durrbach et al., 1996, Flanagan & Lin, 1980, Hussain et al., 2011). The 
knockdown of genes involves in cytoskeleton formation such as ARPC5, ARRB1, 
and WASF1 and the use of drug disrupting the cytoskeleton network such as 
cytochalasin B, have resulted in the decrease in EV71 replication kinetics (Hussain et 
al., 2011, Lui et al., 2013b).  
 
Furthermore, the incubation period for HFMD is between three to seven days 
(Khong et al., 2012, Ooi et al., 2010, Ooi et al., 2009, Ooi et al., 2007). This may 
correspond to the number of days the virus requires to pass through the 
gastrointestinal tract before spreading throughout the body (Khong et al., 2012, Ooi 
et al., 2010, Ooi et al., 2009, Ooi et al., 2007). Therefore, the in vitro model of 
human epithelial colorectal cell line (HT29) and EV71 may be more clinically 
relevant and mimics the mechanism of pathogenesis of EV71 closer. 
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2.5 CONCLUSION 
In conclusion, we have established the use of HT29 cells as a clinically 
relevant in vitro model of EV71 replication.  We have demonstrated for the first time 
an increase of viral concentration in a time course of 72 hours upon infection with 
the use of cell viability, qPCR and western blot. In addition, this is the first report on 
the presence of SCARB2 in HT29 cells, an essential receptor for all EV71 strains 
which established HT29 cells as a viable in vitro model to study EV71 pathogenesis. 
Our study has provided valuable knowledge toward the study of EV71 pathogenesis 
and virus-host interaction and this could lead to future investigation for the 
development of antiviral therapeutics against EV71. Therapeutic agents against 
EV71 could be developed by potentially inhibiting several key stages of the viral life 
cycle such as viral attachment, translation, polyprotein processing and RNA 
replication with the use of HT29  as an in vitro model for EV71 replication (Chen et 
al., 2008). 
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Chapter 3: Elucidating the host-pathogen 
interaction between human 
colorectal cells and invading 
enterovirus71 using 
transcriptomic profiling 
Abstract 
Enterovirus 71 (EV71) is one of the main etiological agents for Hand, Foot and 
Mouth Disease (HFMD) which has been shown to be associated with severe clinical 
manifestations. Currently, due to a lack in understanding of EV71 pathogenesis, 
there are no antiviral therapeutics for the treatment of HFMD patients. This study 
seeks to elucidate the transcriptomic changes as the results of EV71 infection. 
Human whole genome microarray was employed to monitor changes in genomic 
profiles between infected and uninfected cells. The results reveal altered expression 
of human genes involved in critical pathways including immune response and stress 
response. Together, data from this study provides valuable insights on the host-
pathogen interaction between human colorectal cells and EV71. 
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3.1 INTRODUCTION 
Enterovirus71 (EV71) is a positive sense, single stranded, non-enveloped RNA 
virus belonging to Enterovirus genus of the Picornaviridae family (Lui et al., 2013b, 
McMinn, 2002, McMinn, 2012, Ooi et al., 2010). It is one of the main etiological 
agents for Hand, Foot and Mouth Disease (HFMD) which commonly affects infants 
and children. This disease is usually self-limiting, characterised by various symptoms 
such as fever, rashes, poor appetite and multiple ulcers in mouth (Wong et al., 2010, 
Ho et al., 2011, Huang et al., 2012). The route of transmission of EV71 was 
postulated to happen via direct contact of vesicular fluid, or droplet from the infected 
or via faecal-oral route (Wong et al., 2010, Lee et al., 2009, Liu et al., 2000, Brown 
et al., 1999). EV71 was shown to replicate within the gastrointestinal tract, bypass 
the gut barrier and infect skeletal muscle cells before entering into the bloodstream 
and the central nervous system (Wong et al., 2010, Lee et al., 2009, Liu et al., 2000, 
Brown et al., 1999). However, unlike other HFMD causing enteroviruses, EV71 
have been commonly associated with severe clinical diseases, including neurological 
diseases leading to cardiopulmonary failure and death.  
 
EV71 was first described in 1974 in California (USA) after it was isolated from 
patients with central nervous system disease in 1969 (Schmidt et al., 1974). Recent 
molecular evolution studies have predicted that EV71 could have emerged in the 
human population as early as 1941 (Lee et al., 2012, Tee et al., 2010, van der Sanden 
et al., 2009). Large fatal outbreaks of HFMD first appeared in Bulgaria in 1975, and 
disease outbreaks were subsequently identified in Hungary in 1978 and re-emerged 
after two decades in Malaysia in 1997 and Taiwan in 1998 (Chumakov et al., 1979, 
Nagy et al., 1982, Ho et al., 1999, Lu et al., 2002, Solomon et al., 2010). Since then, 
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there have been various outbreaks, epidemics and pandemics that have periodically 
been reported worldwide with outbreaks occurring every two to three years in 
countries including Australia, China, Taiwan, Japan, Korea, Malaysia, Vietnam, 
Thailand and Singapore (Schmidt et al., 1974, Chumakov et al., 1979, McMinn et 
al., 2001, Huang et al., 2012).  
 
Currently and due in part to a lack of understanding of viral pathogenesis of 
EV71 causing  HFMD, there are no effective antiviral therapies or vaccines approved 
by the United States of America Food and Drug Administration (FDA) to prevent 
HFMD. There is therefore a need to gain a better understanding of the mechanism of 
EV71 pathogenesis. The ability to cause infection directly correlates to the 
interaction between the host and pathogen. In order to survive and proliferate during 
infection, the pathogen must be able to sense, react and adapt to the ever-changing 
microenvironment within the host. Such adaptations and the use of the host resources 
to proliferate are prerequisites for the successful colonisation of the host and 
establish disease. Viruses, being obligate intracellular parasites have developed 
highly sophisticated mechanisms not only to exploit the biosynthetic machinery for 
replication, but also to specifically evade the host immune system.  
 
During infection, viruses regulate host gene expression to enhance their 
survival. Such activities include altering the cellular microenvironment to allow 
successful virus replication and evasion of the host immune system (Scaria et al., 
2006, Ghosh et al., 2009, Roberts & Jopling, 2010). Elucidating the mechanism that 
the virus uses to bypass host defence systems and establish infections will provide us 
with a better understanding of the pathogenesis mechanism of the EV71 virus and 
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will thus aid in the development of potential antiviral therapeutics for HFMD 
patients. In this study, transcriptomic profiling was performed using colorectal cells 
infected with EV71 using mRNA microarray.  
 
3.2 MATERIALS AND METHODS 
Cell culture and virus propagation 
Human colorectal cell line (HT29) (ATCC® catalog no. HTB-38™) was 
maintained in Roswell Park Memorial Institute medium 1640 (RPMI) (PAA 
Laboratories, Austria) supplemented with 10% (v/v) Fetal Bovine Serum (FBS) 
(PAA Laboratories, Austria) and 2% penicillin–streptomycin (PAA Laboratories, 
Austria) at 37°C with 5% CO2.  The EV71 strain used in this study was isolated from 
a fatal case of HFMD during October 2000 outbreak in Singapore, Enterovirus 
5865/sin/000009 strain from subgenogroup B4 (accession number 316321; hereby 
designated as Strain 41). The virus stock was prepared by propagation of viruses 
using 90% confluent HT29 cells monolayer in RPMI 1640 with 10% FBS at 37°C 
with 5% CO2. The virus titres were determined using 50% tissue culture infective 
dose (TCID50) per millilitre (mL) according to Reed and Muench method (Reed & 
Muench, 1938).  
 
EV71 infection for mRNA profiling 
HT29 cells were seeded at a concentration of 5 × 105 cells/ml in each well of 
a 6-well plate and incubated for 24h at 37°C with 5% CO2. Cells were washed twice 
with phosphate buffered saline (PBS) and infected with EV71 at multiplicity of 
infection (MOI) of 1 or nil respectively. The culture media were removed and 
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replaced with 2 mL fresh RPMI 1640 medium after 1h of incubation at 37°C with 
5% CO2. The respective infected cells were harvested at 36 hours posts infection 
(hpi). The total cellular RNA of HT29 cells were extracted using the miRNeasy mini 
kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Briefly, 
the cells were lysed and homogenised using the lyses solution provided (Qiagen, 
Hilden, Germany). Total RNA were purified using the RNeasy spin column and 
eluted (Qiagen, Hilden, Germany). Harvested total RNA was quantitated using 
Nanodrop 100 spectrophotometer (ThermoScientific, Waltham, USA). 
 
mRNA microarray analysis 
Extracted total RNA were labelled with GeneChip HT 3' IVT Express Kit 
following manufacturer’s instruction. Hybridization to GeneChip PrimeView Human 
Gene Expression Array was performed in accordance to manufacturer’s 
recommendations. Every chip was scanned at a high resolution by the Affymetrix 
GeneChip Scanner 3000 according to the GeneChip Expression Analysis Technical 
Manual procedures (Affymetrix, Santa Clara, CA). Briefly, total extracted RNA 
underwent two rounds of cDNA synthesis prior to in vitro transcription to synthesise 
biotin-modified amplified RNA (Affymetrix, Santa Clara, CA). The amplified RNA 
was purified and fragment for the hybridisation onto the GeneChip PrimeView 
Human Gene Expression Array (Affymetrix, Santa Clara, CA). Raw data for the 
microarray were analysed with the Partek® Genomics Suite (Partek Incorporated, 
Saint Louis, USA) where p<0.05 is considered statistically significant.  
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cDNA synthesis and Quantitative real time polymerase chain reaction 
For the conversion of mRNA to cDNA, 1μg of the total RNA was reverse 
transcribed using the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, CA, 
USA) in accordance to the manufacturer’s instructions. Briefly, 1μg of the extracted 
RNA was mixed with enzyme reverse transcriptase and buffer to a volume of 20μl 
and subjected to thermal profile of 25ºC for 5m, 42ºC for 30m followed by 85ºC for 
5m in accordance to the manufacturer’s instructions.  
The quantitative real time polymerase chain reaction (qPCR) was performed using 
the iTaq™ Universal SYBR® Green Supermix (Bio-Rad Laboratories, CA, USA) on 
the BioRad CFX96TM Real-Time PCR system (Bio-Rad Laboratories, CA, USA). 
The primers used in this study are listed in Table 3.1. Briefly, 1μl cDNA and 1μl of 
the forward and the reverse primers were added to iTaq™ Universal SYBR® Green 
Supermix. The reaction mix was then subjected to thermal cycling profile of 
denaturation at 95ºC for 30s, followed by amplification and quantification in 40 
cycles at 95ºC for 5s followed by 60ºC for 30s. At the end of amplification cycles, 
melting temperature analysis was performed by the BioRad CFX96TM Real-Time 
PCR system (Bio-Rad Laboratories, CA, USA). Relative gene expression was 
quantified based on 2-∆∆CT method using the housekeeping gene β-actin as the 
reference gene (Livak & Schmittgen, 2001). 
 
Data analysis 
All statistical analysis was performed on GraphPad Prism Version 6.0c 
(GraphPad Software, USA). Student’s t test was used to compare two groups. p 
values of < 0.05 were considered statistically significant. 
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Table 3.1 Primers used in this study 
 
Primers 5′-3' 
EV71-VP1-Reverse GCTCTATAGGAGATAGTGTGAGTAGGG 
EV71-VP1-Forward ATGACTGCTCACCTGCGTGTT 
IL29/IFN lambda1-Forward ACCGTGGTGCTGGTGACTT 
IL29/IFN lambda1-Reverse CTAGCTCCTGTGGTGACAGA 
IFN beta1-Forward ATGACCAACAAGTGTCTCCTCC 
IFN beta1-Reverse GGAATCCAAGCAAGTTGTAGCTC 
IFN gamma1-Forward TCTTTGGGTCAGAGTTAAAGCCA 
IFN gamma1-Reverse TTCCATCTCGGCATACAGCAA 
ISG54-Forward AAGCACCTCAAAGGGCAAAAC 
ISG54-Reverse TCGGCCCATGTGATAGTAGAC 
ISG56-Forward TTGATGACGATGAAATGCCTGA 
ISG56-Reverse CAGGTCACCAGACTCCTCAC 
β-actin Forward ACCAACTGGGACGACATGGAGAAA 
β-actin Reverse TAGCACAGCCTGGATAGCAACGTA 
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3.3 RESULTS AND DISCUSSION 
Systemic analyses of host response to EV71 provide critical clues to 
understand the molecular mechanism of EV71 pathogenesis during infection of a 
human host. Regulation and alteration of the host cellular system can also be 
monitored by studying the host cellular transcriptomic change following enterovirus 
infection. Transcriptomic analysis via RNA-sequencing, mRNA microarray and PCR 
array have been previously used to analyse host gene expression (Fook & Chow, 
2010, Leong & Chow, 2006, Xu et al., 2013). However, these studies have been 
performed on rhabdomyosarcoma (RD) cells or SH-SY5Y cells, of muscle cells or 
neuronal origin respectively. In a clinical context, this may not be a good 
representative model during EV71 infection of a human host, as various studies have 
demonstrated that the gastrointestinal tract is the first site for EV71 proliferation 
(Chen et al., 2007, Chen et al., 2004, Khong et al., 2012). Considering that different 
cell types have varying cellular content, host-pathogen interaction may differ 
between cell types (Lu et al., 2011, Lui et al., 2013a, Lui et al., 2013b). We have 
previously reported a human colorectal adenocarcinoma cell line (HT29) with 
epithelioid morphology as a useful in vitro model to study the pathogenesis of EV71 
(Lui et al., 2013a). To this end, this study utilised HT29 as a model for the 
transcriptomic analysis of host response to EV71 infection.  
 
Identification of deregulated mRNAs during EV71 infection 
To identify the differentially transcribed mRNAs in HT29 during EV71 
infection, we perform mRNAs profiling using GeneChip PrimeView Human Gene 
Expression Array. Comparative mRNAs expression between EV71 infected cells and 
control non-infected cells were performed. Microarray hybridisation identified 699 
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genes being differentially expressed significantly during EV71 infection (p<0.05) 
(Figure 3.1). Using Partek® Genomics Suite, 699 differentially transcribed genes 
between EV71 infected and control non-infected HT29 were further analyses to 
generate pathways with enrichment score of <2 (Figure 3.2). These differentially 
transcribed genes were involved in critical pathways including immune response, 
stress response, metabolism, cytotoxicity, cytokines and cytoskeleton network etc 
(Figure 3.2).   
 
In response to viral infection, cells were known to induce an immunological 
response to combat invading pathogens. In particular, immune response cytokines 
IL29 / interferon (IFN)-λ1 and IFN-β1 were significantly up-regulated in EV71 
infected cells (Appendix A). The microarray results were validated using qPCR. In 
line with the microarray findings, qPCR revealed that both IL29 and IFN-β1 were 
significantly up-regulated by approximately 20 fold and 3 fold in EV71 infected cells 
respectively (Figure 3.3a and 3.3b). This is not surprising as that both IL29 and IFN-
β1 are cytokines which play important roles in host antiviral responses (Park et al., 
2012, Osterlund et al., 2005, Pagliaccetti et al., 2008). In addition, IL29 has been 
previously reported to be up regulated during viral infections such as influenza A, 
hepatitis C virus and Sendai viruses (Park et al., 2012, Osterlund et al., 2005, 
Pagliaccetti et al., 2008). A key characteristic of cytokines is the ability to interact 
with one another to establish coordinated defence mechanism against invading 
pathogens. IL29 functions by binding to a unique receptor, through a signalling 
pathway identical to IFN-β1 and IFN-γ1 receptors inducing cellular antiviral activity 
to inhibit virus replication (Park et al., 2012, Osterlund et al., 2005, Pagliaccetti et 
al., 2008). Synergetic effects between IL29, IFN-β1 and IFN-γ1 were shown to 
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promote cellular antiviral response (Park et al., 2012, Osterlund et al., 2005, 
Pagliaccetti et al., 2008). Indeed, the use of IL29, IFN-β1 and IFN-γ1 as antiviral 
treatments has been shown to inhibit various viruses including herpes simplex-1 
virus, mouse hepatitis virus type 2, human T-lymphotropic virus-1, cytomegalovirus 
and hepatitis C virus (Sainz & Halford, 2002, Pierce et al., 2005, Fuchizaki et al., 
2003, D'Onofrio et al., 1992, Sainz et al., 2005, Okuse et al., 2005, Larkin et al., 
2003). As such during EV71 infection, HT29 may up regulate cytokines such as 
IL29, IFN-β1 and IFN-γ1 (type I, II and III IFN) to induce interferon stimulated 
genes (ISG) as part of cellular antiviral response to slow down virus replication. 
 
To verify this hypothesis, we performed qPCR on IFN-gamma1 receptors, 
ISG54 and ISG56 to investigate if these genes have been up regulated during EV71 
infection. In agreement with our hypothesis, our qPCR results show significant up 
regulation of these cytokines in response to EV71 infection (Figure 3.3c, 3.4a and 
3.4b). This supports the notion that the host colorectal cells up-regulate cytokines 
such as IL29, IFN-β1 and IFN-γ1 (type I, II and III IFN) possibly by a series of JAK-
STAT signalling pathways to induce ISG such as ISG54 and ISG56 (Figure 3.5). 
However, Lei et al (2010, 2011, 2013) previously reported that EV71 3C protein 
suppressed the host immune response such as type I interferon during infection in 
RD cells (muscle cells) (Lei et al., 2010, Lei et al., 2011, Lei et al., 2013). As such, 
the mechanism whereby EV71 mediates host immune system may differ between 
cell types. To support this hypothesis, Chi et al (2013) have compared the expression 
of IFN-signalling pathway between intestinal epithelial cells and muscle cells, and 
demonstrated that intestinal cells have indeed a significant higher expression of 
cytokines in response to infection in comparison with muscle cells (Chi et al., 2013). 
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This may explain the fact it takes three times longer for the virus to kill HT29 cells in 
comparison with RD cells (Lu et al., 2011, Lui et al., 2013a). In addition, IFN 
signalling pathways such as type I interferon was previously demonstrated to play an 
important role during EV71 pathogenesis (Liu et al., 2005).  
 
Effectively, the intestinal epithelial immune system, being the initial site of 
infection plays a critical role in the disease progression and clinical prognosis. 
Impaired or immature immunity has previously been associated with increased 
morbidity and mortality in EV71 of young children and immune deficient adults (Liu 
et al., 2005). The ability to eliminate viral pathogen such as EV71 at the initial site of 
infection is critical as a weaker immune response results in a higher viral titre leading 
to a systemic spread with more serve complication (Chi et al., 2013). One of the key 
antiviral responses that the intestinal epithelial immune system utilises may be the 
type I, II and III IFN to eliminate invading EV71 (Figure 3.5). 
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Figure 3.3 Expression level of Type I, II and III IFN signalling pathways in 
response to EV71 infection. Confluent HT29 cells were infected with or without 
EV71 (MOI of 1). Total intracellular RNA were harvested 36hpi, converted to cDNA 
and measured by quantitative real time polymerase chain reaction (qPCR). (A) 
Expression of IL29/ IFN-λ1 (B) Expression of IFN-β1 (C) Expression of IFN-γ1 
(n=3, *= p values of < 0.05). 
96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Expression level of interferon stimulated genes in response to EV71 
infection. Confluent HT29 cells were infected with or without EV71 (MOI of 1). 
Total intracellular RNA were harvested 36hpi, converted to cDNA and measured by 
quantitative real time polymerase chain reaction (qPCR). (A) Expression of ISG54 
(B) Expression of ISG56 (n=3, *= p values of < 0.05). 
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Figure 3.5 Schematic illustration of the interplay between Type I, II and III IFN 
pathways and invading viral pathogen-EV71. Following EV71 infection, host 
activate Type I, II and III IFN pathways through a series of JAK-STAT signalling 
cascade to mobilise interferon stimulated genes such as ISG54 and ISG56 in attempt 
to slow down virus replication. 
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3.4 CONCLUSION 
In conclusion, this study utilised HT29 as an in vitro model to investigate the 
transcriptomic changes in human colorectal cells in response to EV71 infection. 
Human whole genome microarray was employed to monitor changes in profiles 
between EV71 infected cells and uninfected control cells. The result reveals altered 
expression of human mRNAs in selected pathways including immune response, 
stress response, metabolism, cytotoxicity, cytokines and cytoskeleton network. 
Interestingly, our results shows significant up regulation of type I, II and III IFN 
which suggest that during EV71 infection, this may be the key antiviral response 
HT29 cells undertake to eliminate invading EV71. Taken together, data from this 
study provide valuable fundamental information toward understanding of host-
pathogen interaction between human colorectal cells and invading EV71. Elucidating 
the mechanism that the virus uses to bypass host defence systems and establish 
infections will provide us with a better understanding of the pathogenesis mechanism 
of the EV71 virus and will thus aid in the development of potential antiviral 
therapeutics for HFMD patients. 
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Chapter 4: EV71 utilise host microRNAs to 
mediate host immune system 
enhancing survival during 
infection 
Abstract 
Hand, Foot and Mouth Disease (HFMD) is a self-limiting viral disease that 
mainly affects infants and children. In contrast with other HFMD causing 
enteroviruses, Enterovirus71 (EV71) has commonly been associated with severe 
clinical manifestation leading to death. Currently, due to a lack in understanding of 
EV71 pathogenesis, there are no antiviral therapeutics for the treatment of HFMD 
patients. Therefore, the need to better understand the mechanism of EV71 
pathogenesis is warranted. We have previously reported a human colorectal 
adenocarcinoma cell line (HT29) based model to study the pathogenesis of EV71. 
Using this system, we showed that knockdown of DGCR8, an essential cofactor for 
microRNAs biogenesis, resulted in a reduction of EV71 replication. We also 
demonstrated that there are miRNAs changes during EV71 pathogenesis and EV71 
utilise host miRNAs to attenuate antiviral pathways during infection. Together, data 
from this study provide critical information on the role of miRNAs during EV71 
infection. 
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4.1 INTRODUCTION 
Hand, Foot and Mouth Disease (HFMD) is a contagious viral disease that 
commonly affects infants and children, with blisters and flu like symptoms (Lui et 
al., 2013b, McMinn, 2002, McMinn, 2012, Ooi et al., 2010, Patel & Bergelson, 
2009, Solomon et al., 2010). HFMD is caused by a group of enteroviruses such as 
enterovirus 71 (EV71) and coxsackievirus A16 (CA16) (Wong et al., 2010, Ho et al., 
2011, Huang et al., 2012). However, unlike other HFMD causing enteroviruses, 
EV71 is also commonly associated with severe clinical diseases, including 
neurological diseases such as aseptic meningitis, brainstem and cerebellar 
encephalitis leading to cardiopulmonary failure and death (Chu et al., 2001, Lee et 
al., 2011, Lee & Chang, 2010, Lee et al., 2012, McMinn, 2012). Due in part to a lack 
of understanding of viral pathogenesis of EV71 causing HFMD, there are no antiviral 
therapies or vaccines approved by the United States of America Food and Drug 
Administration (FDA) to prevent HFMD infections. There is therefore a need to gain 
a better understanding of the mechanism of EV71 pathogenesis. During infection, 
viruses attenuate host gene expression to enhance their survival (Viswanathan et al., 
2010, tenOever, 2013, Taylor & Mossman, 2013, Randall & Goodbourn, 2008, 
Rajsbaum & Garcia-Sastre, 2013). Such activities include altering the cellular 
microenvironment to allow successful virus replication and evasion of the host 
immune system (Munday et al., 2012).   
 
The host innate system is the first line of defence with the interferon (IFNs) 
being a key component against viral infection (Versteeg & Garcia-Sastre, 2010, 
Thompson et al., 2011, Randall & Goodbourn, 2008, Rajsbaum & Garcia-Sastre, 
2013, Oudshoorn et al., 2012, de Weerd & Nguyen, 2012, Brennan & Bowie, 2010, 
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Boss & Renne, 2011). The release of IFNs begins with the recognition of pathogen-
associated molecular patterns (PAMPs) which include Toll like receptors (TLRs), 
NOD like receptors (NLRs), retinoic acid-inducible gene I (RIG-I) like receptors 
(Kanarek & Ben-Neriah, 2012, Brennan & Bowie, 2010). This family of cytokines 
act in an autocrine and paracrine manner to induce expression of transcription 
factors, gamma activated sequence and IFN stimulated response element and the 
consequent induction of IFN-stimulated genes (ISGs) which function to slow down 
viral infection (Versteeg & Garcia-Sastre, 2010, Thompson et al., 2011, Oudshoorn 
et al., 2012). Antiviral pathways such as the programmed cell death (apoptosis) could 
also be activated by the host cells in attempt to control the infection by limiting viral 
replication (Munday et al., 2012).  
 
Many viruses have evolved to counteract with strategies by host cells to 
establish infection. One of the mediators for such regulation includes genes that 
encode for microRNA (miRNAs). microRNAs are small single-stranded RNA 
species of approximately 20-24 bases in length that play a pivotal role in the post 
transcriptional regulation of gene expression (Sullivan & Ganem, 2005, Scaria et al., 
2006). These small RNA were first discovered in Caenorhabditis elegans, but were 
later discovered in a wide range of organisms from uni to multicellular eukaryotes 
(Ghosh et al., 2009, Lau et al., 2001, Lee et al., 1993). miRNAs are found to regulate 
many cellular functions including cell proliferation, differentiation, homeostasis, 
immune activation and apoptosis (Skalsky & Cullen, 2010, Scaria et al., 2006, 
Nathans et al., 2009, Mack, 2007, Ghosh et al., 2009). As such, miRNAs can 
contribute to the repertoire of host-pathogen interactions during infection by 
modulating and directing host and viral gene expression thereby playing a pivotal 
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role during infection. Elucidating the mechanism that the virus uses to bypass host 
defence systems and establish infections will provide us with a better understanding 
of the pathogenesis mechanism of the EV71 virus, allowing development of potent 
antiviral therapeutics for HFMD patients.  
 
In this study, we explore the role of miRNAs in the pathogenesis of EV71 
infected HT29 cells and identified key miRNA changes due to EV71 infection which 
might play a key role during EV71 pathogenesis. 
 
4.2 MATERIALS AND METHODS 
Cell culture and virus propagation 
The EV71 strain used in this study was isolated from a fatal case of HFMD 
during October 2000 outbreak in Singapore, Enterovirus 5865/sin/000009 strain from 
subgenogroup B4 (accession number 316321; hereby designated as Strain 41) ( a gift 
from Mrs Phoon Meng Chee, Department of Microbiology, National University of 
Singapore). Human colorectal cell line (HT29) (ATCC catalog no. HTB-38™) was 
maintained in Roswell Park Memorial Institute medium 1640 (RPMI) (PAA 
Laboratories, Austria) supplemented with 10% (v/v) Fetal Bovine Serum (FBS) 
(PAA Laboratories, Austria) and 2% penicillin–streptomycin (PAA Laboratories, 
Austria) at 37 °C with 5% CO2.  Human skeleton muscle cell line (RD) (ATCC 
catalog no. CCL-136™) and Human colorectal cell line (RKO) (ATCC catalog no. 
CRL-2577™) were maintained in Eagle’s minimum essential medium (EMEM) 
(PAA Laboratories, Austria) supplemented with 10% (v/v) Fetal Bovine Serum 
(FBS) (PAA Laboratories, Austria) and 2% penicillin–streptomycin (PAA 
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Laboratories, Austria) at 37 °C with 5% CO2. The virus stock was prepared by 
propagation of viruses using 90% confluent HT29 cells monolayer in RPMI with 
10% FBS at 37 °C with 5% CO2. The virus titres were determined using 50% tissue 
culture infective dose (TCID50) per millilitre (mL) according to Reed and Muench 
method (Reed & Muench, 1938).  
 
DsiRNA transfection and EV71 infection 
HT29, RD and RKO cells were seeded at a concentration of 2 × 105 cells/ml 
in 6-well plates and incubated for 8 h at 37 °C with 5% CO2. Cells were washed 
twice with phosphate buffered saline (PBS) and transfected using Lipofectamine 
RNAiMAX (Invitrogen Corporation, CA, USA) with TriFECTa™ Dicer-Substrate 
RNAi KIT (Integrated DNA Technology, Coralville, IA, USA). Briefly, 10nM of 
DGCR8 DsiRNA (NM_001190326 duplex 2), NC1, negative control duplex -
scrambled DsiRNA (NM_001190326) and TYE™ 563 DS Transfection Control, 
fluorescent-labeled transfection control duplex (NM_001190326) were used to 
transfect the cells respectively (Integrated DNA Technology, Coralville, IA, USA). 
24 h after transfection, cells were washed twice with PBS and infected with EV71 at 
multiplicity of infection (MOI) of 1. The culture media were removed and replaced 
with 2mL of fresh RPMI 1640 medium after 1 h of incubation at 37°C with 5% CO2.  
 
EV71 infection for miRNA profiling 
HT29 cells were seeded at a concentration of 5 × 105 cells/ml in 6-well plates 
and incubated for 24 h at 37 °C with 5% CO2. Cells were washed twice with 
phosphate buffered saline (PBS) and infected with EV71 at multiplicity of infection 
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(MOI) of 1 or nil respectively. The culture media were removed and replaced with 2 
mL of fresh RPMI medium after 1 h of incubation at 37 °C with 5% CO2.  
 
Total cellular RNA extraction  
The respective infected cells were harvested at 12 or 36 hours posts infection 
(hpi) respectively. The total cellular RNA from HT29, RD and RKO cells were 
extracted using the miRNeasy mini kit (Qiagen, Hilden, Germany) in accordance to 
the manufacturer’s instructions. Briefly, the cells were lysed and homogenised using 
lyses solution provided (Qiagen, Hilden, Germany). Total RNA was harvested using 
the RNeasy spin column and washed twice before elution (Qiagen, Hilden, 
Germany). Harvested total RNA was quantitated using Nanodrop 100 
spectrophotometer (ThermoScientific, Waltham, USA). 
 
miRNA microarray analysis 
The extracted total RNA was labelled with FlashTag™ Biotin HSR RNA 
Labeling Kits for the Affymetrix GeneChip miRNA array according to 
manufacturer’s instruction. Briefly, one microgram of total RNA was incubated with 
ATP and Poly A polymerase at 37 °C for 15m to add a 3′ polyA tail. A ligation 
reaction was performed to covalently attach to the miRNA population a multiple-
biotin molecule containing a 3DNA dendrimer. Labelled samples will subsequently 
be processed according to manufacturer's instructions for the Affymetrix miRNA 
Array 2.0 (Affymetrix, Santa Clara, CA). After hybridisation for 16 h at 48 °C, the 
arrays were washed and stained in an Affymetrix Fluidics station 450, then scanned 
in an Affymetrix 3000 7G scanner. Raw data for the microarray (GSE57372) was 
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analysed with Partek Genomics Suite (Partek Incorporated, Saint Louis, USA) where 
p<0.05 is considered significant. 
 
cDNA synthesis  
For the conversion of mRNA to cDNA, 1μg of the total RNA was reverse 
transcripted using RT2 First Strand kit (Qiagen, Hilden, Germany) in accordance to 
the manufacturer’s instructions. Briefly, 1 μg of the extracted RNA was first mixed 
with Buffer GE to a total volume of 10 μl for genomic DNA elimination and 
incubated at 42ºC for 5 m and on ice for 1 m. Reverse-transcription mix which 
consist of enzyme reverse transcriptase and buffer was then added to a volume of 20 
μl and subjected to thermal profile of 42 ºC for 15 m followed by 95 ºC for 5 m. 91 
μl of RNase free water was then added to each reaction in accordance to the 
manufacturer’s instructions.  
 
For conversion of microRNA to cDNA, 10 ng of the total RNA was reverse 
transcribed using the Universal cDNA Synthesis kit (Exiqon, Denmark) the 
manufacturer’s instructions. Briefly, 10ng of the extracted RNA was mixed with 
enzyme reverse transcriptase and buffer to a volume of 10 μl. The reaction mix was 
then subject to a thermal cycling profile of 25 ºC for 5 m, 42 ºC for 30 m followed by 
85 ºC for 5 m according to the manufacturer’s instructions. 
 
Quantitative real time polymerase chain reaction 
The EV71 specific primers targeting the conserved VP1 regions were 5′-
GCTCTATAGGAGATAGTGTGAGTAGGG-3′ and the reverse primer 5′-
ATGACTGCTCACCTGCGTGTT-3′ (Tan et al., 2008a). Primers for DGCR8 were 
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5′- ACTTGTGCATGTTAGCTGTGTAGA-3′ and the reverse primer 5′- 
GCTTAAGACTAGTTTACAAGACCAGAGT-3′ were designed to span exon-exon 
boundaries. The primers for the house keeping gene actin (β-ACT) used were 5′- 
ACCAACTGGGACGACATGGAGAAA-3′ and the reverse primer 5′-
TAGCACAGCCTGGATAGCAACGTA-3′. The qPCR was performed using the 
iTaq™ Universal SYBR Green Supermix (Bio-Rad Laboratories, CA, USA) on the 
BioRad CFX96 Real-Time PCR system (Bio-Rad Laboratories, CA, USA). Briefly, 
1 μl of cDNA and 1μl of the forward and the reverse primers were added iTaq™ 
Universal SYBR Green Supermix. The reaction mix was then subjected to thermal 
cycling profile of denaturation at 95 ºC for 30s, followed by amplification and 
quantification in 40 cycles at 95 ºC for 5s followed by 60 ºC for 30 s. At the end of 
amplification cycles, melting temperature analysis was performed by the BioRad 
CFX96 Real-Time PCR system (Bio-Rad Laboratories, CA, USA). Relative gene 
expression was quantified based on 2-∆∆CT method (Livak & Schmittgen, 2001). 
 
For RT2 profiler PCR array, PCR arrays were performed with customized 
PCR containing pre-dispensed primers to monitor Human antiviral response PAHS-
122ZD-2 (Qiagen, Hilden, Germany). qPCR was performed using RT2 SYBR Green 
qPCR mastermix (Qiagen, Hilden, Germany). Briefly, a total volume of 25 μl of 
cDNA and RT2 SYBR Green qPCR mastermix were added into each well of the 
Human antiviral response array 96 wells plate PAHS-122ZD-2 (Qiagen, Hilden, 
Germany) in accordance to the manufacturer’s instructions. The reaction mix was 
then subjected to thermal profile of denaturation at 95 ºC for 10m, followed by 
amplification and quantification in 40 cycles at 95ºC for 15 s followed by 60 ºC for 
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1m. At the end of amplification cycles, melting temperature analysis was performed 
by the BioRad CFX96 Real-Time PCR system (Bio-Rad Laboratories, CA, USA). 
 
For the detection of microRNA, qPCR was performed using the ExiLENT 
SYBR Green Master mix (Exiqon, Denmark) on the BioRad CFX96 Real-Time PCR 
system (Bio-Rad Laboratories, CA, USA). Briefly, 2.5 μl of cDNA and 1 μl of the 
forward and the reverse primers was added to ExiLENT SYBR Green Master mix 
(Exiqon, Denmark) according to the manufacturer’s instructions. The reaction mix 
will then subjected to thermal cycling profile of denaturation at 95 ºC for 10 m, 
followed by amplification and quantification in 40 cycles at 95 ºC for 10 s, 60 ºC for 
30 s followed by 50 ºC for 30 s. At the end of amplification cycles, melting 
temperature analysis was performed by the BioRad CFX96 Real-Time PCR system 
(Bio-Rad Laboratories, CA, USA). Primers for microRNA qPCR were designed and 
purchased from Exiqon, Denmark. U6snRNA was used as reference RNA for the 
normalization of microRNA (miRNA) qPCR data. Relative gene expression was 
quantified based on 2-∆∆CT method (Livak & Schmittgen, 2001). 
 
Western blot 
Total cellular protein for HT29 cells and control cells were collected using a 
lysis mix in mammalian cell lysis solution – CelLytic M (Sigma-Aldrich Pte Ltd, 
USA) in accordance with manufacturer’s instructions. Equal protein concentrations 
(20 μg) from each samples were added onto 10% Mini-PROTEAN TGX™ (Bio-Rad 
Laboratories, CA, USA) and separated by electrophoresis. Separated proteins were 
transferred onto nitrocellulose membrane (Bio-Rad Laboratories, CA, USA). The 
membranes were incubated with mouse anti EV71 antibody (AbD serotech, Oxford, 
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UK) or anti-tubulin antibody (Santa Cruz Biotechnology inc, California, USA) 
respectively in shaker 4 ºC overnight. The membranes were washed three times in 
Tris-buffered saline with 0.05% tween-20 and incubatted with secondary antibodies 
conjugated to horseradish peroxidase (HRP) for 30m. (ThermoScientific, Waltham, 
USA). After three washes with Tris-buffered saline and 0.05% tween-20, membrane 
was subjected to Clarity™ Western ECL Substrate (Bio-Rad Laboratories, CA, 
USA) in accordance with manufacturer’s instructions. The membranes were then 
scanned using the LI-COR C-DiGit Blot Scanner (LI-COR Biosciences, Lincoln, 
Nebraska, USA).  
Cell viability and counts  
Cell count and viability was performed at 0 h, 48 h and 72 h on the Luna 
Automated Cell Counter system (Logos Biosystem, USA) in accordance to the 
manufacturer’s instructions. Briefly, the cells were trypsinised and topped up with 
fresh media to a total volume of 1000 μl of media and 10 μl of this cell suspension 
were mixed with 10 μl of trypan blue. 10 μl of this diluted cell suspension were then 
loaded onto the Luna counting slide for analysis.  
 
Statistical analysis 
All statistical analysis was performed on GraphPad Prism Version 6.0c 
(GraphPad Software, USA). Student’s t test was used to compare two groups. p 
values of < 0.05 were considered statistically significant. 
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4.3 RESULTS 
We have previously reported a human colorectal adenocarcinoma cell line 
(HT29) with epithelioid morphology as a useful model to study the pathogenesis of 
EV71 (Lui et al., 2013a). Utilising the HT29 as a model, this study further elucidate 
the role of miRNAs during EV71 infection.  
 
Knockdown of DGCR8 resulted in the reduction of EV71 replication 
In order to characterise the role of miRNAs during EV71 pathogenesis, 
DGCR8 expression was knocked down prior to infection. HT29 cells were 
transfected with DsiRNA specific to DGCR8, an essential cofactor for miRNAs 
biogenesis. As control, HT29 cells were transfected with NC1, negative control 
duplex-scrambled DsiRNA. Knockdown of DGCR8 was verified using qPCR 
(Figure 4.1a). Transfection was shown to be successful using TYE™ 563 DS 
Transfection Control, fluorescent-labelled transfection control duplex (Figure 4.1b).   
 
miRNAs is essential for EV71 replication  
To investigate the role of miRNAs in EV71 infection, we compared EV71 
replication in miRNA-depleted HT29 cells against control cells (scrambled 
DsiRNA). Using established protocols, the kinetics of EV71 RNA synthesis in both 
infected DGCR8 knockdown cells and control cells were examined quantitatively 
using real time quantitative polymerase chain reaction (qPCR) at 36h post infection 
(hpi).  Interestingly, DGCR8 knockdown (miRNAs depleted) HT29 cells were 
unable to support EV71 proliferation compared to control cells (Figure 4.2).  There is 
a significant decrease in viral RNA between DGCR8 knockdown HT29 cell in 
contrast with control cells (scrambled DsiRNA) (Figure 4.2a). Consistent with our 
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qPCR analysis, protein analysis of viral VP1 protein representation of EV71 
replication, were shown to be highly downregulated in EV71 infected DGCR8 
knockdown cells (Figure 4.2b).  
 
To further elucidate the effect of miRNAs during EV71 infection, we asked if 
the host cells survivability was enhanced in EV71 infected miRNAs depleted cells. 
Indeed, it was observed that at 72hpi, there was a statistically significant percentage 
of living cells in EV71 infected DGCR8 knockdown cells compared to control cells 
infected with EV71 (Figure 4.2c and Figure 4.3). In order to validate our findings in 
HT29 cells, we further tested this on another colorectal cell line (RKO) and skeleton 
muscle cell line (RD) where we knocked down DGCR8 and examined the effect on 
EV71 replication (Figure 4.4). Consistent with our findings in HT29 model, EV71 is 
unable to establish infection in miRNAs depleted cells (HT29, RKO and RD cells) 
(Figure 4.2 and 4.4). 
 
Taken together, DGCR8 or rather miRNAs affected EV71 replication and 
recused its detrimental phenotype. 
 
Identification of deregulated miRNAs during EV71 infection 
To pinpoint the differentially transcribed miRNAs used by EV71 during 
infection, we performed profiling using Affymetrix GeneChip miRNA array. 
Specifically, comparative miRNAs expression between EV71 infected cells and 
control non-infected cells were performed. Microarray hybridisation identified 78 
miRNAs being differentially expressed during EV71 infection (p<0.05) (Figure 4.5 
and Appendix B).  To confirm the microarray results, relative abundance of the 
122 
 
selected miRNAs were assayed using qPCR. The expression pattern from 10 selected 
miRNAs qPCR data showed similar direction of response in microarray analysis data 
with both methodologies showing similar trends (Figure 4.6 and 4.7). This indicates 
high quality and reliability of the microarray data analysis. 
 
EV71 down regulates host immune system using host miRNAs during infection 
To understand why miRNA-depleted cells resulted in the inability of EV71 to 
established infection; we examined the expression of 84 key genes involved in the 
innate antiviral immune response between EV71 infected miRNAs depleted HT29 
cells in comparison with control cells (scrambled DsiRNA). In particular, we 
examined the host antiviral expression profile between infected DGCR8 knockdown 
cells against control cells. Using qPCR, quantitative expression of 52 antiviral genes 
from various antiviral signalling pathways such as Toll-like receptor signalling, Nod-
like receptor signalling, RIG-1-like receptor signalling and type 1 interferon 
signalling were statistically significantly up regulated in DGCR8 knockdown cells 
(Figure 4.8a, 4.8b 4.8c, 4.8d). Of note, CASP1, OAS2, DDX58, DHX58, CCL5, 
CXCL10, CXCL11, IRF7, IFBB1, ISG15, MX1 and STAT1 were increased 10-550 
fold (Figure 4.8a, 4.8b 4.8c, 4.8d). 
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4.4 DISCUSSION 
Viruses have developed highly sophisticated gene-silencing mechanisms to 
evade host-immune response in order to establish infection. One of such mediators 
used by viruses is miRNAs. miRNAs are a new paradigm of RNA-directed gene 
expression regulation which contribute to the repertoire of host-pathogen interactions 
during viral infection. Cellular miRNAs could be involved during viral infection with 
either positive or negative effects on viral replication kinetics (Berkhout & Jeang, 
2007, Lecellier et al., 2005). Indeed, computational prediction reveal that one 
miRNAs may regulate hundreds of genes, while one gene may be in turn regulated 
by hundreds of miRNAs (Gottwein & Cullen, 2008). However, the role of cellular 
miRNAs in the defence against viral infection has remained elusive. Given the scope 
of miRNA-mediated gene regulation in the mammalian system, cellular miRNAs 
may directly or indirectly affect virus pathogenesis. Cellular miRNA expression 
could be remodelled by viral infection, which can alter the host cellular 
microenvironment and attributing to both host antiviral defence and viral factors 
(Sullivan, 2008, Berkhout & Jeang, 2007, Boss & Renne, 2011, Boss & Renne, 2010, 
Skalsky & Cullen, 2010).  
 
The biogenesis of miRNAs begins with the transcription of a long primary 
transcript known as pri-miRNA by RNA polymerase II (Ghosh et al., 2009, Roberts 
& Jopling, 2010, Scaria et al., 2006, Skalsky & Cullen, 2010, Sullivan, 2008, 
Sullivan & Ganem, 2005). Pri-miRNAs are cleaved/processed by RNase III enzyme 
(Drosha), double-stranded-RNA-binding protein, (DiGeorge Syndrome Critical 
Region; DGCR8) and RNAse III-like Dicer to become functional miRNAs. In this 
study, we have demonstrated that abolishing functional miRNAs in human epithelial 
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colorectal cell line (HT29) impair EV71 replication while this was not observed in 
control cells treated with scrambled DsiRNA. On the contrary, global knockdown of 
miRNAs has been previously shown to enhance HIV-1 infection (Chable-Bessia et 
al., 2009, Triboulet et al., 2007). Knock down of DGCR8, a precursor to miRNAs 
biogensis was shown to enhance human immunodeficiency virus (HIV) replication 
(Chable-Bessia et al., 2009, Triboulet et al., 2007). This implies that EV71 utilises 
miRNAs during infection and in the absence of miRNAs, EV71 was unable to 
successfully mount the infection.  
 
Another study reported by Otsuka and colleagues showed a similar finding in 
Vesicular stomatitis virus (VSV) infection (Otsuka et al., 2007). Otsuka and 
colleagues observed that impaired miRNA production in dicer-deficient mice 
resulted in the hypersensitivity toward infection by VSV (Otsuka et al., 2007). It was 
observed there is no alteration of interferon-mediated antiviral response by dicer 
deficiency, instead the change in virus replication is due to miR-24 and miR-93 
(Otsuka et al., 2007). Otsuka and colleagues shown that miR-24 and miR-93 could 
target VSV viral protein and thus in miRNA depleted cells, VSV replication was 
enhanced in the absence of miR-24 and miR-93 (Otsuka et al., 2007).  
 
In recent years, there are reported evidence of specific host-cellular miRNAs 
modulating host-pathogen interaction (Buck et al., 2010, Cameron et al., 2008, 
Huang et al., 2007, Jopling et al., 2008, Lanford et al., 2010, Martinez et al., 2008, 
Otsuka et al., 2007, Yoshikawa et al., 2012).   Cytomegalovirus (CMV) for example 
was observed to down regulate miR-27a (Buck et al., 2010). Overexpression of miR-
27a using miRNAs mimics was shown to inhibit CMV proliferation and virus titres 
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suggesting that miR-27a or miR-27a-regulated genes plays a role during CMV 
infection (Buck et al., 2010, Wiertz et al., 1997). Hepatitis C virus (HCV), an 
enveloped RNA virus of the Flavivirus family, responsible for both acute and chronic 
hepatitis in humans induced a liver-specific cellular miRNA, miR-122 for the 
facilitation of HCV replication (Jopling et al., 2006, Jopling et al., 2008, Jopling et 
al., 2005, Randall et al., 2007, Randall & Goodbourn, 2008, Yoshikawa et al., 2012). 
It was suggested that miR-122 is a valuable target for antiviral intervention and 
therapeutics. In vivo treatment of HCV-infected chimpanzees with antisense miR-
122 successfully reduced HCV virus titres demonstrating promising antiviral 
treatment against virus induced diseases (Jopling et al., 2006, Jopling et al., 2008, 
Jopling et al., 2005, Lanford et al., 2010).  
 
Indeed, various miRNAs have been identified to play a role during EV71 
pathogenesis. Recent publications of investigations into the role of miRNA in 
enterovirus infection have reported that enterovirus-induced miRNAs such as miR-
23b, miR-296-5p, miR-141 and miR-146a play a role in EV71 replication (Ho et al., 
2011, Wen et al., 2013, Zheng et al., 2013, Ho et al., 2014). The use of miRNA 
inhibitors or mimics have demonstrated that miRNAs plays an important role in 
EV71 pathogenesis. miRNA inhibitors or mimics on these miRNAs either inhibited 
or enhanced EV71 replication during infection.  
 
In particular, our results revealed miR-548 to be significantly up regulated in 
EV71 infected cells at 36hpi in comparison with control non-infected cells. Further 
bioinformatics analysis revealed that miR-548 was involved in antiviral response 
during infection (de Weerd & Nguyen, 2012, Randall & Goodbourn, 2008, Li et al., 
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2013, Gottwein & Cullen, 2008, Boss & Renne, 2011). Consistent with our findings, 
Li and colleagues have recently identified the involvement of miR-548 in IFN 
signalling pathways during viral infection (Li et al., 2013). Li and colleagues 
demonstrated that miR-548 down-regulates host antiviral response via direct 
targeting of IFN-λ1 (Li et al., 2013).  In contrast, in EV71 infected 
rhabdomyosarcoma (RD) cells, miR-548 was observed to decrease in a time 
dependent manner (Li et al., 2013). In view that the host innate system is the first 
line of defence, with IFNs being a key player during viral infection, it is atypical that 
miR-548 was up regulated to down regulate the host immune system (Versteeg & 
Garcia-Sastre, 2010, Thompson et al., 2011, Randall & Goodbourn, 2008, Rajsbaum 
& Garcia-Sastre, 2013, Oudshoorn et al., 2012, de Weerd & Nguyen, 2012, Brennan 
& Bowie, 2010, Boss & Renne, 2011). The use of miR-548 mimics and inhibitors 
were shown to enhance or inhibit EV71 replication in RD cells respectively (Li et al., 
2013).   
 
The innate immune system has evolved an arsenal of mechanism to sense and 
destroy invading pathogens. An interesting question that arises is whether EV71 is 
able to regulate host cellular miRNA transcription and processing during infection 
thereby leading to the down-regulation of deleterious cellular miRNA and/or the up-
regulation of advantageous cellular miRNAs to enhance its replication in the host 
cells. To add to this intriguing interplay between cellular miRNAs and viral 
pathogens, Huang and colleagues have demonstrated that HIV, an enveloped RNA 
virus of the Retreoviridae family utilise host cellular miR-28, miR-125b, miR-150, 
miR-223 and miR-382 to control viral protein synthesis in order to evade host 
immune system (Huang et al., 2007). Epstein-Barr virus (EBV), a DNA virus of the 
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Herpes family, for example induce the expression of miR-29b, miR-155 and miR-
146a to mediate the down regulation of innate immune response and IFN signalling 
pathways to enhances its survival (Cameron et al., 2008, Lo et al., 2007, Xiao & 
Rajewsky, 2009). Lecellier and colleagues have shown that in primate foamy virus 
type 1 (PFV-1), overexpression of cellular miRNA miR-32 could induce an antiviral 
response to inhibit virus replication (Lecellier et al., 2005).  
 
To test this reasoning that EV71 down regulate host miRNAs during infection 
to enhance its survival, we next ask if the innate response and signalling pathways 
were altered in EV71 infected miRNA-depleted cells. Therefore, we analysed the 
expression of 84 key genes involved in the innate antiviral immune response between 
EV71 infected miRNAs depleted HT29 cells in comparison with control cells 
(scrambled DsiRNA). Quantitative analysis \ revealed 52 antiviral genes from 
various antiviral signalling pathways such as Toll-like receptor signalling, Nod-like 
receptor signalling, RIG-1-like receptor signalling and type 1 interferon signalling 
were significantly up regulated in EV71 infected miRNAs depleted HT29 cells. In 
particular, CASP1, OAS2, DDX58, DHX58, CCL5, CXCL10, CXCL11, IRF7, 
IFBB1, ISG15, MX1 and STAT1 were increased 10-550 fold. The enhanced host 
antiviral response in miRNA-depleted cells during EV71 infection may result in the 
inability for EV71 to replicate during infection (Figure 4.9). 
 
The host immune response is responsible for the eradication of invading 
pathogens, as such viruses has developed means to counteract with the induction, 
signalling and antiviral pathways (Thompson et al., 2011, Taylor & Mossman, 2013, 
Boss & Renne, 2011, Boss & Renne, 2010, Versteeg & Garcia-Sastre, 2010). RNA 
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viruses generally block and inhibit IFN and antiviral molecules detrimental to virus 
replication (Brennan & Bowie, 2010, Versteeg & Garcia-Sastre, 2010). Despite all 
the sophisticated mechanism used by viruses to inhibit host immune system, host has 
been under evolutionary pressure against viral antagonism of IFN system (Brennan 
& Bowie, 2010, Thompson et al., 2011, Boss & Renne, 2010, Versteeg & Garcia-
Sastre, 2010). Our result suggests that EV71 attenuate host miRNAs to mediate host 
immune system during infection (Figure 4.9). As a result of DGCR8 knockdown, 
EV71 is unable to regulate host miRNAs to enhance cellular microenvironment 
leading to the inability to establish infection (Figure 4.9). Notwithstanding, IFN 
signalling molecules such as type I interferon were previously demonstrated to play 
an important role during EV71 pathogenesis (Liu et al., 2005, Lui et al., 2014b). 
These results warrant further studies for the identification of specific miRNAs which 
play a pivotal role during EV71 pathogenesis specifically targeting the host antiviral 
signalling pathway.  
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Figure 4.1 Knockdown of DGCR8 using DsiRNA. (A) Relative expression of 
DGCR8 gene measured by qPCR verifying knockdown. (n=3, ****= p values of < 
0.0001) (B) Transfection Control using fluorescent-labeled transfection control 
duplex TYE™ 563 DS to monitor transfection efficiency. 
130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 miRNA depleted cells are not able to support EV71 replication. 
DGCR8 knockdown cells and control cells (scrambled DsiRNA) were infected with 
EV71 (MOI of 1).   Total intracellular RNA was harvested at 36hpi, converted to 
cDNA and measured by qPCR with primers specific to viral VP1. Total intracellular 
protein were harvested at at 36hpi and measured by Western blot (A) Relative 
expression of EV71 viral RNA measured by qPCR. (n=3, ****= p values of < 
0.0001) (B) Western blot analysis for EV71 VP1 viral protein. (C) Cell viability 
assessed at 72hpi using vital dye trypan blue. (n=3, **= p values of < 0.01). 
131 
 
 
 
 
 
 
 
 
Figure 4.3 Cell viability assessed 24h after transfection and throughout 72h post 
EV71 infection using vital dye trypan blue. (n=3, *= p values of < 0.05). 
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Figure 4.4 EV71 is unable to establish infection in both RKO and RD miRNAs 
depleted cells. DGCR8 knockdown cells and control cells (scrambled DsiRNA) in 
both RKO and RD cell line were infected with EV71 (MOI of 1).   Total intracellular 
RNA were harvested at 12hpi, converted to cDNA and measured by qPCR with 
primers specific to viral VP1. (A) Relative expression of DGCR8 gene in miRNAs 
depleted RKO cells measured by qPCR verifying knockdown. (n=3, *= p values of < 
0.05) (B) Relative expression of DGCR8 gene in miRNAs depleted RD cells 
measured by qPCR verifying knockdown. (n=3, *= p values of < 0.05) (C) Relative 
expression of EV71 viral RNA in miRNAs depleted RKO cells measured by qPCR. 
(n=3, *= p values of < 0.05) (D) Relative expression of EV71 viral RNA in miRNAs 
depleted RKO cells measured by qPCR. (n=3, *= p values of < 0.05) 
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4.5 CONCLUSION 
In conclusion, we provided evidence for an intricate physiological interplay 
between host miRNAs machinery and invading pathogen, EV71. We reported three 
salient findings. First, DGCR8, an essential cofactor for microRNAs biogenesis 
contributes to a central role during EV71 pathogenesis. We have shown that EV71 is 
not able to replicate efficiently in miRNAs depleted cells. Secondly, our results 
suggest that EV71 may remodel the cellular miRNAs composition thereby utilising 
the host cellular miRNAs to enhance cellular microenvironment for viral replication. 
Specifically, our result suggests that EV71 may be at least partially responsible for 
the up regulation of host miR-548 to enhance cellular microenvironment for viral 
replication. Thirdly, remodelling of miRNAs during EV71 infection plays a 
significant role specifically in the antiviral response. We have demonstrated that in 
EV71 infected miRNA-depleted cells, host antiviral responses from various antiviral 
signalling pathways such as Toll-like receptor signalling, Nod-like receptor 
signalling, RIG-1-like receptor signalling and type 1 interferon signalling were 
significantly upregulated in comparison with EV71-infected control cells. This may 
explain our result on the inability for EV71 to infect miRNA-depleted cells given the 
enhanced host antiviral response. Taken together, our study has provided valuable 
knowledge toward the study of host-pathogen interaction during EV71 pathogenesis 
and this could lead to future investigation for the development of antiviral 
therapeutics using miRNAs inhibitors against EV71. This will open the door toward 
novel host-defence mechanism that exists in mammalian cells as well as to the 
antiviral mechanisms employed during EV71 pathogenesis. 
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Chapter 5: Beta-actin Variant is Necessary 
for enterovirus 71 Replication 
Abstract 
Enterovirus 71 (EV71) is one of the main etiological agents of Hand, Foot and 
Mouth Disease (HFMD) and has been known to cause fatal neurological 
complications such as herpangina, aseptic meningitis, poliomyelitis-like paralysis 
and encephalitis. EV71 is endemic in the asia pacific region and causes occasional 
epidemics. In order to better understand EV71 infection, we compared the proteome 
between EV71-susceptible and EV71-resistant human rhabdomyosarcoma (RD) cell 
line. We found significant differences in the β-actin variants between the EV71-
susceptible RD cells and EV71-resistant RD cells, suggesting that β-actin, in 
association with other proteins such as annexin 2 is required in vesicular transport of 
EV71. This finding further support our previous study that actin potentially plays a 
role in pathogenesis and the establishment of the disease in HFMD. 
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5.1 INTRODUCTION 
Enterovirus 71 (EV71) is a positive sense, single stranded, non-enveloped 
RNA virus belonging to Enterovirus genus of the Picornaviridae family (Nasri et al., 
2007a, Nasri et al., 2007b). It is one of the main etiological agents of the Hand, Foot 
and Mouth Disease (HFMD) which commonly infects infants and children (Shimizu 
et al., 1999, Nasri et al., 2007a, Nasri et al., 2007b). The virus is usually spread from 
one person to another through direct contact of vesicular fluid or droplets from the 
infected or via faecal-oral route (Wong et al., 2010, Lee et al., 2009, Liu et al., 2000, 
Brown et al., 1999). Symptoms of EV71 infection include persistent high fever, 
repeated vomiting, myoclonic jerks, persistent drowsiness or sudden limb weakness 
(Lee et al., 2009, Liu et al., 2000). In addition, EV71 infection has been known to 
cause fatal neurological complications like aseptic meningitis, poliomyelitis-like 
paralysis and encephalitis (Liu et al., 2000, Shimizu et al., 1999, Brown et al., 1999).  
 
EV71 was first described in 1974 in California (USA) after it was isolated from 
a patient with central nervous system disease in 1969 (Schmidt et al., 1974).  Since 
then, there have been periodic outbreaks, epidemics and pandemics reported 
worldwide every two to three years in various countries such as Australia, China, 
Taiwan, Japan, Korea, Malaysia, Vietnam, Thailand and Singapore (Huang et al., 
2012, McMinn et al., 2001, Chu et al., 2001, Chumakov et al., 1979, Schmidt et al., 
1974). Large fatal outbreaks first occurred in Bulgaria in 1975 and subsequently re-
emerged in Hungary in 1978,  Malaysia in 1997 and Taiwan in 1998 (Solomon et al., 
2010, Lu et al., 2002, Ho et al., 1999, Nagy et al., 1982, Chumakov et al., 1979, 
Schmidt et al., 1974). In the recent years there has been several large epidemics of 
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HFMD in the Asian-Pacific region, including Singapore, resulting in  sudden deaths 
among young children due to EV71 infections (Singh et al., 2002, Chu et al., 2001). 
Although EV71 has been widely studied, the exact mechanism of pathogenesis 
remains unknown with particular debates on the mode of entry and viral shuttling in 
the host cell.  
 
In order to better understand EV71 infection, we performed proteomic analyses 
between EV71-susceptible and EV71-resistant human rhabdomyosarcoma (RD) cell 
line, using 2-dimensional electrophoresis (2DE).  
 
5.2 MATERIALS AND METHODS 
Infection of Cell Line  
The RD cell line (ATCC® catalog no. CCL-136™) was maintained in T75 
flasks using Minimum Essential Medium (MEM) supplemented with 10% fetal 
bovine serum and 2% penicillin–streptomycin at 37°C with 5% CO2 in a humidified 
incubator. The EV71 resistant cells were obtained by continuous passaging to an 
estimated 100 times. Cells were confirmed to be resistant by their inability to show 
cytopathic effects after infection with EV71 for 2 days (data not shown). The 
EV71viral strain used was 5865/sin/000009 (accession number 316321; designated 
as Strain 41) isolated from a fatal case from a HFMD patient during the outbreak in 
Singapore in October 2000. When seeded cells reach approximately 95% confluency, 
they were infected with the virus at a MOI of 10 and harvested 2 hours post 
infection. 
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Protein Extraction and 2-Dimensional Electrophoresis  
Cellular proteins were extracted using ProteoExtract Complete Mammalian 
Proteome Extraction Kit (Merck, Darmstadt, Germany) according to the 
manufacturer's instruction. The samples were then used to perform two-dimensional 
gel electrophoresis (2DE). Protein concentration were first quantitated using 
Nanodrop 100 spectrophotometer (ThermoScientific, Waltham, USA) and then 
diluted to 100mg/ml with rehydration buffer (Bio-Rad Laboratories, CA, USA) 
before applying it to the pH 4-7 ReadyStrip IPG Strips (11cm, Bio-Rad Laboratories, 
CA, USA). After a 12 hours passive rehydration process, isoelectric focusing (IEF) 
was performed using the Protean IEF cell (Bio-Rad Laboratories, CA, USA) at the 
following conditions; 250 V for 20 min with linear ramp, 8,000 V for 2.5 hours with 
linear ramp and finally 8,000 V for 25,000 v-hours with rapid ramping.  
 
After IEF, the IPG strips were equilibrated with equilibration buffers (Bio-
Rad Laboratories, CA, USA) before applying it to the second-dimensional SDS-
PAGE at 200 V for 65mins using 12.5% Tris–HCl Criterion gel (Bio-Rad 
Laboratories, CA, USA). After gel electrophoresis, the gels were stained with 
InstantBlue ultrafast protein stain (ExpedeonTM, Cambridge, UK) for 2 hours before 
imaging them using VersaDocTM Imaging System (4000MP, Bio-Rad Laboratories, 
CA, USA). Protein spots of interest were excised and washed twice with water as 
previously described by (Lee et al., 2011). The gels were first destained in 100μl of 
50mM ammonium bicarbonate / 50% (v/v) acetonitrile for 5 min. The destaining 
stage was then repeated twice followed by an addition of 50μl acetonitrile. Reduction 
was then performed by covering the gel in freshly prepared 100mM ammonium 
bicarbonate containing 10mM DTT after drying down using a vacuum centrifuge. 
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Following incubation at 56°C for 1 hour, alkylation was performed using 55mM 
iodoacetamide (Sigma Aldrich, St Louis, USA) in 100 mM ammonium bicarbonate. 
The gel was subsequently dehydrated with acetonitrile and dried with a vacuum 
centrifuge. Digestion was performed with the use of 12.5ng/μl of sequencing grade 
modified trypsin (Promega, Wisconsin, USA) in 50mM ammonium bicarbonate and 
incubated for 30 min at 4°C. The peptides were extracted three times using 25μl of 
5% formic acid in 50% aqueous acetonitrile. The extracts were incubated for 10 min 
and concentrated by centrifugation. 
 
The trypsin-digested peptides were mixed with freshly prepared matrix 
solution (10mg of CHCA in 1 ml of 0.5% TFA and 50% acetonitrile) in a 1:1 (v/v) 
ratio. The peptides were then analysed using the ABI 4700 Proteomics Analyzer with 
TOF/TOF™ optics (Applied Biosystems, CA, USA). Peptide tolerance was set at 
100 ppm with fixed modification of cysteine carbamidomethyl, variable modification 
of methionine oxidated and permitted missed cleavage of up to 1. Trypsin cleavage 
of the protein is at the C-terminal side of KR unless next residue is P. The proteins 
were identified by searching in the National Center for Biotechnology Information 
nonredundant (NCBInr) database using MASCOT program 
(http://www.matrixscience.com). The experiment was performed with triplicates to 
ensure reproducibility. 
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5.3 RESULTS AND DISCUSSION 
Comparison of the proteomes of EV71-susceptible and EV71-resistant RD cell 
lines showed a significant difference (Figure 5.1). In particular, two variants of β-
actin, labelled as β1 (BAD96752.1, BLAST score 785, identity 100%) and β2 
(BAD96645.1, BLAST score 721, identity 93%), were found in the EV71-
susceptible RD cells, compared to EV71-resistant RD cells that contains only one 
variant β1. The variant form of actin, β1 and β2 differ from each other by a domain 
comprising of ATP, gelsolin and profiling binding sites that spans 24 amino acids. In 
addition, the intensity of γ-actin (NP_001605.1, BLAST score 750, identity 100%) 
and β-actin variant β1 were also shown to be lower in the EV71-resistant RD cell.  
 
Although the specific function of the different β-actin variants in response to 
EV71 infection awaits discovery, it is tempting to propose that EV71 infection is 
dependent on a specific variant of β-actin. For example, viruses such as adenovirus 
and HIV were reported to enter host in an actin-dependent manner (Ploubidou & 
Way, 2001). Furthermore, an actin-binding protein, annexin 2, was previously 
reported to bind to the VP1 capsid protein of EV71 and is necessary for the 
propagation of infection (Yang et al., 2011).  
 
Annexin 2 binds to cytoplasmic F-actin and is responsible for organization of 
cytoplasmic actins and intracellular vesicular transport (Lee et al., 2011, Hayes et al., 
2006, Gerke & Moss, 2002). Therefore, we proposed that β2 is one of the actin 
isoforms that annexin 2 binds to and possibly harnesses for vesicular transport in 
normal cell processes. In the EV71-resistant cells, the loss of β2 variant result in the 
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failure of the virus to be transported into the cytoplasm after binding to annexin 2. 
The ability of EV71-resistant cells to survive and retain its morphology might also be 
due to the presence of other cytoplasmic actins such as γ-actin and β-actin variants. 
This finding further support our previous report in which actin plays a role in 
pathogenesis and the establishment of the disease in an in vitro system (Lee et al., 
2011). 
 
In addition, Hussain and colleagues (2011) also demonstrated that the 
cytoskeletal system comprising both actin and microtubules were involved endocytic 
kinetics (Buss et al., 2001, Durrbach et al., 1996, Flanagan & Lin, 1980, Hussain et 
al., 2011). The knockdown of genes such as ARPC5, ARRB1, and WASF1 that were 
important in actin polymerisation, and the use of actin disrupting drug such as 
cytochalasin B, have resulted in the decrease in EV71 replication kinetics (Buss et 
al., 2001, Durrbach et al., 1996, Flanagan & Lin, 1980, Gerke & Moss, 2002, Hayes 
et al., 2006, Hussain et al., 2011, Ploubidou & Way, 2001, Soldati & Schliwa, 2006, 
Yang et al., 2011). 
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Figure 5.1  Proteome of EV71 infection-resistant and susceptible RD cells. (A) 
Proteome of mock infected RD cells. (B) Proteome of EV71 infected RD cells 
harvested at 2hpi. (C) Proteome of EV71 infection resistant RD cells harvested at 
2hpi. γ denotes γ-actin, β1 and β2 denotes β-actin variants . 
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5.4 CONCLUSION 
In conclusion, we demonstrated that RD cells resistant to EV71 infection lack a 
variant of β-actin, compared to EV71-susceptible RD cells. EV71 infection may be 
actin dependent and might involve an actin-binding protein, annexin 2. The further 
characterisation of the identified protein in this study may pave way for the 
elucidation of the mechanism of pathogenesis of EV71 in HFMD and uncover 
antiviral therapeutics targets for the treatment of HFMD patients. 
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Chapter 6: Droplet Digital PCR as a useful 
tool for the quantitative 
detection of Enterovirus71 
Abstract 
Hand, Foot and Mouth Disease (HFMD) is a contagious viral disease that 
frequently affects infants and children and present with blisters and flu-like 
symptoms. This disease is caused by a group of enteroviruses such as enterovirus 71 
(EV71) and coxsackievirus A16 (CA16). However, unlike other HFMD causing 
enteroviruses, EV71 have also been shown to be associated with more severe clinical 
manifestation such as aseptic meningitis, brainstem and cerebellar encephalitis which 
may lead to cardiopulmonary failure and death. Clinically, HFMD caused by EV71 
is indistinguishable from other HFMD causing enteroviruses such as CA16. 
Molecular diagnosis methods such as the use of real-time PCR has been used 
commonly for the identification of EV71. In this study, two platforms namely the 
real-time PCR and the droplet digital PCR were compared for the detection 
quantitation of known EV71 viral copy number. The results reveal accurate and 
consistent results between the two platforms. In summary, the droplet digital PCR 
was demonstrated to be a promising technology for the identification and 
quantitation of EV71 viral copy number. 
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6.1 INTRODUCTION 
Enterovirus71 (EV71) is a positive sense, single stranded, non-enveloped RNA 
virus of the Picornaviridae family (Nasri et al., 2007a, Nasri et al., 2007b). EV71 is 
one of the main etiological agents for Hand Foot and Mouth Disease (HFMD) that 
commonly affects infants and children (Lui et al., 2013b, McMinn, 2002, McMinn, 
2012, Ooi et al., 2010, Patel & Bergelson, 2009, Solomon et al., 2010). This disease 
is caused by a group of enteroviruses and is usually self-limiting, characterised by 
various symptoms such as fever, rashes, poor appetite and multiple ulcers in mouth 
(Wong et al., 2010, Ho et al., 2011, Huang et al., 2012). However, unlike other 
HFMD causing enteroviruses, EV71 been commonly associated with severe clinical 
diseases, including neurological diseases such as aseptic meningitis, brainstem and 
cerebellar encephalitis leading to cardiopulmonary failure and death (Chu et al., 
2001, Lee et al., 2011, Lee & Chang, 2010, Lee et al., 2012, McMinn, 2012). 
Clinically, HFMD caused by EV71 is indistinguishable from other HFMD causing 
enteroviruses such as coxsackievirus A16 (CA16) (Lui et al., 2013b, McMinn, 2002, 
McMinn, 2012, Ooi et al., 2010, Patel & Bergelson, 2009, Solomon et al., 2010, Lui 
et al., 2014a, Lui et al., 2014b). 
 
Currently, the gold standard for identification of enteroviruses involves 
propagation by cell culture followed by neutralisation with specific antisera to 
confirm the serotype (Tan et al., 2006, Tan et al., 2008b). However, this procedure is 
limited by its long turnaround time which may take a few weeks. Furthermore, some 
enteroviruses may proliferate sub-optimally in cell cultures, require several passages 
or may not be typeable (Tan et al., 2006, Tan et al., 2008a, Tan et al., 2008b). Recent 
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technological advances have resulted in the development of molecular methods e.g. 
such as PCR and real-time PCR, which are more sensitive and have shorter 
turnaround time (Mackay et al., 2002). Quantitative real-time PCR (qPCR) has been 
widely implemented and use to determine viral load in both clinical and research 
laboratories (Mackay et al., 2002).  
 
Over the past two decade, fluorescence based qPCR chemistry have 
revolutionised nucleic acid diagnostics and become the gold standard for quantitation 
of viral load (Henrich et al., 2012, Hayden et al., 2013). Quantitative determination 
of viral load has been used to monitor the efficiency of antiviral therapy and to 
determine changes in that therapy (Hindson et al., 2013, McDermott et al., 2013). 
Rising viral burden has been used as a trigger for pre-emptive treatment to prevent 
symptomatic infection (Henrich et al., 2012, Hayden et al., 2013). Although qPCR 
has made major impact in the advance of disease diagnostics, this technology has 
notable limitation (Palmer, 2013, Sanders et al., 2013).  
 
Quantitative determination of the viral load in the real-time PCR cycler is 
dependent on  a series of known standards across a linear range compared to an 
unknown sample to determine the concentration to that of the calibration curve 
(Henrich et al., 2012, Hayden et al., 2013, Sanders et al., 2013, Sedlak & Jerome, 
2013). However, the variation in performance and material in the assay lead to 
disagreement between different laboratories (Henrich et al., 2012, Hayden et al., 
2013, Sanders et al., 2013, Sedlak & Jerome, 2013). The use of international 
standards made by the World Health Organisation (WHO) mitigates the issue 
however these standards are only available for a few common targets (Hayden et al., 
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2013). As such, Droplet digital PCR (ddPCR), an emerging nucleic acid detection 
methodology that provides absolute quantitation of targeted sequence would be a 
useful tool to resolve this issue. This method relinquishes the need for 
calibration/standard curve and the reliance of rate-based measurement (Ct values) 
(Hayden et al., 2013). Since the establishment of this technology, this platform has 
been used to determine the presence of microorganisms such as HIV, 
cytomegaloviruses and other viral pathogens in patients to monitor antiviral 
therapeutics and the quality of water (Henrich et al., 2012, Hayden et al., 2013, 
Palmer, 2013, Strain et al., 2013, Racki et al., 2014). The objective of this study is to 
evaluate if ddPCR is a comparable platform for the detection and quantitation of 
EV71. 
 
6.2 MATERIALS AND METHODS 
Quantitation of EV71 
The standard used in this study was generated and used previously in the 
laboratory (Tan et al., 2006). The EV71 strain used in this study was isolated from a 
fatal case of HFMD during October 2000 outbreak in Singapore, Enterovirus 
5865/sin/000009 strain from subgenogroup B4 (accession number 316321; hereby 
designated as Strain 41). Briefly the standard was generated by conventional PCR to 
amplify a 204 bp VP1 fragment using forward primer 5′-
GAGAGTTCTATAGGGGACAGT-3′, and the reverse primer 5′- 
AGCTGTGCTATGTGAATTAGGAA-3′ from within the VP1 region of EV71 
(nt2466 to nt2669). The PCR product (204bp) was then cloned into the pGEM-T 
plasmid vector and subsequently transformed into E.coli JM109 competent cells 
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(Promega, USA). RNA was synthesized in vitro from the recombinant plasmids and 
the concentration was measured spectrophotometrically at 260nm. The number of 
viral copies was then calculated. A series of ten-fold dilutions were then prepared, 
yielding a series of viral copies ranging from 2.5 X 100 copies to 2.5 X 107 copies.  
 
Quantitative real time polymerase chain reaction  
The quantitative real time polymerase chain reaction (qPCR) was performed 
using the iQ™ Multiplex Powermix (Bio-Rad Laboratories, CA, USA) on the 
BioRad CFX96TM Real-Time PCR system (Bio-Rad Laboratories, CA, USA). The 
EV71 specific primers targeting the conserve VP1 regions were 5′-
GAGAGTTCTATAGGGGACAGT-3′, Taqman probe 5′-HEX-
GATGACTGCTCACCTGTGTGTTTTGACC-BHQ-1 and the reverse primer 5′- 
AGCTGTGCTATGTGAATTAGGAA-3′ (Tan et al., 2006). Briefly, standard of 
viral copies ranging of from 2.5 X 100 copies to 2.5 X 106 copies were added with 
primers and probe to iQ™ Multiplex Powermix (Lui et al., 2013a, Lui et al., 2013b, 
Tan et al., 2008a, Tan et al., 2008b). The reaction mix was then subjected to thermal 
profile of denaturation at 95ºC for 10m, followed by amplification and quantification 
in 40 cycles at 95ºC for 10s, 60ºC for 30s followed by 50ºC for 30s. At the end of 
amplification cycles, melting temperature analysis was performed by the BioRad 
CFX96TM Real-Time PCR system (Bio-Rad Laboratories, CA, USA).  
 
Droplet digital PCR 
The droplet digital polymerase chain reaction (ddPCR) was performed using 
the ddPCR mastermix (Bio-Rad Laboratories, CA, USA) on the BioRad QX100 
droplet digital PCR system (Bio-Rad Laboratories, CA, USA). Briefly, standard of 
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viral copies ranging of from 2.5 X 100 copies to 2.5 X 103 copies were added with 
primers and probe to the ddPCR in a final volume of 20 μl in accordance to the 
manufacturer’s instructions (Bio-Rad Laboratories, CA, USA). The reaction mixture 
was then processed with a 70 μl of droplet generation oil (Bio-Rad Laboratories, CA, 
USA) using the droplet generator (Bio-Rad Laboratories, CA, USA). The droplets 
generated were then transferred into a 96 well plate (Eppendorf, Germany) and PCR 
amplification was performed with a thermal cycling profile of denaturation at 95ºC 
for 10m, followed by 40 cycles at 94ºC for 30s, 60ºC for 60s followed by 98ºC for 
10m on a T100 thermal cycler (Bio-Rad Laboratories, CA, USA). Finally, the plate 
was loaded onto the droplet reader (Bio-Rad Laboratories, CA, USA) and the data 
was generated and analysed using the QuantaSoft analysis software (Bio-Rad 
Laboratories, CA, USA).  
 
Data analysis 
GraphPad Prism Version 6.0c (GraphPad Software, USA) was used to 
generate standard curve from real-time PCR and ddPCR data. All statistical analysis 
was performed on GraphPad Prism Version 6.0c (GraphPad Software, USA). 
 
6.3 RESULTS 
Viral load testing procedures has been used extensively in research laboratories 
and are now integrated to a diverse setting ranging from drug companies to clinical 
diagnostics laboratories. Quantitative values have been used to monitor the efficacy 
of antiviral treatment and/or to determine changes in the therapy (Sedlak & Jerome, 
2013, Kiselinova et al., 2014).  Despite the advances and the use of a highly 
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established platforms like real-time PCR, challenges in viral load testing remains due 
to the intrinsic limitation of the method which are central to the issues of precision, 
accuracy and standardisation (Hayden et al., 2013, Hindson et al., 2013, Sanders et 
al., 2013, Sedlak & Jerome, 2013, Strain et al., 2013, Kiselinova et al., 2014). 
ddPCR, a direct measurement of target molecules which relinquishes the need for 
calibration/standard curve and obviates the need for developing costly international 
standards is an attractive tool for viral load testing (Henrich et al., 2012, Sanders et 
al., 2013, Sedlak & Jerome, 2013).  
 
To investigate if ddPCR is a comparable platform for the detection and 
quantitation of EV71, real-time PCR and ddPCR were performed using known 
standards of EV71 (Tan et al., 2006, Tan et al., 2008b). Known standards of EV71 
viral copies were used for the determination of linear regression correlation 
coefficients (R2) for the log transformed copy number obtain from both real-time 
PCR and ddPCR data. The expected copy numbers measured both methods from 
real-time PCR and ddPCR shows R2 values (close to 1) of 0.9951 and 0.9923 
respectively (Figure 6.1 and 6.2). ddPCR was performed by partitioning the whole 
PCR reaction into 20,000 droplets. Each droplet would ideally contains 1 or less 
copies of targeted DNA. Following PCR amplification, enumeration of both the 
fluorescence and non- fluorescence droplets would allow the absolute quantification 
of target molecules in the original sample. An example of the visual readout of 
positive and negative individual ddPCR was generated using QuantaSoft analysis 
software (Bio-Rad Laboratories, CA, USA) (Figure 6.3).  
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6.4 DISCUSSION  
One of the key limitations of ddPCR in comparison to real-time PCR is the 
need to perform dilution to samples as concentration of more than 75,000 copies of 
target molecules lead to significant loss of linearity at high concentration/ 
“overloading” (Hayden et al., 2013, Henrich et al., 2012). In order to solve this issue, 
ddPCR was performed on standards ranging from 2.5 X 100 copies to 2.5 X 103 
copies (Figure 6.2 and 6.3). Despite this limitation, ddPCR is a promising platform to 
monitor EV71 viral replication as it show good correlation to the real-time PCR. The 
large scale partitioning involved in ddPCR allows a greater precision and sensitivity 
in comparison with real-time PCR (Hayden et al., 2013).  
 
The positive counts could then be used together with the Poisson’s distribution 
to determine a direct high confidence measurement of the targeted molecules 
(Hindson et al., 2013, Palmer, 2013, Sanders et al., 2013, Kiselinova et al., 2014, 
Racki et al., 2014). In addition, partitioning reactions in picoliter droplet allow 
ddPCR to have less interference with PCR inhibitors and be able to handle larger 
amount of input DNA (Sanders et al., 2013). As a result, ddPCR is a promising 
platform for the investigation of low viral count in diagnostics. Other studies on low 
viremia in HIV-patients demonstrated that the low detection of HIV-1 viral load as a 
useful tool in the prediction of the retroviral therapy in HIV-infected patients 
(Henrich et al., 2012, Kiselinova et al., 2014, Palmer, 2013).  
 
The move toward absolute quantitation of viral load is driven by the need to 
monitor the efficiency of antiviral therapy without the variability in material and the 
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availability international standards. In this study, ddPCR platforms was demonstrated 
to be generally comparable to real-time PCR for the detection and quantitation of 
EV71 viral copy number. 
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Figure 6.1  Quantitative analysis of real-time TaqMan PCR for the detection of 
EV71. The standard curve was obtained by plotting the Ct values against the starting 
concentration. The correlation coefficients (R2) and the linear equation are as shown 
(n=3, *= p values of < 0.05). 
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Figure 6.2  Quantitative analysis of ddPCR for the detection of EV71. The 
standard curve was obtained by plotting the positive count against the starting 
concentration. The correlation coefficients (R2) and the linear equation are as shown 
(n=3, *= p values of < 0.05). 
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Figure 6.3 Visual representation of ddPCR results for known EV71 standards 
after flow enumeration. Positive droplets (Upper cluster) and negative droplets 
(lower cluster) are shown for 4 serially diluted EV71 standards and negative control 
(n=3). The Y axis represents the fluorescent intensity and X axis represents the total 
number of event in each dilution.  
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Chapter 7: General Discussion 
7.1 OVERALL DISCUSSION 
Over the past few decades, with the near eradication of poliovirus, EV71 has 
emerged to become the most important of the neurotropic enteroviruses (Huang et 
al., 2012, Lee et al., 2012, Wu et al., 2010). Since its first discovery in 1974 in 
California (USA), after being isolated from patients with central nervous system 
disease in 1969, EV71 has periodically been reported worldwide (Schmidt et al., 
1974, Chumakov et al., 1979, McMinn et al., 2001, Huang et al., 2012). Outbreaks 
of disease caused by EV71 (HFMD) occurs every two to three years in countries 
including Australia, China, Taiwan, Japan, Korea, Malaysia, Vietnam, Thailand and 
Singapore (Schmidt et al., 1974, Chumakov et al., 1979, McMinn et al., 2001, 
Huang et al., 2012). Although the consistent presence and outbreaks of HFMD push 
for an urgent need to develop a vaccine or antiviral therapies against enteroviruses,  
there are no available antiviral therapies or vaccines approved by the United States of 
America FDA to prevent HFMD infections (Pourianfar et al., 2012, McMinn et al., 
2001, Tan et al., 2007a, Tan et al., 2007b, Tan et al., 2010).  
 
The ability to further understand the pathogenesis of EV71 has been 
hampered by the lack of a relevant infection model in humans for this enterovirus. 
Although in vivo models of viral infections using rhesus and cynomolgus monkeys 
have been reported with EV71, the use of these models is not highly relevant at the 
experimental level as only approximately 10% of the infected animals develop 
neurological complications and this finding is in agreement with epidemiological 
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data (Khong et al., 2012, Ooi et al., 2009, Ooi et al., 2007). Notwithstanding, the use 
of primate models has been limited due to economical and ethical reasons 
(Hashimoto & Hagiwara, 1983, Khong et al., 2012, Liu et al., 2011, Nagata et al., 
2004, Zhang et al., 2011).  
 
The use of a mouse model of EV71 infection has also been reported using 1 
day old mouse neonates subjected to high doses of EV71 (Chen et al., 2007, Sasaki 
et al., 1986, Tan et al., 2007b). Although results from such studies do provide novel 
insight into EV71 infections of host cells, they might not accurately mimic the actual 
EV71 pathogenesis mechanisms used by the virus in a human host (Khong et al., 
2011, Khong et al., 2012). The maturity of the immune system using such models 
also needs to be taken into consideration (Khong et al., 2011, Khong et al., 2012). In 
addition, this murine model is also not suitable for EV71 drug testing as the 
susceptibility window is only a few days and passive immunity from the mothers in 
combination with the high dosage of EV71 as well as the size of a neonatal mouse 
makes it a less than ideal model for studying EV71 pathogenesis (Khong et al., 2011, 
Khong et al., 2012). Studies of EV71 frequently make use of in vitro models using 
human and animal cell lines such as rhabdomyosarcoma (RD), HeLa, Vero and 
Primary Monkey Kidney (D P Schnurr., 1999). These cells were derived from 
various human tissues including muscle, cervix and kidney. However, the natural 
route of transmission of EV71 is postulated as being by direct contact of infected 
vesicular fluid via the faecal-oral route (Wong et al., 2010, Lee et al., 2009, Liu et 
al., 2000, Brown et al., 1999). EV71 was shown in vivo (mice) to replicate within the 
gastrointestinal tract, bypass the gut barrier and infect into the skeletal muscle cell 
before entering into the bloodstream and the central nervous system (Wong et al., 
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2010, Lee et al., 2009, Liu et al., 2000, Brown et al., 1999). Taking into 
consideration that the gastrointestinal tract is the initial site of infection, we 
hypothesised that it is more relevant and necessary to study EV71 using an in vitro 
model using cells (e.g. HT29) derived from the human gastrointestinal tract. 
 
The kinetics of viral replication plays an important role in the understanding 
of viral pathogenesis (Baccam et al., 2006, Chang et al., 2006, Major et al., 2004). 
The replication kinetics of viruses such as hepatitis C, Nipah and influenza have been 
reported in various studies and have provided valuable information, particularly 
regarding responses to antiviral therapeutics, that can contribute to the understanding 
of host-pathogen interactions (Baccam et al., 2006, Chang et al., 2006, Major et al., 
2004). By comparison, the only information on the replication kinetics of EV71 was 
reported by Lu et al (2011) who demonstrated that EV71 proliferated in an in vitro 
model of rhabdomyosarcoma (RD) muscle cells (Lu et al., 2011). In a clinical 
context, this human muscle cell model may not be a good representative model for 
EV71 infections of humans considering gastrointestinal tract is the initial site of 
infection. In Chapter two, we sought to set up an EV71 infection model using human 
colorectal cells (HT29) and we succeeded in establishing EV71 replication kinetics 
as evidence by results presented in Chapter two of this thesis. We demonstrated that 
upon EV71 infection of human epithelial colorectal cancer cells (HT29), significant 
cell death only occurs at 72hpi. This varies from the rhabdomyosarcoma (RD) cells 
previously reported by Lu et al (2011) where most host cell death occurred within 
24hpi with EV71.  
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Similarly Chen et al (2007) and Khong et al (2012) proposed that skeletal 
muscle cells compared to other cell types are more effective in supporting viral 
replication which allow persistent enterovirus infection to represent viral source of 
entry into the central nervous system (CNS) (Chen et al., 2007, Khong et al., 2012). 
In contrast to EV71 RNA synthesis, RNA was first detected at 12hpi while viral 
protein synthesis was only observed at a later stage during the infection. This may be 
possibly due to the translation time required. Lu et al (2011) showed a similar trend 
where virus RNA was first detected at 3hpi while virus protein was observed at 6hpi 
in the RD model. Correlating to HFMD, the onset of disease and the incubation 
period for HFMD is between three to seven days (Khong et al., 2012, Ooi et al., 
2010, Ooi et al., 2009, Ooi et al., 2007). This may correspond to the number of days 
the virus requires to pass through the gastrointestinal tract before spreading 
throughout the body (Khong et al., 2012, Ooi et al., 2010, Ooi et al., 2009, Ooi et al., 
2007). Therefore the in vitro model of EV71 infection of the human epithelial 
colorectal cell line (HT29) may be more clinically relevant than the EV71-RD model 
for studying the pathogenesis of this virus and may more closely mimic what occurs 
in vivo in human infections with this enterovirus.  
 
Receptor binding is another essential and vital process of the virus infection 
of host cells (Patel & Bergelson, 2009, Tan et al., 2013, Yamayoshi et al., 2012). 
Host cellular receptors therefore play an important role in the pathogenicity of 
viruses, since viruses have been found to use multiple receptors for entry into 
susceptible host cells (Patel & Bergelson, 2009, Hayes et al., 2006, Yamayoshi et al., 
2009). Thus the identification and characterisation of cellular receptors displayed on 
host cells for viral attachment would also be likely to be important to assist in our 
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understanding of EV71 pathogenesis. One host cell receptor, defined as Scavenger 
Receptor Class B, member 2 (SCARB2) was first reported by Yamayoshi et al., 
(2009) to be a receptor for all EV71 strains and expressed at the sites of EV71 
replication in vivo (Hayes et al., 2006, Yamayoshi et al., 2009). SCARB2 is 
composed of 478 amino acids and belongs to the CD36 family of cell receptors 
(Yamayoshi et al., 2012). SCARB2 is commonly found in abundance on the 
lysosomal membrane of the cell and it assists in internalising the EV71 virus in host 
cells via clathrin-mediated endocytosis (Hussain et al., 2011, Lui et al., 2013b, 
Yamayoshi et al., 2012).  In line with this, we detected the presence of SCARB2 in 
our EV71-HT29 in vitro model, data that further supports our proposal for the use of 
the HT29 cell line as a viable in vitro model to more closely mimic EV71 
pathogenesis in vivo.  
 
During infections of susceptible host cells, viruses can regulate the expression 
of certain host genes to enhance their survival (Scaria et al., 2006, Ghosh et al., 
2009, Roberts & Jopling, 2010). Such activities can include viral regulation of host 
genes that may alter the cellular microenvironment to allow the virus to successfully 
replicate and evade the host immune system (Scaria et al., 2006, Ghosh et al., 2009, 
Roberts & Jopling, 2010). Elucidating the mechanism(s) that viruses use to bypass 
host defence systems and establish infection is likely to provide us with a better 
understanding of the pathogenesis mechanisms of the EV71 virus and aid in the 
development of antiviral therapeutics with higher efficacy for HFMD patients. 
Systemic analyses of host responses to EV71 infections provide us with critical clues 
to understand the molecular mechanisms of EV71 pathogenesis during infections of 
human hosts. Regulation and alteration of the host cellular system can also be 
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elucidated by examining changes in the host cellular transcriptomes following EV71 
infection. Transcriptomic analysis via RNA-sequencing, mRNA microarray and PCR 
array have previously been used to analyse the expression of host genes following 
viral infections (Fook & Chow, 2010, Leong & Chow, 2006, Xu et al., 2013). Again, 
these studies have been done using rhabdomyosarcoma (RD) cells or SH-SY5Y 
cells, of muscle cells and neuronal origin respectively. Although various pathways 
were found to be altered during EV71 infection of these afore-mentioned host cells, 
in a clinical context, these may not be good representative models for EV71 infection 
of humans, as the gastrointestinal tract is the first in vivo site for EV71 proliferation 
(Chen et al., 2007, Chen et al., 2004, Khong et al., 2012).  
 
To investigate the regulation and alteration of host cellular systems following 
viral infection and replication in vitro, we used our HT29-EV71 in vitro system to 
generate data to provide an in-depth transcriptomic analysis to elucidate the host-
pathogen interaction between our established human colorectal cells and invading 
EV71. The results of these investigation are presented and discussed in Chapter 
Three. Comparing the mRNA expression between EV71-infected host cells and non-
infected host cells identified 699 genes that were significantly differentially 
expressed during EV71 infection (p<0.05). These differentially expressed genes were 
involved in critical pathways in the host cells including pathways involved in 
immune response, stress response, metabolism, cytotoxicity, cytokines and 
cytoskeleton network. In particular, expression of genes for IL29/IFN-λ1, IFN-β1 
and IFN-γ1 (type I, II and III IFN) were significantly up regulated.  
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A key characteristic of cytokines is the ability to interact with one another to 
establish coordinated defence mechanism against invading pathogens. IL29 functions 
by binding to a unique receptor through a pathway identical to IFN-β1 and IFN-γ1 
receptors, inducing cellular antiviral activity to inhibit virus replication (Park et al., 
2012, Osterlund et al., 2005, Pagliaccetti et al., 2008). Synergetic effects between 
IL29, IFN-β1 and IFN-γ1 were shown to promote cellular antiviral responses (Park et 
al., 2012, Osterlund et al., 2005, Pagliaccetti et al., 2008).  Indeed, the use of IL29, 
IFN-β1 and IFN-γ1 as antiviral treatments has been shown to be able to successfully 
inhibit replication in various viruses, both in vitro and in vivo including herpes 
simplex-1 virus, mouse hepatitis virus type 2, human T-lymphotropic virus-1, 
cytomegalovirus and hepatitis C virus (Sainz & Halford, 2002, Pierce et al., 2005, 
Fuchizaki et al., 2003, D'Onofrio et al., 1992, Sainz et al., 2005, Okuse et al., 2005, 
Larkin et al., 2003).  
 
We proposed that in EV71 infection of susceptible host cells, infected cells 
may up-regulate cytokines such as IL29, IFN-β1 and IFN-γ1 to induce interferon 
stimulated genes (ISG) as part of the cellular antiviral response to slow down viral 
replication. In agreement with our hypothesis, our qPCR results demonstrated 
significant up-regulation of ISG54 and ISG56 in response to EV71 infection of the 
host cell. We proposed that following EV71 infections the host colorectal cells up-
regulate the expression of cytokines such as IL29, IFN-β1 and IFN-γ1 (type I, II and 
III IFN) by a series of JAK-STAT signalling pathways to induce ISG such as ISG54 
and ISG56 as part of cellular antiviral response to slow down virus replication. 
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Lei et al., (2010, 2011, 2013) previously reported that EV71 3C protein 
suppressed the host immune system such as type I interferon during infection in RD 
cells (muscle cells) (Lei et al., 2010, Lei et al., 2011, Lei et al., 2013). On the other 
hand, Chi et al., (2013) have compared the expression of the IFN-signalling pathway 
between intestinal epithelial cells and muscle cells and their results demonstrated that 
intestinal cells indeed have a significantly higher expression of cytokines in response 
to EV71 infection in comparison with the expression levels of cytokines from muscle 
cells following enterovirus infections (Chi et al., 2013). In addition, IFN signalling 
pathways such as those involving type I interferons previously were demonstrated to 
play important roles during EV71 infections (Liu et al., 2005). Therefore it would 
appear that the mechanisms by which EV71 virus mediates changes in the host 
immune systems may differ between host cell types. This may therefore explain the 
phenomenon we observed in our study where  it took three times longer for the virus 
to lyse HT29 cells in comparison with viral–induced lysis of  host RD cells (Lu et 
al., 2011, Lui et al., 2013a). The intestinal epithelial cells, HT29 derived cancer cells 
were able to respond to EV71infection by inducing host cellular antiviral responses 
to slow down virus replication in these cells; this is in contrast with what occurs 
following viral infections of RD (muscle) cells (Chi et al., 2013, Lu et al., 2011, Lui 
et al., 2013a).  
 
The innate system of the host is the first line of immune defence against 
invading pathogens with the interferons (IFNs) being a key component against viral 
infection (Versteeg & Garcia-Sastre, 2010, Thompson et al., 2011, Randall & 
Goodbourn, 2008, Rajsbaum & Garcia-Sastre, 2013, Oudshoorn et al., 2012, de 
Weerd & Nguyen, 2012, Brennan & Bowie, 2010, Boss & Renne, 2011). The release 
194 
 
of IFNs begins with the recognition of pathogen-associated molecular patterns 
(PAMPs) which include Toll like receptors (TLRs), NOD like receptors (NLRs), 
retinoic acid-inducible gene I (RIG-I) like receptors (Kanarek & Ben-Neriah, 2012, 
Brennan & Bowie, 2010). This family of cytokines acts both in an autocrine and 
paracrine manner to induce the expression of transcription factors, gamma activated 
sequence and IFN stimulated response elements and the consequent induction of 
IFN-stimulated genes (ISGs) which function to slow down viral infection (Versteeg 
& Garcia-Sastre, 2010, Thompson et al., 2011, Oudshoorn et al., 2012). Antiviral 
pathways such as the programmed cell death or apoptosis could also be activated by 
the host cells in attempt to control the infection by limiting viral replication (Munday 
et al., 2012).  
 
However, what triggers these differences in cellular immune response against 
EV71 infection remains unknown. Many viruses have evolved mechanisms to 
counteract the host immune response with strategies by host cells to establish 
infection (Versteeg & Garcia-Sastre, 2010, Thompson et al., 2011, Oudshoorn et al., 
2012).  One of the mediators for such regulation includes genes that encode for 
miRNAs. miRNAs are a new paradigm in the regulation of RNA-directed gene 
expression that contribute to the repertoire of host-pathogen interactions during viral 
infection (Skalsky & Cullen, 2010, Scaria et al., 2006, Nathans et al., 2009, Mack, 
2007, Ghosh et al., 2009). Cellular miRNAs could be involved during viral infection 
with either positive or negative effects on viral replication kinetics (Berkhout & 
Jeang, 2007, Lecellier et al., 2005). Indeed, computational predictions reveal that a 
single miRNA may regulate hundreds of genes while one gene may be in turn 
regulated by hundreds of miRNAs (Gottwein & Cullen, 2008). However, the role of 
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cellular miRNAs in the defence against viral infection has thus remained elusive. 
Given the scope of miRNA-mediated gene regulation in the mammalian system, 
cellular miRNAs may directly or indirectly affect virus pathogenesis (Bartel, 2009, 
Lindsay, 2008, Xiao & Rajewsky, 2009). Cellular miRNA expression could be 
attenuated by viral infection, which can alter the host cellular microenvironment 
attributing both to host antiviral defence and to viral factors (Sullivan, 2008, 
Berkhout & Jeang, 2007, Boss & Renne, 2011, Boss & Renne, 2010, Skalsky & 
Cullen, 2010).  
 
To evaluate the importance of miRNA during EV71 pathogenesis, we 
knocked-down DGCR8, an essential cofactor for miRNA biogenesis to create 
miRNA-depleted cells (Chapter Four). Surprisingly, EV71 is not able to replicate 
efficiently in miRNA-depleted cells. This is in contrast with other reported studies 
where the global knockdown of miRNAs has previously been shown to enhance 
human immunodeficiency virus (HIV) replication (Chable-Bessia et al., 2009, 
Triboulet et al., 2007). This implies that EV71 utilise host miRNAs during infection 
and in the absence of miRNAs, EV71 was unable to successfully replicate in the host 
cells. Indeed, various miRNAs have been identified to play roles during EV71 
pathogenesis (Ho et al., 2011, Wen et al., 2013, Zheng et al., 2013). Recent results 
from investigations into the role of miRNA in enterovirus infections by use of 
miRNA inhibitors or mimics have shown that enterovirus-induced miRNAs such as 
miR-23b, miR-296-5p and miR-141 each play a role in EV71 replication (Ho et al., 
2011, Wen et al., 2013, Zheng et al., 2013).  
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Considering that host miRNAs play such critical roles during EV71 
pathogenesis, we undertook miRNA profiling of EV71 infected host cells in our in 
vitro model of infection in an attempt to identify any differentially-expressed 
miRNAs that may play key roles during EV71 infections. Results showed that 78 
miRNAs that were differentially expressed during EV71 infection of our host cells 
(p<0.05). Our results revealed miR-548 to be significantly up regulated in EV71 
infected cells at 36hpi in comparison with non-infected control cells. Interestingly, 
miR-548 has previously been implicated in antiviral responses during viral infections 
of susceptible host cells (de Weerd & Nguyen, 2012, Randall & Goodbourn, 2008, Li 
et al., 2013, Gottwein & Cullen, 2008, Boss & Renne, 2011).  
 
Consistent with our findings, Li and colleagues recently identified the 
involvement of miR-548 in IFN signalling pathways during viral infection (Li et al., 
2013). Briefly, Li and colleagues demonstrated that miR-548 down-regulates host 
antiviral response via direct targeting of IFN- λ1 (Li et al., 2013).  In contrast to that, 
in EV71 infected rhabdomyosarcoma (RD) cells, miR-548 was observed to decrease 
in a time-dependent manner (Li et al., 2013). In view that the host innate system is 
the first line of defence with IFNs being a key player during viral infection, it is 
atypical that miR-548 was up regulated to negatively regulate the host immune 
system (Versteeg & Garcia-Sastre, 2010, Thompson et al., 2011, Randall & 
Goodbourn, 2008, Rajsbaum & Garcia-Sastre, 2013, Oudshoorn et al., 2012, de 
Weerd & Nguyen, 2012, Brennan & Bowie, 2010, Boss & Renne, 2011).  
 
An interesting question that arises is whether EV71 is able to regulate host 
cellular miRNA transcription and processing during infection, thereby leading to the 
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down-regulation of deleterious cellular miRNA and/or the up-regulation of 
advantageous cellular miRNA to enhance its replication in the host cells. 
Specifically, could EV71 up regulate specific miRNAs to alter the host antiviral 
response? Striking examples of the interplay between cellular miRNAs and viral 
pathogens includes; HIV-1, an enveloped RNA virus of the Retreoviridae family 
utilising host cellular miR-28, miR-125b, miR-150, miR-223 and miR-382 to control 
viral protein synthesis in order to evade host immune system (Huang et al., 2007). 
Epstein-Barr virus (EBV), a DNA virus of the Herpes family, for example induce the 
expression of miR-29b, miR-155 and miR-146a to mediate the down regulation of 
innate immune response and IFN signalling pathways to enhances its survival 
(Cameron et al., 2008, Lo et al., 2007, Xiao & Rajewsky, 2009). Lecellier and 
colleagues have shown in primate studies that overexpression of cellular miRNA 
miR-32 could induce an antiviral response to inhibit virus replication in foamy virus 
type 1 (PFV-1) infections (Lecellier et al., 2005).  
 
Therefore, we asked the question “Could EV71 manipulate specific host 
miRNAs in a similar manner to change the host microenvironment for enhanced viral 
survival?” To test this question we investigated whether or not the innate response 
and signalling pathways were altered in EV71 infected miRNA-depleted HT29 cells. 
We analysed the transcriptomes of miRNA-depleted, EV71-infected HT29 cells and 
compared the results with transcriptomes taken from control (i.e. non-miRNA-
depleted) EV71-infected HT29 cells. Quantitative analysis of the transcriptome from 
miRNA depleted- EV71 –infected cells revealed 52 antiviral genes from various 
antiviral signalling pathways, such as Toll-like receptor signalling, Nod-like receptor 
signalling, RIG-1-like receptor signalling and type 1 interferon signalling, which 
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were significantly up regulated. The enhanced antiviral response by miRNA-depleted 
cells during EV71 infection may result in the inability for EV71 to replicate during 
infection. A similar finding was reported by Otsuka and colleagues following 
Vesicular stomatitis virus (VSV) infection of host cells (Otsuka et al., 2007). Otsuka 
and colleagues observed in a murine model that impaired miRNA production in mice 
with Dicer deficiencies resulted in hypersensitivity toward infection by VSV (Otsuka 
et al., 2007). However, it was also observed there was no alteration of interferon-
mediated antiviral response by Dicer deficiency (Otsuka et al., 2007). Instead the 
change in virus replication was due to host miR-24 and miR-93 targeting VSV viral 
protein. As such, in miRNA depleted cells, VSV replication was enhanced in the 
absence of miR-24 and miR-93 (Otsuka et al., 2007).  
 
The inherent complexity of EV71 lies in its ability to manipulate host 
miRNAs to enhance its microcellular environment thereby allowing it to exert 
pathogenic effects on its host. Alteration of host miRNAs to down-regulate host 
immune response and specifically the host antiviral signalling pathway may be 
unique to EV71. It would be interesting to delineate the specific miRNAs governing 
the antiviral pathways vital for the elimination of EV71 (Bartel, 2009, Lindsay, 2008, 
Xiao & Rajewsky, 2009). Effectively, intestinal epithelial cells, being the initial sites 
of EV71 infection and the immune responses induced in the viral-infected host cells 
are proposed (from results of this study) to both play critical roles in the disease 
progression and clinical prognosis in human infections with EV71.  Interestingly, 
impaired or immature host immunity previously has been associated with increased 
morbidity and mortality of young children and immune deficient adults following 
EV71 infections (Liu et al., 2005).  
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The ability of the host to eliminate viral pathogens such as EV71 at the initial 
site of infection is critical in the control of disease progression as a weaker immune 
response results in a higher viral titre leading to a systemic spread as well as more 
serve complications (Chi et al., 2013). Furthermore, Khong et al (2012) reported that 
mice that were adminstered EV71 via the intraperitoneal route exhibited 100% 
mortality as compared to mice that were adminstered with EV71 via the oral route 
that only showed 10-30% mortality (Khong et al., 2012). The key differences may be 
the inability of other cell types to induce a robust antiviral response against EV71. 
Interestingly the mortality results of mice adminstered EV71 via the oral route 
(gastrointestinal tract) reported by Khong et al (2012) corresponded to the percentage 
of EV71 infected human patient with central nervous system complications (Khong 
et al., 2012).  
 
Comparative proteomic analyses were performed on EV71-susceptible and 
EV71-resistant host cells (Chapter Five). We have demonstrated that cells resistant to 
EV71 infection lack a variant of β-actin, compared to EV71-susceptible cells. As 
such, EV71 infection may be actin dependent and might involve an actin-binding 
protein, annexin 2. During viral infection, the host cellular cytoskeleton network is 
subjected to reconfiguration and reorganisation by the viruses in every stage of the 
infection to optimise viral replication and virion production (Bockhorn et al., 2013, 
Buss et al., 2001, Durrbach et al., 1996, Pellegrino et al., 2013, Ploubidou & Way, 
2001, Taylor et al., 2011, Valastyan & Weinberg, 2011). The degree of 
cytoskeletonal reorganisation varies between different viral pathogens and the types 
of cell they invade (Ploubidou & Way, 2001, Taylor et al., 2011).  
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Consistent with our hypothesis, Hussain and colleagues (2011) also 
demonstrated that the cytoskeletal system comprising of both actin and microtubules 
play a key role during EV71 infection (Buss et al., 2001, Durrbach et al., 1996, 
Flanagan & Lin, 1980, Hussain et al., 2011). Knockdown of genes such as ARPC5, 
ARRB1, and WASF1 that were important in actin polymerisation and the use of 
actin disrupting drug such as cytochalasin B, have resulted in the decrease in EV71 
replication kinetics (Buss et al., 2001, Durrbach et al., 1996, Flanagan & Lin, 1980, 
Gerke & Moss, 2002, Hayes et al., 2006, Hussain et al., 2011, Ploubidou & Way, 
2001, Soldati & Schliwa, 2006, Yang et al., 2011).  
 
Viral load testing procedures have been used extensively in research 
laboratories and are now integrated for use in diverse settings ranging from drug 
companies to clinical diagnostics laboratories (Hayden et al., 2013, Hindson et al., 
2013, Sanders et al., 2013, Sedlak & Jerome, 2013, Strain et al., 2013, Kiselinova et 
al., 2014). Quantitative values have been used to monitor the efficacy of antiviral 
treatments and/or to determine changes in antiviral therapy (Sedlak & Jerome, 2013, 
Kiselinova et al., 2014).  Despite the advances and the use of a highly established 
platforms such as real-time PCR, challenges in viral load testing remain due to the 
intrinsic limitation of the method which centres on the issue of precision, accuracy 
and standardisation (Hayden et al., 2013, Hindson et al., 2013, Sanders et al., 2013, 
Sedlak & Jerome, 2013, Strain et al., 2013, Kiselinova et al., 2014). ddPCR, a direct 
measurement of target molecules which relinquishes the need for calibration/standard 
curve and obviates the need to develop costly international standards is an attractive 
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tool for viral load testing (Henrich et al., 2012, Sanders et al., 2013, Sedlak & 
Jerome, 2013).  
 
The move toward absolute quantitation of viral load is driven by the need to 
monitor the efficiency of antiviral therapy without the variability in material and the 
availability international standards. In Chapter Six, we demonstrated that the ddPCR 
platform was generally comparable, if not better, than real-time PCR for the 
detection and absolute quantitation of EV71 viral copy number. 
 
One of the limitation of this study was the use of carcinoma cell lines for in 
vitro work on EV71 pathogenesis. Carcinoma cell lines could have acquired various 
mutations which might not be the best representative of the in vivo human 
gastrointestinal cells. The host-pathogen interaction between the gastrointestinal cells 
and EV71 may be better represented using in vivo models such as non-cancerous 
cells – human gastrointestinal primary cell lines or even the use of in vivo clinical 
samples from severe EV71-infected patients. However, the ease of using cancerous 
cell lines for the in vitro study of virus pathogenesis and the challenges in obtaining 
clinical samples (gastrointestinal cells) from patients resulted in a mammoth tasks for 
the use of an “ideal model” for EV71 pathogenesis. An alternate method would be a 
combination of both models where in vivo clinical samples could be used to screen 
for the key mRNAs and/or miRNAs. Subsequently, functional assay such as gene 
silencing or the use of miRNAs mimics/inhibitors could be performed to validate the 
importance of the gene and/or miRNAs during EV71 infection of a human host. 
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7.2 FUTURE DIRECTIONS 
Owing to the diverse clinical outcomes following EV71 infection, the ability 
to administer specific miRNA mimics or inhibitors to attenuate the host antiviral 
response in an attempt to impair EV71 replication during infection of a human host 
may be invaluable. One of the enigmatic features of miRNAs is the complexity 
where one miRNAs may regulate hundreds of genes while one gene may be in turn 
regulated by hundreds of miRNAs. Based on evidences from our study, future 
studies should therefore be focused on the identification of key miRNAs which could 
be used as therapeutics against EV71 infection. One of the limitation of this study 
was the use of carcinoma cell lines for in vitro work on EV71 pathogenesis. The use 
of primary cell line (in vitro) or clinical samples from EV71-infected HFMD patients 
(in vivo) would be a useful platform for the screening of key miRNAs which may 
play a role during EV71 infection of a human host. The challenging identification 
and development of miRNAs mimics or inhibitors would play a key role in the 
treatment of HFMD patients.  
 
Another promising strategy that could be utilised for EV71 infections is the 
attenuation of EV71 to create a live attenuated vaccine for EV71 (Barnes et al., 2008, 
McMinn, 2012). The incorporation of miRNA homology sequence could be 
engineered into EV71 thus creating an avirulent EV71 strain (Barnes et al., 2008, 
McMinn, 2012, Vignuzzi et al., 2008). The resulting engineered EV71 with 
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deleterious miRNAs sequence would render it susceptible, thereby losing its ability 
to replicate during EV71 infection. Using polioviruses as an example, Barnes and 
colleagues (2008) have demonstrated that the insertion of a homologous sequence of 
miRNA to limit viral replication results in a strong protective immunity in mice 
without causing disease (Barnes et al., 2008, McMinn, 2012).  
 
EV71 is an existing public health problem with frequent/consistent outbreaks 
and the potential to cause severe complications in South East Asia Pacific regions. It 
is therefore crucial to understand the complex interplay between the host 
environment and the pathogen in order to determine what gives the microbe its 
ability to survive within the host. The work in this thesis has provided valuable 
knowledge toward the study of host-pathogen interaction during EV71 pathogenesis 
and will open the door to use of the knowledge of novel host-defence mechanisms 
that exist in mammalian cells as well as to the antiviral mechanisms employed during 
EV71 pathogenesis. This could also lead to future investigations for the development 
of antiviral therapeutics or EV71 vaccines using miRNA inhibitors against EV71 
and/or the creation of a live attenuated vaccine (an avirluent EV71 through the 
incorporation of deleterious miRNA homology sequence) respectively.  
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Appendices 
Appendix A 
Altered mRNA expression profile of EV71 infected and non-infected control colorectal cells, HT29. 
Column 
# 
Column ID Entrez Gene Gene Symbol Gene Title RefSeq 
Transcript ID 
p-
value(Infected 
vs. Control) 
Fold-
Change(Infected 
vs. Control) 
3633 11718724_at 57561 ARRDC3 arrestin domain containing 3 NM_020801 0.000102 3.77318 
43130 11758221_s_at 57561 ARRDC3 arrestin domain containing 3 NM_020801 3.87E-07 3.7577 
49355 AFFX-
M27830_M_at 
--- --- --- --- 0.000171 2.80778 
3632 11718723_at 57561 ARRDC3 arrestin domain containing 3 NM_020801 0.001566 2.30754 
10571 11725662_a_at 151473 SLC16A14 solute carrier family 16, member 14 
(monocarboxylic acid transporter 
14) 
NM_152527 0.003781 2.05637 
44671 11759762_a_at 440836 ODF3B outer dense fiber of sperm tails 3B NM_001014440 0.003513 1.98264 
20813 11735904_at 282618 IL29 interleukin 29 (interferon, lambda 
1) 
NM_172140 0.001237 1.9206 
44230 11759321_a_at 196264 MPZL3 myelin protein zero-like 3 NM_198275 0.000768 1.9043 
16278 11731369_x_at 79973 ZNF442 zinc finger protein 442 NM_030824 0.001441 1.88819 
3412 11718503_a_at 56261 GPCPD1 glycerophosphocholine 
phosphodiesterase GDE1 homolog 
(S. cerevisiae) 
NM_019593 0.00022 1.87381 
33804 11748895_a_at 134266 GRPEL2 GrpE-like 2, mitochondrial (E. coli) NM_152407 9.22E-06 1.86842 
250 
 
2099 11717190_s_at 10628 TXNIP thioredoxin interacting protein NM_006472 7.62E-06 1.86782 
22969 11738060_s_at 121504 /// 
554313 /// 
8294 /// 8359 
/// 8360 /// 
8361 /// 8362 
/// 8363 /// 
8364 /// 83 
HIST1H4A /// 
HIST1H4B /// 
HIST1H4C /// 
HIST1H4D /// 
HIST1H4E /// 
HIST1H4F /// 
HIST1H4H /// 
HIST1H4I /// 
HIST1H4J /// 
HIST1H4K /// 
HIST1H4L /// 
HIST2H4A /// 
HIST2H4B /// 
HIST4H4 
histone cluster 1, H4a /// histone 
cluster 1, H4b /// histone cluster 1, 
H4c /// histon 
NM_001034077 
/// NM_003495 
/// NM_003538 
/// NM_003539 
/// NM_003540 
/// NM_003541 
///  
0.009641 1.82976 
614 11715705_a_at 10724 MGEA5 meningioma expressed antigen 5 
(hyaluronidase) 
NM_001142434 
/// NM_012215 
1.09E-06 1.80531 
41340 11756431_s_at 10628 TXNIP thioredoxin interacting protein NM_006472 5.32E-06 1.79276 
37674 11752765_s_at 10628 TXNIP thioredoxin interacting protein NM_006472 5.72E-06 1.78761 
19109 11734200_at 284391 ZNF844 zinc finger protein 844 NM_001136501 1.76E-05 1.75669 
615 11715706_x_at 10724 MGEA5 meningioma expressed antigen 5 
(hyaluronidase) 
NM_001142434 
/// NM_012215 
3.16E-06 1.75181 
33453 11748544_s_at 10628 TXNIP thioredoxin interacting protein NM_006472 6.03E-05 1.74939 
38336 11753427_a_at 390 RND3 Rho family GTPase 3 NM_001254738 
/// NM_005168 
0.000853 1.74621 
1234 11716325_a_at 1195 CLK1 CDC-like kinase 1 NM_001024646 
/// 
0.004308 1.71591 
251 
 
NM_001162407 
/// NM_004071 
/// NR_027855 
/// NR_027856 
33452 11748543_a_at 10628 TXNIP thioredoxin interacting protein NM_006472 0.001977 1.71264 
4669 11719760_at 91947 ARRDC4 arrestin domain containing 4 NM_183376 0.005599 1.71178 
18260 11733351_at 55175 KLHL11 kelch-like 11 (Drosophila) NM_018143 0.012659 1.67587 
18477 11733568_x_at 163059 ZNF433 zinc finger protein 433 NM_001080411 
/// NM_152602 
0.001603 1.66142 
21510 11736601_at 83990 BRIP1 BRCA1 interacting protein C-
terminal helicase 1 
NM_032043 0.000358 1.64957 
29037 11744128_x_at 2920 CXCL2 chemokine (C-X-C motif) ligand 2 NM_002089 0.001577 1.62624 
43785 11758876_at 153222 CREBRF CREB3 regulatory factor NM_001168393 
/// 
NM_001168394 
/// NM_153607 
0.000516 1.60036 
402 11715493_a_at 3491 CYR61 cysteine-rich, angiogenic inducer, 
61 
NM_001554 0.00027 1.59476 
16277 11731368_at 79973 ZNF442 zinc finger protein 442 NM_030824 0.002515 1.57275 
9376 11724467_at 3859 KRT12 keratin 12 NM_000223 0.011131 1.56759 
8481 11723572_at 23252 OTUD3 OTU domain containing 3 NM_015207 0.041063 1.5639 
41374 11756465_s_at 390 RND3 Rho family GTPase 3 NM_001254738 
/// NM_005168 
0.002659 1.55294 
4670 11719761_at 91947 ARRDC4 arrestin domain containing 4 NM_183376 0.000446 1.53056 
19726 11734817_at 323 APBB2 amyloid beta (A4) precursor 
protein-binding, family B, member 
2 
NM_001166050 
/// 
NM_001166051 
0.001824 1.52967 
252 
 
/// 
NM_001166052 
/// 
NM_001166053 
/// 
NM_001166054 
/// NM 
13385 11728476_a_at 2921 CXCL3 chemokine (C-X-C motif) ligand 3 NM_002090 0.025571 1.51915 
26462 11741553_a_at 6498 SKIL SKI-like oncogene NM_001145097 
/// 
NM_001145098 
/// 
NM_001248008 
/// NM_005414 
0.000966 1.49154 
30633 11745724_at 100507645 /// 
378938 
LOC100507645 
/// MALAT1 
uncharacterized LOC100507645 /// 
metastasis associated lung 
adenocarcinoma transcript 1 
NR_002819 /// 
XR_110915 /// 
XR_110916 /// 
XR_110917 /// 
XR_111190 /// 
XR_111191 /// 
XR_ 
9.80E-05 1.4796 
35561 11750652_a_at 2444 FRK fyn-related kinase NM_002031 0.023839 1.46959 
44568 11759659_at 1E+08 LOC100130428 IGYY565 XR_110533 /// 
XR_111228 
0.009338 1.46816 
48097 11763188_a_at 27131 SNX5 sorting nexin 5 NM_014426 /// 
NM_152227 
0.001321 1.46308 
5205 11720296_at 79666 PLEKHF2 pleckstrin homology domain 
containing, family F (with FYVE 
NM_024613 0.00206 1.4612 
253 
 
domain) member 2 
43392 11758483_s_at 91947 ARRDC4 arrestin domain containing 4 NM_183376 0.000513 1.44954 
37466 11752557_a_at 153222 CREBRF CREB3 regulatory factor NM_001168393 
/// 
NM_001168394 
/// NM_153607 
0.00642 1.44726 
34200 11749291_a_at 2353 FOS FBJ murine osteosarcoma viral 
oncogene homolog 
NM_005252 7.89E-05 1.43973 
44434 11759525_at 4616 GADD45B growth arrest and DNA-damage-
inducible, beta 
NM_015675 0.003623 1.43547 
40609 11755700_a_at 25976 TIPARP TCDD-inducible poly(ADP-ribose) 
polymerase 
NM_001184717 
/// 
NM_001184718 
/// NM_015508 
0.036261 1.43522 
32051 11747142_a_at 80012 PHC3 polyhomeotic homolog 3 
(Drosophila) 
NM_024947 0.00253 1.43029 
35041 11750132_a_at 255967 PAN3 PAN3 poly(A) specific ribonuclease 
subunit homolog (S. cerevisiae) 
NM_175854 0.005458 1.42743 
896 11715987_a_at 2688 GH1 growth hormone 1 NM_000515 /// 
NM_022559 /// 
NM_022560 /// 
NM_022561 /// 
NM_022562 
0.007867 1.42049 
28805 11743896_at 55758 RCOR3 REST corepressor 3 NM_001136223 
/// 
NM_001136224 
/// 
NM_001136225 
0.000893 1.41962 
254 
 
/// NM_018254 
40819 11755910_a_at 26043 UBXN7 UBX domain protein 7 NM_015562 0.000898 1.41872 
4649 11719740_a_at 167227 DCP2 DCP2 decapping enzyme homolog 
(S. cerevisiae) 
NM_001242377 
/// NM_152624 
/// NR_038352 
0.016116 1.41834 
12090 11727181_a_at 6498 SKIL SKI-like oncogene NM_001145097 
/// 
NM_001145098 
/// 
NM_001248008 
/// NM_005414 
0.003174 1.41831 
35448 11750539_a_at 10242 KCNMB2 potassium large conductance 
calcium-activated channel, 
subfamily M, beta member 2 
NM_005832 /// 
NM_181361 
0.010573 1.41745 
351 11715442_s_at 1490 CTGF connective tissue growth factor NM_001901 0.002323 1.41468 
19568 11734659_a_at 2353 FOS FBJ murine osteosarcoma viral 
oncogene homolog 
NM_005252 5.18E-05 1.41385 
34561 11749652_a_at 49854 ZNF295 zinc finger protein 295 NM_001098402 
/// 
NM_001098403 
/// NM_020727 
0.00395 1.41373 
41315 11756406_x_at 133 ADM adrenomedullin NM_001124 0.000118 1.41276 
25347 11740438_a_at 2528 FUT6 fucosyltransferase 6 (alpha (1,3) 
fucosyltransferase) 
NM_000150 /// 
NM_001040701 
0.007178 1.40876 
7793 11722884_at 153222 CREBRF CREB3 regulatory factor NM_001168393 
/// 
NM_001168394 
0.000552 1.40832 
255 
 
/// NM_153607 
47515 11762606_x_at 645261 LOC645261 PP565 NM_001039781 0.046925 1.405 
40284 11755375_a_at 160851 DGKH diacylglycerol kinase, eta NM_001204504 
/// 
NM_001204505 
/// 
NM_001204506 
/// NM_152910 
/// NM_178009 
0.000702 1.40429 
37042 11752133_a_at 79598 CEP97 centrosomal protein 97kDa NM_024548 0.04284 1.40126 
12165 11727256_a_at 100529855 /// 
7568 
ZNF20 /// 
ZNF625-
ZNF20 
zinc finger protein 20 /// ZNF625-
ZNF20 readthrough 
NM_001203250 
/// NM_021143 
/// NR_037802 
2.32E-05 1.39579 
10572 11725663_a_at 151473 SLC16A14 solute carrier family 16, member 14 
(monocarboxylic acid transporter 
14) 
NM_152527 0.001988 1.39573 
1619 11716710_a_at 133 ADM adrenomedullin NM_001124 0.00012 1.39486 
46688 11761779_a_at 196264 MPZL3 myelin protein zero-like 3 NM_198275 0.002432 1.39473 
7791 11722882_at 153222 CREBRF CREB3 regulatory factor NM_001168393 
/// 
NM_001168394 
/// NM_153607 
0.008605 1.39171 
12755 11727846_a_at 55602 CDKN2AIP CDKN2A interacting protein NM_017632 0.006151 1.3883 
28591 11743682_s_at 7071 KLF10 Kruppel-like factor 10 NM_001032282 
/// NM_005655 
0.000817 1.38344 
33024 11748115_a_at 63876 PKNOX2 PBX/knotted 1 homeobox 2 NM_022062 0.021506 1.3782 
16671 11731762_s_at 6196 RPS6KA2 ribosomal protein S6 kinase, 90kDa, NM_001006932 0.009433 1.37529 
256 
 
polypeptide 2 /// NM_021135 
24859 11739950_a_at 57082 CASC5 cancer susceptibility candidate 5 NM_144508 /// 
NM_170589 
0.003455 1.37191 
17977 11733068_s_at 7071 KLF10 Kruppel-like factor 10 NM_001032282 
/// NM_005655 
0.000694 1.37008 
24876 11739967_a_at 120526 DNAJC24 DnaJ (Hsp40) homolog, subfamily 
C, member 24 
NM_181706 0.018804 1.36822 
10607 11725698_x_at 331 XIAP X-linked inhibitor of apoptosis NM_001167 /// 
NM_001204401 
/// NR_037916 
0.007849 1.36765 
29036 11744127_at 2920 CXCL2 chemokine (C-X-C motif) ligand 2 NM_002089 0.016053 1.36714 
22968 11738059_x_at 3013 HIST1H2AD histone cluster 1, H2ad NM_021065 0.028426 1.36563 
40151 11755242_a_at 6498 SKIL SKI-like oncogene NM_001145097 
/// 
NM_001145098 
/// 
NM_001248008 
/// NM_005414 
0.000608 1.36492 
11303 11726394_a_at 121512 FGD4 FYVE, RhoGEF and PH domain 
containing 4 
NM_139241 0.021325 1.3649 
34814 11749905_a_at 3491 CYR61 cysteine-rich, angiogenic inducer, 
61 
NM_001554 0.000101 1.36416 
10991 11726082_a_at 905 CCNT2 cyclin T2 NM_001241 /// 
NM_058241 /// 
NR_037649 
0.021307 1.3577 
8843 11723934_a_at 29944 PNMA3 paraneoplastic Ma antigen 3 NM_013364 0.00317 1.35372 
49354 AFFX- --- --- --- --- 0.011792 1.35371 
257 
 
M27830_5_at 
7792 11722883_a_at 153222 CREBRF CREB3 regulatory factor NM_001168393 
/// 
NM_001168394 
/// NM_153607 
0.010315 1.3514 
47313 11762404_at 148 ADRA1A adrenoceptor alpha 1A NM_000680 /// 
NM_033302 /// 
NM_033303 /// 
NM_033304 
0.001237 1.35038 
9075 11724166_a_at 23127 GLT25D2 glycosyltransferase 25 domain 
containing 2 
NM_015101 0.027852 1.3503 
32025 11747116_a_at 133746 JMY junction mediating and regulatory 
protein, p53 cofactor 
NM_152405 0.003651 1.34977 
24544 11739635_at 9969 MED13 mediator complex subunit 13 NM_005121 0.035394 1.34761 
15268 11730359_a_at 90693 CCDC126 coiled-coil domain containing 126 NM_138771 0.031644 1.34594 
11127 11726218_a_at 639 PRDM1 PR domain containing 1, with ZNF 
domain 
NM_001198 /// 
NM_182907 
0.039496 1.34377 
34761 11749852_s_at 2353 FOS FBJ murine osteosarcoma viral 
oncogene homolog 
NM_005252 0.006148 1.34042 
19708 11734799_s_at 51132 RLIM ring finger protein, LIM domain 
interacting 
NM_016120 /// 
NM_183353 
0.001525 1.34023 
11533 11726624_a_at 901 CCNG2 cyclin G2 NM_004354 0.000319 1.33927 
15962 11731053_a_at 96459 FNIP1 folliculin interacting protein 1 NM_001008738 
/// NM_133372 
0.036329 1.33758 
39243 11754334_s_at 1958 EGR1 early growth response 1 NM_001964 0.001395 1.33756 
8206 11723297_a_at 11217 /// 
445815 
AKAP2 /// 
PALM2-
A kinase (PRKA) anchor protein 2 
/// PALM2-AKAP2 readthrough 
NM_001004065 
/// 
0.019993 1.33685 
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AKAP2 NM_001136562 
/// 
NM_001198656 
/// NM_007203 
/// NM_147150 
20674 11735765_a_at 27314 RAB30 RAB30, member RAS oncogene 
family 
NM_014488 0.04587 1.33545 
22070 11737161_a_at 905 CCNT2 cyclin T2 NM_001241 /// 
NM_058241 /// 
NR_037649 
0.003839 1.33262 
45830 11760921_a_at 26036 ZNF451 zinc finger protein 451 NM_001031623 
/// 
NM_001257273 
/// NM_015555 
/// 
XM_003118557 
/// 
XM_003403792 
0.02704 1.33241 
11518 11726609_at 22823 MTF2 metal response element binding 
transcription factor 2 
NM_001164391 
/// 
NM_001164392 
/// 
NM_001164393 
/// NM_007358 
0.027257 1.33137 
14299 11729390_a_at 57708 MIER1 mesoderm induction early response 
1 homolog (Xenopus laevis) 
NM_001077700 
/// 
NM_001077701 
/// 
0.007522 1.3308 
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NM_001077702 
/// 
NM_001077703 
/// 
NM_001077704 
/// NM 
36846 11751937_s_at 55582 KIF27 kinesin family member 27 NM_017576 0.028873 1.33035 
22071 11737162_at 222584 FAM83B family with sequence similarity 83, 
member B 
NM_001010872 0.023157 1.32977 
2769 11717860_a_at 1958 EGR1 early growth response 1 NM_001964 0.001233 1.32915 
11534 11726625_at 901 CCNG2 cyclin G2 NM_004354 0.00406 1.32856 
7188 11722279_a_at 80012 PHC3 polyhomeotic homolog 3 
(Drosophila) 
NM_024947 0.043937 1.32831 
46947 11762038_at 284391 ZNF844 zinc finger protein 844 NM_001136501 0.048406 1.32687 
35590 11750681_a_at 153222 CREBRF CREB3 regulatory factor NM_001168393 
/// 
NM_001168394 
/// NM_153607 
0.012134 1.3268 
27139 11742230_x_at 1E+08 FAM48B1 family with sequence similarity 48, 
member B1 
NM_001136234 0.031498 1.32651 
18674 11733765_at 3456 IFNB1 interferon, beta 1, fibroblast NM_002176 0.015741 1.32647 
43308 11758399_s_at 2846 LPAR4 lysophosphatidic acid receptor 4 NM_005296 0.029642 1.32621 
22334 11737425_x_at 115727 RASGRP4 RAS guanyl releasing protein 4 NM_001146202 
/// 
NM_001146203 
/// 
NM_001146204 
0.005792 1.32503 
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/// 
NM_001146205 
/// 
NM_001146206 
/// NM 
22732 11737823_at 84197 SGK196 protein kinase-like protein SgK196 NM_032237 0.00932 1.32502 
37849 11752940_a_at 1958 EGR1 early growth response 1 NM_001964 0.006409 1.32323 
12658 11727749_a_at 2494 NR5A2 nuclear receptor subfamily 5, group 
A, member 2 
NM_003822 /// 
NM_205860 
0.003697 1.32303 
21037 11736128_a_at 55211 DPPA4 developmental pluripotency 
associated 4 
NM_018189 0.009001 1.32237 
44972 11760063_x_at 388372 /// 
9560 
CCL4L1 /// 
CCL4L2 
chemokine (C-C motif) ligand 4-
like 1 /// chemokine (C-C motif) 
ligand 4-like 2 
NM_001001435 
/// NM_207007 
0.039822 1.3213 
16788 11731879_a_at 22861 NLRP1 NLR family, pyrin domain 
containing 1 
NM_001033053 
/// NM_014922 
/// NM_033004 
/// NM_033006 
/// NM_033007 
0.009596 1.32096 
36413 11751504_a_at 79691 QTRTD1 queuine tRNA-ribosyltransferase 
domain containing 1 
NM_001256835 
/// 
NM_001256836 
/// 
NM_001256837 
/// NM_024638 
0.026976 1.31678 
47260 11762351_x_at 7576 ZNF28 zinc finger protein 28 NM_006969 /// 
NR_036599 /// 
NR_036600 
0.006452 1.3146 
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17271 11732362_x_at 51710 ZNF44 zinc finger protein 44 NM_001164276 
/// NM_016264 
0.008115 1.31441 
26248 11741339_a_at 2549 GAB1 GRB2-associated binding protein 1 NM_002039 /// 
NM_207123 
0.004962 1.3136 
19727 11734818_at 323 APBB2 amyloid beta (A4) precursor 
protein-binding, family B, member 
2 
NM_001166050 
/// 
NM_001166051 
/// 
NM_001166052 
/// 
NM_001166053 
/// 
NM_001166054 
/// NM 
0.032037 1.31093 
46501 11761592_a_at 22944 KIN KIN, antigenic determinant of recA 
protein homolog (mouse) 
NM_012311 /// 
NR_045609 /// 
NR_045610 
0.040734 1.3106 
21794 11736885_at 56903 PAPOLB poly(A) polymerase beta (testis 
specific) 
NM_020144 0.037413 1.30936 
221 11715312_at 2303 FOXC2 forkhead box C2 (MFH-1, 
mesenchyme forkhead 1) 
NM_005251 0.036523 1.30891 
10541 11725632_at 4929 NR4A2 nuclear receptor subfamily 4, group 
A, member 2 
NM_006186 /// 
NM_173171 /// 
NM_173172 /// 
NM_173173 
0.007935 1.30885 
14600 11729691_a_at 54800 KLHL24 kelch-like 24 (Drosophila) NM_017644 0.001649 1.30856 
29148 11744239_a_at 126075 CCDC159 coiled-coil domain containing 159 NM_001080503 0.008035 1.30716 
262 
 
30453 11745544_a_at 100302736 /// 
353376 
TICAM2 /// 
TMED7-
TICAM2 
toll-like receptor adaptor molecule 2 
/// TMED7-TICAM2 readthrough 
NM_001164468 
/// 
NM_001164469 
/// NM_021649 
0.026865 1.30633 
24577 11739668_a_at 26039 SS18L1 synovial sarcoma translocation gene 
on chromosome 18-like 1 
NM_015558 /// 
NM_198935 
0.012679 1.30595 
22825 11737916_a_at 79858 NEK11 NIMA (never in mitosis gene a)- 
related kinase 11 
NM_001146003 
/// NM_024800 
/// NM_145910 
0.010577 1.30463 
15558 11730649_at 389320 C5orf48 chromosome 5 open reading frame 
48 
NM_207408 0.024246 1.30137 
8219 11723310_at 8793 TNFRSF10D tumor necrosis factor receptor 
superfamily, member 10d, decoy 
with truncated death doma 
NM_003840 0.000684 1.29951 
11863 11726954_at 140766 ADAMTS14 ADAM metallopeptidase with 
thrombospondin type 1 motif, 14 
NM_080722 /// 
NM_139155 
0.010339 1.2977 
25042 11740133_a_at 800 CALD1 caldesmon 1 NM_004342 /// 
NM_033138 /// 
NM_033139 /// 
NM_033140 /// 
NM_033157 
0.020841 1.29622 
44500 11759591_at 79969 ATAT1 alpha tubulin acetyltransferase 1 NM_001031722 
/// 
NM_001190724 
/// 
NM_001254952 
/// NM_024909 
/// NR_033821 
0.010046 1.2956 
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/// NR_03382 
7427 11722518_a_at 23137 SMC5 structural maintenance of 
chromosomes 5 
NM_015110 0.007102 1.29527 
2989 11718080_a_at 10018 BCL2L11 BCL2-like 11 (apoptosis facilitator) NM_001204106 
/// 
NM_001204107 
/// 
NM_001204108 
/// 
NM_001204109 
/// 
NM_001204110 
/// NM 
0.005602 1.29476 
26091 11741182_s_at 148137 C19orf55 chromosome 19 open reading frame 
55 
NM_001039887 
/// NM_144692 
0.044211 1.29425 
8829 11723920_at 10324 KBTBD10 kelch repeat and BTB (POZ) 
domain containing 10 
NM_006063 0.025575 1.29385 
396 11715487_a_at 4170 MCL1 myeloid cell leukemia sequence 1 
(BCL2-related) 
NM_001197320 
/// NM_021960 
/// NM_182763 
0.006242 1.29168 
2916 11718007_a_at 29116 MYLIP myosin regulatory light chain 
interacting protein 
NM_013262 0.000422 1.29103 
47656 11762747_at 4322 MMP13 matrix metallopeptidase 13 
(collagenase 3) 
NM_002427 0.018962 1.29037 
44359 11759450_x_at 6248 /// 84301 DDI2 /// 
RSC1A1 
DNA-damage inducible 1 homolog 
2 (S. cerevisiae) /// regulatory solute 
carrier protein, 
NM_006511 /// 
NM_032341 
0.00731 1.28986 
40173 11755264_a_at 23097 CDK19 cyclin-dependent kinase 19 NM_015076 0.035616 1.28974 
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20232 11735323_at 126068 ZNF441 zinc finger protein 441 NM_152355 0.006537 1.28901 
6803 11721894_at 2619 GAS1 growth arrest-specific 1 NM_002048 0.039973 1.28898 
48404 11763495_s_at 9256 BZRAP1 benzodiazapine receptor 
(peripheral) associated protein 1 
NM_001261835 
/// NM_004758 
/// NM_024418 
0.018835 1.28894 
32821 11747912_a_at 11044 PAPD7 PAP associated domain containing 
7 
NM_001171805 
/// 
NM_001171806 
/// NM_006999 
0.044264 1.28818 
28598 11743689_a_at 57540 PTCHD2 patched domain containing 2 NM_020780 0.007156 1.28793 
34028 11749119_a_at 121512 FGD4 FYVE, RhoGEF and PH domain 
containing 4 
NM_139241 0.019764 1.28777 
29998 11745089_a_at 7182 NR2C2 nuclear receptor subfamily 2, group 
C, member 2 
NM_003298 0.030307 1.28679 
4446 11719537_a_at 119587 CPXM2 carboxypeptidase X (M14 family), 
member 2 
NM_198148 0.0221 1.28661 
44910 11760001_at 54766 BTG4 B-cell translocation gene 4 NM_017589 0.003711 1.28448 
7440 11722531_a_at 800 CALD1 caldesmon 1 NM_004342 /// 
NM_033138 /// 
NM_033139 /// 
NM_033140 /// 
NM_033157 
0.006582 1.2839 
36949 11752040_s_at 80012 PHC3 polyhomeotic homolog 3 
(Drosophila) 
NM_024947 0.023829 1.28293 
48123 11763214_at 51735 RAPGEF6 Rap guanine nucleotide exchange 
factor (GEF) 6 
NM_001164386 
/// 
NM_001164387 
0.015816 1.28218 
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/// 
NM_001164388 
/// 
NM_001164389 
/// 
NM_001164390 
/// NM 
42900 11757991_s_at 23253 ANKRD12 ankyrin repeat domain 12 NM_001083625 
/// 
NM_001204056 
/// NM_015208 
0.010279 1.28048 
8567 11723658_at 79759 ZNF668 zinc finger protein 668 NM_001172668 
/// 
NM_001172669 
/// 
NM_001172670 
/// NM_024706 
0.033049 1.27896 
33047 11748138_x_at 25956 SEC31B SEC31 homolog B (S. cerevisiae) NM_015490 /// 
NM_198138 
0.011356 1.27772 
35779 11750870_a_at 23279 NUP160 nucleoporin 160kDa NM_015231 0.017281 1.27757 
41944 11757035_a_at 2532 DARC Duffy blood group, chemokine 
receptor 
NM_001122951 
/// NM_002036 
0.020641 1.27729 
9071 11724162_a_at 283464 GXYLT1 glucoside xylosyltransferase 1 NM_001099650 
/// NM_173601 
0.015681 1.27635 
10688 11725779_a_at 8618 CADPS Ca++-dependent secretion activator NM_003716 /// 
NM_183393 /// 
NM_183394 
0.038957 1.2759 
37114 11752205_a_at 79781 IQCA1 IQ motif containing with AAA NM_024726 0.020593 1.2758 
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domain 1 
47540 11762631_a_at 196441 ZFC3H1 zinc finger, C3H1-type containing NM_144982 0.041071 1.27519 
2165 11717256_at 5292 PIM1 pim-1 oncogene NM_001243186 
/// NM_002648 
0.006294 1.27507 
28804 11743895_a_at 55758 RCOR3 REST corepressor 3 NM_001136223 
/// 
NM_001136224 
/// 
NM_001136225 
/// NM_018254 
0.022609 1.27491 
19645 11734736_a_at 84188 FAR1 fatty acyl CoA reductase 1 NM_032228 0.002165 1.27446 
39822 11754913_a_at 7227 TRPS1 trichorhinophalangeal syndrome I NM_014112 0.018214 1.27441 
10951 11726042_a_at 9262 STK17B serine/threonine kinase 17b NM_004226 0.003861 1.27401 
8497 11723588_at 149041 RC3H1 ring finger and CCCH-type domains 
1 
NM_172071 0.045208 1.27349 
49116 11764207_at --- --- --- --- 0.031855 1.27316 
37442 11752533_a_at 149095 DCST1 DC-STAMP domain containing 1 NM_001143687 
/// NM_152494 
0.029453 1.27231 
10245 11725336_a_at 51132 RLIM ring finger protein, LIM domain 
interacting 
NM_016120 /// 
NM_183353 
0.000128 1.27114 
20876 11735967_at 59351 PBOV1 prostate and breast cancer 
overexpressed 1 
NM_021635 0.048078 1.27064 
22558 11737649_a_at 51479 ANKFY1 ankyrin repeat and FYVE domain 
containing 1 
NM_001257999 
/// NM_016376 
/// NM_020740 
/// NR_047571 
0.008471 1.2696 
23170 11738261_at 284443 ZNF493 zinc finger protein 493 NM_001076678 0.003182 1.26959 
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/// NM_145326 
/// NM_175910 
16748 11731839_a_at 9331 B4GALT6 UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 6 
NM_004775 0.020911 1.26887 
29161 11744252_at 5991 RFX3 regulatory factor X, 3 (influences 
HLA class II expression) 
NM_002919 /// 
NM_134428 
0.000558 1.26819 
9419 11724510_at 5366 PMAIP1 phorbol-12-myristate-13-acetate-
induced protein 1 
NM_021127 0.004854 1.26818 
7893 11722984_a_at 203447 NRK Nik related kinase NM_198465 0.010236 1.26778 
22669 11737760_s_at 390 RND3 Rho family GTPase 3 NM_001254738 
/// NM_005168 
0.001363 1.26711 
40424 11755515_s_at 6248 /// 84301 DDI2 /// 
RSC1A1 
DNA-damage inducible 1 homolog 
2 (S. cerevisiae) /// regulatory solute 
carrier protein, 
NM_006511 /// 
NM_032341 
0.00491 1.26703 
18471 11733562_a_at 23008 KLHDC10 kelch domain containing 10 NM_014997 0.035458 1.26636 
37955 11753046_x_at 10150 MBNL2 muscleblind-like splicing regulator 
2 
NM_144778 /// 
NM_207304 
0.030541 1.26615 
44136 11759227_at 170482 CLEC4C C-type lectin domain family 4, 
member C 
NM_130441 /// 
NM_203503 
0.036563 1.26454 
9544 11724635_at 55432 YOD1 YOD1 OTU deubiquinating enzyme 
1 homolog (S. cerevisiae) 
NM_018566 6.51E-05 1.2645 
5270 11720361_at 55023 PHIP pleckstrin homology domain 
interacting protein 
NM_017934 0.002029 1.26433 
15755 11730846_x_at 8503 PIK3R3 phosphoinositide-3-kinase, 
regulatory subunit 3 (gamma) 
NM_001114172 
/// NM_003629 
0.007165 1.26381 
39054 11754145_x_at 100287723 /// 
642424 
LOC100287723 
/// LOC642424 
ig kappa chain V-I region Walker-
like /// ig kappa chain V-I region 
XM_003403530 
/// 
0.018219 1.26232 
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Walker-like XM_003403532 
/// 
XM_003403621 
12145 11727236_a_at 147339 C18orf25 chromosome 18 open reading frame 
25 
NM_001008239 
/// NM_145055 
0.010095 1.26101 
13950 11729041_a_at 9940 DLEC1 deleted in lung and esophageal 
cancer 1 
NM_007335 /// 
NM_007336 /// 
NM_007337 /// 
NM_007338 
0.025826 1.26077 
1209 11716300_x_at 3685 ITGAV integrin, alpha V NM_001144999 
/// 
NM_001145000 
/// NM_002210 
0.035373 1.26019 
4968 11720059_a_at 57348 TTYH1 tweety homolog 1 (Drosophila) NM_001005367 
/// 
NM_001201461 
/// NM_020659 
0.003954 1.26 
17901 11732992_s_at 54798 DCHS2 dachsous 2 (Drosophila) NM_001142552 
/// 
NM_001142553 
/// NM_017639 
/// NM_199348 
0.045637 1.25982 
45747 11760838_at 23116 FAM179B family with sequence similarity 
179, member B 
NM_015091 0.004454 1.2585 
36104 11751195_a_at 56479 KCNQ5 potassium voltage-gated channel, 
KQT-like subfamily, member 5 
NM_001160130 
/// 
NM_001160132 
/// 
0.01754 1.25825 
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NM_001160133 
/// 
NM_001160134 
/// NM_019842 
44365 11759456_x_at 347688 TUBB8 tubulin, beta 8 class VIII NM_001164154 
/// NM_177987 
0.037874 1.25729 
36323 11751414_a_at 26298 EHF ets homologous factor NM_001206615 
/// 
NM_001206616 
/// NM_012153 
0.003309 1.2572 
13010 11728101_at 195828 ZNF367 zinc finger protein 367 NM_153695 0.000217 1.25631 
14831 11729922_a_at 5973 RENBP renin binding protein NM_002910 0.018833 1.25587 
7007 11722098_a_at 253260 RICTOR RPTOR independent companion of 
MTOR, complex 2 
NM_152756 0.023253 1.25455 
42881 11757972_s_at 29116 MYLIP myosin regulatory light chain 
interacting protein 
NM_013262 0.00034 1.25441 
952 11716043_a_at 130074 FAM168B family with sequence similarity 
168, member B 
NM_001009993 0.005366 1.25419 
12095 11727186_a_at 7474 WNT5A wingless-type MMTV integration 
site family, member 5A 
NM_001256105 
/// NM_003392 
0.005417 1.25419 
48932 11764023_at --- --- --- --- 0.004665 1.25399 
27101 11742192_a_at 1240 CMKLR1 chemokine-like receptor 1 NM_001142343 
/// 
NM_001142344 
/// 
NM_001142345 
/// NM_004072 
0.005271 1.25351 
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915 11716006_a_at 10525 HYOU1 hypoxia up-regulated 1 NM_001130991 
/// NM_006389 
0.02518 1.25322 
46553 11761644_at 51227 PIGP phosphatidylinositol glycan anchor 
biosynthesis, class P 
NM_153681 /// 
NM_153682 /// 
NR_028352 
0.003661 1.2529 
22191 11737282_x_at 92092 ZC3HAV1L zinc finger CCCH-type, antiviral 1-
like 
NM_080660 0.03066 1.2529 
27429 11742520_at 81328 OR4A15 olfactory receptor, family 4, 
subfamily A, member 15 
NM_001005275 0.003666 1.25262 
6783 11721874_at 3433 IFIT2 interferon-induced protein with 
tetratricopeptide repeats 2 
NM_001547 0.01022 1.25256 
8365 11723456_x_at 221476 PI16 peptidase inhibitor 16 NM_001199159 
/// NM_153370 
0.012259 1.25166 
21758 11736849_a_at 83856 FSD1L fibronectin type III and SPRY 
domain containing 1-like 
NM_001145313 
/// NM_031919 
/// NM_207647 
0.04386 1.25165 
4807 11719898_s_at 1839 HBEGF heparin-binding EGF-like growth 
factor 
NM_001945 0.003253 1.25078 
8307 11723398_at 4804 NGFR nerve growth factor receptor NM_002507 0.032872 1.25049 
2194 11717285_a_at 8976 WASL Wiskott-Aldrich syndrome-like NM_003941 0.028548 1.25039 
19117 11734208_s_at 1270 /// 
386607 
CNTF /// 
ZFP91-CNTF 
ciliary neurotrophic factor /// 
ZFP91-CNTF readthrough (non-
protein coding) 
NM_000614 /// 
NM_170768 /// 
NR_024091 
0.002783 1.24955 
29317 11744408_x_at 23015 GOLGA8A golgin A8 family, member A NM_181077 /// 
NR_027409 
0.026889 1.24951 
42762 11757853_s_at 117581 TWIST2 twist homolog 2 (Drosophila) NM_057179 0.00447 1.2495 
28782 11743873_x_at 64321 SOX17 SRY (sex determining region Y)- NM_022454 0.00444 1.24948 
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box 17 
1883 11716974_a_at 5166 PDK4 pyruvate dehydrogenase kinase, 
isozyme 4 
NM_002612 0.020372 1.24945 
26280 11741371_at 392862 GRID2IP glutamate receptor, ionotropic, delta 
2 (Grid2) interacting protein 
NM_001145118 0.038358 1.24934 
14825 11729916_s_at 221079 ARL5B ADP-ribosylation factor-like 5B NM_178815 0.004488 1.24866 
21132 11736223_a_at 64376 IKZF5 IKAROS family zinc finger 5 
(Pegasus) 
NM_022466 0.009314 1.24823 
6274 11721365_a_at 3658 IREB2 iron-responsive element binding 
protein 2 
NM_004136 0.005775 1.247 
21806 11736897_x_at 79056 PRRG4 proline rich Gla (G-
carboxyglutamic acid) 4 
(transmembrane) 
NM_024081 0.016473 1.24684 
39538 11754629_s_at 9120 SLC16A6 solute carrier family 16, member 6 
(monocarboxylic acid transporter 7) 
NM_001174166 
/// NM_004694 
0.023591 1.24683 
11519 11726610_s_at 22823 MTF2 metal response element binding 
transcription factor 2 
NM_001164391 
/// 
NM_001164392 
/// 
NM_001164393 
/// NM_007358 
0.000565 1.24652 
18126 11733217_s_at 54532 USP53 ubiquitin specific peptidase 53 NM_019050 0.002523 1.24647 
40890 11755981_a_at 1839 HBEGF heparin-binding EGF-like growth 
factor 
NM_001945 0.011996 1.24633 
45295 11760386_at 3603 IL16 interleukin 16 NM_001172128 
/// NM_004513 
/// NM_172217 
0.001816 1.24611 
272 
 
7438 11722529_a_at 11099 PTPN21 protein tyrosine phosphatase, non-
receptor type 21 
NM_007039 0.012155 1.24601 
46135 11761226_at 2694 GIF gastric intrinsic factor (vitamin B 
synthesis) 
NM_005142 0.001051 1.24582 
32742 11747833_a_at 8462 KLF11 Kruppel-like factor 11 NM_001177716 
/// 
NM_001177718 
/// NM_003597 
0.006155 1.24577 
23517 11738608_a_at 341359 SYT10 synaptotagmin X NM_198992 0.004228 1.24543 
21565 11736656_a_at 11245 GPR176 G protein-coupled receptor 176 NM_007223 0.01871 1.24512 
41948 11757039_a_at 331 XIAP X-linked inhibitor of apoptosis NM_001167 /// 
NM_001204401 
/// NR_037916 
0.020739 1.24375 
14304 11729395_s_at 143279 HECTD2 HECT domain containing E3 
ubiquitin protein ligase 2 
NM_173497 /// 
NM_182765 
0.047803 1.24322 
12237 11727328_at 50964 SOST sclerostin NM_025237 0.002652 1.24321 
25572 11740663_a_at 283464 GXYLT1 glucoside xylosyltransferase 1 NM_001099650 
/// NM_173601 
0.0036 1.24301 
31603 11746694_a_at 5048 PAFAH1B1 platelet-activating factor 
acetylhydrolase 1b, regulatory 
subunit 1 (45kDa) 
NM_000430 0.009477 1.24257 
2725 11717816_at 9925 ZBTB5 zinc finger and BTB domain 
containing 5 
NM_014872 0.007584 1.24193 
27461 11742552_at 138802 OR13C8 olfactory receptor, family 13, 
subfamily C, member 8 
NM_001004483 0.019104 1.24135 
14983 11730074_a_at 27152 INTU inturned planar cell polarity effector 
homolog (Drosophila) 
NM_015693 0.011 1.24103 
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9788 11724879_at 7764 ZNF217 zinc finger protein 217 NM_006526 0.003191 1.2409 
22112 11737203_a_at 220972 Mar-08 membrane-associated ring finger 
(C3HC4) 8, E3 ubiquitin protein 
ligase 
NM_001002265 
/// 
NM_001002266 
/// NM_145021 
0.034602 1.24087 
21241 11736332_a_at 51230 PHF20 PHD finger protein 20 NM_016436 0.015175 1.24053 
393 11715484_a_at 4170 MCL1 myeloid cell leukemia sequence 1 
(BCL2-related) 
NM_001197320 
/// NM_021960 
/// NM_182763 
0.035193 1.24053 
48603 11763694_a_at 2744 GLS glutaminase NM_001256310 
/// NM_014905 
0.012074 1.24001 
20996 11736087_at 221061 FAM171A1 family with sequence similarity 
171, member A1 
NM_001010924 0.018744 1.24 
44792 11759883_x_at 6728 /// 7310 SRP19 /// 
ZRSR1 
signal recognition particle 19kDa /// 
zinc finger (CCCH type), RNA-
binding motif and se 
NM_001204193 
/// 
NM_001204194 
/// 
NM_001204196 
/// 
NM_001204199 
/// NM_003135 
3.99E-05 1.23945 
23155 11738246_at 4995 OR3A2 olfactory receptor, family 3, 
subfamily A, member 2 
NM_002551 0.008776 1.23922 
29272 11744363_s_at 3635 INPP5D inositol polyphosphate-5-
phosphatase, 145kDa 
NM_001017915 
/// NM_005541 
0.018179 1.23902 
2763 11717854_a_at 65982 ZSCAN18 zinc finger and SCAN domain 
containing 18 
NM_001145542 
/// 
NM_001145543 
0.013494 1.23844 
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/// 
NM_001145544 
/// NM_023926 
/// NR_027135 
29650 11744741_at 29931 LINC00312 long intergenic non-protein coding 
RNA 312 
NM_013343 /// 
NR_024065 
0.003108 1.23786 
24161 11739252_x_at 3283 HSD3B1 hydroxy-delta-5-steroid 
dehydrogenase, 3 beta- and steroid 
delta-isomerase 1 
NM_000862 0.049947 1.23781 
4274 11719365_x_at 26010 SPATS2L spermatogenesis associated, serine-
rich 2-like 
NM_001100422 
/// 
NM_001100423 
/// 
NM_001100424 
/// NM_015535 
0.033337 1.23768 
8487 11723578_a_at 221710 C6orf228 chromosome 6 open reading frame 
228 
NM_001135575 0.00989 1.23738 
36002 11751093_a_at 140578 CHODL chondrolectin NM_001204174 
/// 
NM_001204175 
/// 
NM_001204176 
/// 
NM_001204177 
/// 
NM_001204178 
/// NM 
0.03011 1.23735 
30133 11745224_a_at 55183 RIF1 RAP1 interacting factor homolog NM_001177663 0.018213 1.23664 
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(yeast) /// 
NM_001177664 
/// 
NM_001177665 
/// NM_018151 
13386 11728477_at 2921 CXCL3 chemokine (C-X-C motif) ligand 3 NM_002090 0.007987 1.23654 
26536 11741627_a_at 54879 ST7L suppression of tumorigenicity 7 like NM_017744 /// 
NM_138727 /// 
NM_138728 /// 
NM_138729 /// 
NM_198327 /// 
NM_198328 
0.010353 1.23633 
47359 11762450_at 136259 KLF14 Kruppel-like factor 14 NM_138693 0.043271 1.23607 
14823 11729914_at 221079 ARL5B ADP-ribosylation factor-like 5B NM_178815 0.010794 1.23602 
46061 11761152_at 79958 DENND1C DENN/MADD domain containing 
1C 
NM_024898 0.017763 1.23586 
43577 11758668_s_at 100294341 /// 
100506084 /// 
51326 
ARL17A /// 
ARL17B /// 
LOC100294341 
ADP-ribosylation factor-like 17A /// 
ADP-ribosylation factor-like 17B /// 
ADP-ribosylat 
NM_001039083 
/// 
NM_001103154 
/// 
NM_001113738 
/// NM_016632 
/// NR_003653 
/// XM_00234 
0.019806 1.23567 
39143 11754234_a_at 23008 KLHDC10 kelch domain containing 10 NM_014997 0.038512 1.23523 
23601 11738692_at 79295 OR5H6 olfactory receptor, family 5, 
subfamily H, member 6 
NM_001005479 0.013145 1.2352 
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37627 11752718_a_at 2664 GDI1 GDP dissociation inhibitor 1 NM_001493 0.015251 1.2352 
29104 11744195_at 120114 FAT3 FAT tumor suppressor homolog 3 
(Drosophila) 
NM_001008781 0.047457 1.23493 
46606 11761697_a_at 56683 C21orf59 chromosome 21 open reading frame 
59 
NM_017835 /// 
NM_021254 /// 
NR_036552 
0.025338 1.23413 
24347 11739438_at 160760 PPTC7 PTC7 protein phosphatase homolog 
(S. cerevisiae) 
NM_139283 0.000303 1.23357 
4579 11719670_a_at 10231 RCAN2 regulator of calcineurin 2 NM_001251973 
/// 
NM_001251974 
/// NM_005822 
0.048183 1.23326 
32141 11747232_a_at 121512 FGD4 FYVE, RhoGEF and PH domain 
containing 4 
NM_139241 0.029658 1.23306 
44639 11759730_a_at 100509445 /// 
144203 
LOC100509445 
/// OVOS2 
uncharacterized LOC100509445 /// 
ovostatin 2 
NM_001080502 
/// NM_173498 
/// 
XM_002343151 
/// XR_111273 
0.027874 1.23287 
43030 11758121_s_at 155435 RBM33 RNA binding motif protein 33 NM_001008408 
/// NM_053043 
0.000144 1.23256 
15487 11730578_at 79924 ADM2 adrenomedullin 2 NM_001253845 
/// NM_024866 
0.046445 1.2312 
47366 11762457_a_at 23503 ZFYVE26 zinc finger, FYVE domain 
containing 26 
NM_015346 0.038941 1.2311 
14799 11729890_at 124961 ZFP3 zinc finger protein 3 homolog 
(mouse) 
NM_153018 0.024672 1.23094 
796 11715887_s_at 8396 PIP4K2B phosphatidylinositol-5-phosphate 4- NM_003559 /// 0.003702 1.23093 
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kinase, type II, beta NM_138687 
33940 11749031_a_at 9991 PTBP3 polypyrimidine tract binding protein 
3 
NM_001163788 
/// 
NM_001163790 
/// 
NM_001244896 
/// 
NM_001244897 
/// 
NM_001244898 
/// NM 
0.026234 1.23019 
43024 11758115_s_at 58155 PTBP2 polypyrimidine tract binding protein 
2 
NM_021190 0.001825 1.23012 
16451 11731542_at 91404 SESTD1 SEC14 and spectrin domains 1 NM_178123 0.002545 1.22995 
10719 11725810_at 2979 GUCA1B guanylate cyclase activator 1B 
(retina) 
NM_002098 0.040224 1.22944 
2948 11718039_at 25853 DCAF12 DDB1 and CUL4 associated factor 
12 
NM_015397 0.016767 1.22928 
34468 11749559_x_at 11283 CYP4F8 cytochrome P450, family 4, 
subfamily F, polypeptide 8 
NM_007253 0.017426 1.22924 
40427 11755518_a_at 494470 RNF165 ring finger protein 165 NM_001256758 
/// NM_152470 
/// NR_046357 
0.01622 1.22861 
3849 11718940_a_at 7128 TNFAIP3 tumor necrosis factor, alpha-
induced protein 3 
NM_006290 0.013174 1.22859 
46793 11761884_at 5889 RAD51C RAD51 homolog C (S. cerevisiae) NM_002876 /// 
NM_058216 /// 
NM_058217 
0.006566 1.22801 
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24481 11739572_x_at 55205 ZNF532 zinc finger protein 532 NM_018181 0.010761 1.22762 
33059 11748150_a_at 9656 MDC1 mediator of DNA-damage 
checkpoint 1 
NM_014641 0.046649 1.22729 
38527 11753618_a_at 133 ADM adrenomedullin NM_001124 0.006389 1.22623 
21227 11736318_a_at 154007 SNRNP48 small nuclear ribonucleoprotein 
48kDa (U11/U12) 
NM_152551 0.002368 1.22595 
28803 11743894_at 284323 ZNF780A zinc finger protein 780A NM_001010880 
/// 
NM_001142577 
/// 
NM_001142578 
/// 
NM_001142579 
0.026262 1.22553 
36922 11752013_s_at 80205 CHD9 chromodomain helicase DNA 
binding protein 9 
NM_025134 0.045542 1.22551 
36442 11751533_a_at 2444 FRK fyn-related kinase NM_002031 0.028489 1.22539 
19567 11734658_s_at 2353 FOS FBJ murine osteosarcoma viral 
oncogene homolog 
NM_005252 0.01176 1.22511 
13506 11728597_a_at 7673 ZNF222 zinc finger protein 222 NM_001129996 
/// NM_013360 
0.029226 1.22485 
35353 11750444_a_at 776 CACNA1D calcium channel, voltage-
dependent, L type, alpha 1D subunit 
NM_000720 /// 
NM_001128839 
/// 
NM_001128840 
0.005557 1.22406 
44046 11759137_at 10585 POMT1 protein-O-mannosyltransferase 1 NM_001077365 
/// 
NM_001077366 
0.012201 1.22386 
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/// 
NM_001136113 
/// 
NM_001136114 
/// NM_007171 
37376 11752467_s_at 3635 INPP5D inositol polyphosphate-5-
phosphatase, 145kDa 
NM_001017915 
/// NM_005541 
0.003022 1.22351 
44054 11759145_s_at 9173 IL1RL1 interleukin 1 receptor-like 1 NM_003856 /// 
NM_016232 /// 
NM_173459 
0.016449 1.22324 
44482 11759573_at 10724 MGEA5 meningioma expressed antigen 5 
(hyaluronidase) 
NM_001142434 
/// NM_012215 
0.023199 1.22209 
37498 11752589_a_at 5540 PPYR1 pancreatic polypeptide receptor 1 NM_005972 0.022882 1.22179 
675 11715766_a_at 1843 DUSP1 dual specificity phosphatase 1 NM_004417 0.005511 1.22177 
36906 11751997_a_at 399687 MYO18A myosin XVIIIA NM_078471 /// 
NM_203318 
0.036035 1.22167 
48103 11763194_at 1.01E+08 LOC100506082 uncharacterized LOC100506082 NR_047550 /// 
XR_109054 /// 
XR_111147 
0.007723 1.22163 
10270 11725361_s_at 4089 SMAD4 SMAD family member 4 NM_005359 0.002408 1.2216 
47803 11762894_at 9527 GOSR1 golgi SNAP receptor complex 
member 1 
NM_001007024 
/// 
NM_001007025 
/// NM_004871 
0.033332 1.2212 
34085 11749176_a_at 8780 RIOK3 RIO kinase 3 (yeast) NM_003831 /// 
NM_145906 
0.001997 1.22083 
24118 11739209_a_at 5562 PRKAA1 protein kinase, AMP-activated, NM_006251 /// 0.008875 1.22068 
280 
 
alpha 1 catalytic subunit NM_206907 
25593 11740684_at 341208 HEPHL1 hephaestin-like 1 NM_001098672 0.014642 1.22068 
18994 11734085_a_at 159296 NKX2-3 NK2 homeobox 3 NM_145285 0.028933 1.22047 
41110 11756201_x_at 1117 CHI3L2 chitinase 3-like 2 NM_001025197 
/// 
NM_001025199 
/// NM_004000 
0.040509 1.22015 
28896 11743987_a_at 7407 VARS valyl-tRNA synthetase NM_006295 0.009002 1.21947 
37467 11752558_a_at 540 ATP7B ATPase, Cu++ transporting, beta 
polypeptide 
NM_000053 /// 
NM_001005918 
/// 
NM_001243182 
0.029206 1.21908 
21964 11737055_at 339500 ZNF678 zinc finger protein 678 NM_032755 /// 
NM_178549 /// 
NR_033184 
0.041419 1.21824 
32616 11747707_x_at 79957 PAQR6 progestin and adipoQ receptor 
family member VI 
NM_024897 /// 
NM_198406 
0.031735 1.21708 
6804 11721895_x_at 2619 GAS1 growth arrest-specific 1 NM_002048 0.016278 1.2168 
32689 11747780_x_at 100132565 /// 
100132979 /// 
283768 /// 
390535 /// 
729786 
GOLGA8C /// 
GOLGA8DP /// 
GOLGA8E /// 
GOLGA8F /// 
GOLGA8G 
golgin A8 family, member C /// 
golgin A8 family, member D, 
pseudogene /// golgin A8 fam 
NM_001012420 
/// 
NM_001012423 
/// 
NM_001012452 
/// 
NM_001164328 
/// NR_027407 
/// NR_02 
0.013877 1.21676 
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8770 11723861_a_at 10396 ATP8A1 ATPase, aminophospholipid 
transporter (APLT), class I, type 
8A, member 1 
NM_001105529 
/// NM_006095 
0.015754 1.21643 
4620 11719711_a_at 5170 PDPK1 3-phosphoinositide dependent 
protein kinase-1 
NM_001261816 
/// NM_002613 
/// NM_031268 
0.005326 1.21637 
35697 11750788_a_at 53944 CSNK1G1 casein kinase 1, gamma 1 NM_022048 0.049956 1.21629 
22805 11737896_s_at 6884 TAF13 TAF13 RNA polymerase II, TATA 
box binding protein (TBP)-
associated factor, 18kDa 
NM_005645 0.030982 1.21627 
45350 11760441_at --- --- --- --- 0.021806 1.21615 
16352 11731443_a_at 23365 ARHGEF12 Rho guanine nucleotide exchange 
factor (GEF) 12 
NM_001198665 
/// NM_015313 
0.014638 1.21611 
37257 11752348_a_at 23329 TBC1D30 TBC1 domain family, member 30 NM_015279 0.000506 1.21582 
9174 11724265_x_at 64792 RABL5 RAB, member RAS oncogene 
family-like 5 
NM_001130820 
/// 
NM_001130821 
/// 
NM_001130822 
/// NM_022777 
0.008203 1.21567 
11619 11726710_at 5198 PFAS phosphoribosylformylglycinamidine 
synthase 
NM_012393 0.036226 1.21545 
2726 11717817_a_at 27327 TNRC6A trinucleotide repeat containing 6A NM_014494 0.038278 1.215 
36913 11752004_s_at 285190 /// 
400966 /// 
653489 /// 
727851 /// 
GCC2 /// 
RGPD1 /// 
RGPD2 /// 
RGPD3 /// 
GRIP and coiled-coil domain 
containing 2 /// RANBP2-like and 
GRIP domain containing 1 / 
NM_001024457 
/// 
NM_001037866 
/// 
0.016404 1.21494 
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729540 /// 
729857 /// 
84220 /// 9648 
RGPD4 /// 
RGPD5 /// 
RGPD6 /// 
RGPD8 
NM_001078170 
/// 
NM_001123363 
/// 
NM_001144013 
/// NM 
40005 11755096_x_at 54522 ANKRD16 ankyrin repeat domain 16 NM_001009941 
/// 
NM_001009942 
/// 
NM_001009943 
/// NM_019046 
0.042942 1.21422 
22026 11737117_at 140886 PABPC5 poly(A) binding protein, 
cytoplasmic 5 
NM_080832 0.00566 1.2138 
14824 11729915_at 221079 ARL5B ADP-ribosylation factor-like 5B NM_178815 0.012378 1.21361 
43672 11758763_at 10539 GLRX3 glutaredoxin 3 NM_001199868 
/// NM_006541 
0.020701 1.2136 
27935 11743026_at 441061 Mar-11 membrane-associated ring finger 
(C3HC4) 11 
NM_001102562 0.038116 1.21257 
44027 11759118_at 55033 FKBP14 FK506 binding protein 14, 22 kDa NM_017946 /// 
NR_046478 /// 
NR_046479 
0.046397 1.21246 
44233 11759324_s_at 387119 CEP85L centrosomal protein 85kDa-like NM_001042475 
/// 
NM_001178035 
/// NM_206921 
0.028967 1.21225 
29736 11744827_a_at 1195 CLK1 CDC-like kinase 1 NM_001024646 
/// 
0.00234 1.21213 
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NM_001162407 
/// NM_004071 
/// NR_027855 
/// NR_027856 
19938 11735029_a_at 23332 CLASP1 cytoplasmic linker associated 
protein 1 
NM_001142273 
/// 
NM_001142274 
/// 
NM_001207051 
/// NM_015282 
0.029295 1.21176 
8498 11723589_at 149041 RC3H1 ring finger and CCCH-type domains 
1 
NM_172071 0.027939 1.21146 
27048 11742139_a_at 56244 BTNL2 butyrophilin-like 2 (MHC class II 
associated) 
NM_019602 0.032138 1.21144 
31030 11746121_a_at 79748 LMAN1L lectin, mannose-binding, 1 like NM_021819 0.032029 1.2113 
13991 11729082_at 126326 GIPC3 GIPC PDZ domain containing 
family, member 3 
NM_133261 0.024095 1.21107 
18528 11733619_a_at 130399 ACVR1C activin A receptor, type IC NM_001111031 
/// 
NM_001111032 
/// 
NM_001111033 
/// NM_145259 
0.042315 1.21106 
21814 11736905_a_at 4920 ROR2 receptor tyrosine kinase-like orphan 
receptor 2 
NM_004560 0.009594 1.21083 
6595 11721686_at 404203 SPINK6 serine peptidase inhibitor, Kazal 
type 6 
NM_001195290 
/// NM_205841 
0.018649 1.21066 
26220 11741311_a_at 79027 ZNF655 zinc finger protein 655 NM_001009956 0.03515 1.21041 
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/// 
NM_001009957 
/// 
NM_001009958 
/// 
NM_001009960 
/// 
NM_001083956 
/// NM 
45443 11760534_a_at 145957 NRG4 neuregulin 4 NM_138573 0.036378 1.21026 
33389 11748480_a_at 94015 TTYH2 tweety homolog 2 (Drosophila) NM_032646 /// 
NM_052869 
0.036607 1.21014 
20155 11735246_a_at 162514 TRPV3 transient receptor potential cation 
channel, subfamily V, member 3 
NM_001258205 
/// NM_145068 
0.018568 1.21009 
27466 11742557_s_at 10776 ARPP19 cAMP-regulated phosphoprotein, 
19kDa 
NM_006628 0.018819 1.20926 
5437 11720528_at 4053 LTBP2 latent transforming growth factor 
beta binding protein 2 
NM_000428 0.039292 1.20923 
38468 11753559_at 6290 SAA3P serum amyloid A3 pseudogene NR_026576 0.009259 1.20917 
37985 11753076_a_at 199 AIF1 allograft inflammatory factor 1 NM_001623 /// 
NM_004847 /// 
NM_032955 
0.004023 1.20905 
17761 11732852_a_at 23439 ATP1B4 ATPase, Na+/K+ transporting, beta 
4 polypeptide 
NM_001142447 
/// NM_012069 
0.036087 1.20882 
10271 11725362_x_at 4089 SMAD4 SMAD family member 4 NM_005359 0.002608 1.20881 
1002 11716093_a_at 1316 KLF6 Kruppel-like factor 6 NM_001008490 
/// 
0.000219 1.2088 
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NM_001160124 
/// 
NM_001160125 
/// NM_001300 
/// NR_027653 
46249 11761340_x_at 730092 RRN3P1 RNA polymerase I transcription 
factor homolog (S. cerevisiae) 
pseudogene 1 
NR_003370 0.039998 1.20879 
12397 11727488_s_at 54801 HAUS6 HAUS augmin-like complex, 
subunit 6 
NM_017645 0.020478 1.20876 
25636 11740727_a_at 93426 SYCE1 synaptonemal complex central 
element protein 1 
NM_001143763 
/// 
NM_001143764 
/// NM_130784 
/// NM_201564 
0.010377 1.20872 
44751 11759842_at 5793 PTPRG protein tyrosine phosphatase, 
receptor type, G 
NM_002841 0.030621 1.20791 
44338 11759429_a_at 8609 KLF7 Kruppel-like factor 7 (ubiquitous) NM_003709 0.005981 1.20767 
46903 11761994_at 57679 ALS2 amyotrophic lateral sclerosis 2 
(juvenile) 
NM_001135745 
/// NM_020919 
0.015366 1.20659 
24541 11739632_at 9969 MED13 mediator complex subunit 13 NM_005121 0.026684 1.20602 
2294 11717385_a_at 4495 MT1G metallothionein 1G NM_005950 0.003447 1.20593 
1680 11716771_s_at 150094 SIK1 salt-inducible kinase 1 NM_173354 0.001637 1.20559 
41460 11756551_a_at 54813 KLHL28 kelch-like 28 (Drosophila) NM_017658 0.009263 1.20558 
36273 11751364_a_at 55244 SLC47A1 solute carrier family 47, member 1 NM_018242 0.016366 1.20494 
28133 11743224_a_at 100653339 /// 
440073 
IQSEC3 /// 
LOC100653339 
IQ motif and Sec7 domain 3 /// IQ 
motif and SEC7 domain-containing 
NM_001170738 
/// NM_015232 
0.011637 1.20476 
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protein 3-like /// 
XM_003403736 
38049 11753140_at 257103 LINC00205 long intergenic non-protein coding 
RNA 205 
NM_153454 /// 
XR_040463 /// 
XR_040465 
0.000564 1.20373 
44426 11759517_a_at 80852 GRIP2 glutamate receptor interacting 
protein 2 
NM_001080423 0.040939 1.20373 
1656 11716747_a_at 4299 AFF1 AF4/FMR2 family, member 1 NM_001166693 
/// NM_005935 
0.006439 1.20357 
20978 11736069_at 23210 JMJD6 jumonji domain containing 6 NM_001081461 
/// NM_015167 
0.004452 1.2034 
32360 11747451_a_at 7629 ZNF76 zinc finger protein 76 NM_003427 0.035542 1.20295 
45800 11760891_s_at 150763 GPAT2 glycerol-3-phosphate 
acyltransferase 2, mitochondrial 
NM_207328 0.002945 1.20286 
13461 11728552_a_at 64386 MMP25 matrix metallopeptidase 25 NM_004142 /// 
NM_022468 /// 
NM_022718 
0.040485 1.20244 
33819 11748910_a_at 100129518 /// 
6648 
LOC100129518 
/// SOD2 
uncharacterized LOC100129518 /// 
superoxide dismutase 2, 
mitochondrial 
NM_000636 /// 
NM_001024465 
/// 
NM_001024466 
/// NR_037166 
0.036578 1.20217 
15806 11730897_a_at 23063 WAPAL wings apart-like homolog 
(Drosophila) 
NM_015045 0.004747 1.20202 
46644 11761735_a_at 6257 RXRB retinoid X receptor, beta NM_001270401 
/// NM_021976 
0.040682 1.20177 
25482 11740573_a_at 222389 BEND7 BEN domain containing 7 NM_001100912 
/// NM_152751 
0.034076 1.20144 
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20211 11735302_a_at 84435 GPR123 G protein-coupled receptor 123 NM_001083909 
/// NM_032422 
0.045542 1.20118 
20909 11736000_x_at 163049 ZNF791 zinc finger protein 791 NM_153358 0.046129 1.20101 
20047 11735138_a_at 29951 PDZRN4 PDZ domain containing ring finger 
4 
NM_001164595 
/// NM_013377 
0.00855 1.20018 
44744 11759835_at 55795 PCID2 PCI domain containing 2 NM_001127202 
/// 
NM_001127203 
/// 
NM_001258212 
/// 
NM_001258213 
/// NM_018386 
0.023097 -1.20021 
12646 11727737_s_at 9465 AKAP7 A kinase (PRKA) anchor protein 7 NM_004842 /// 
NM_016377 /// 
NM_138633 
0.005521 -1.20033 
43302 11758393_s_at 84277 DNAJC30 DnaJ (Hsp40) homolog, subfamily 
C, member 30 
NM_032317 0.002108 -1.20051 
14010 11729101_a_at 100653286 /// 
1646 
AKR1C2 /// 
LOC100653286 
aldo-keto reductase family 1, 
member C2 (dihydrodiol 
dehydrogenase 2; bile acid binding 
NM_001135241 
/// NM_001354 
/// NM_205845 
/// 
XM_003403856 
0.000145 -1.20056 
40770 11755861_a_at 64900 LPIN3 lipin 3 NM_022896 0.018203 -1.20081 
35094 11750185_a_at 168455 CCDC71L coiled-coil domain containing 71-
like 
NM_175884 0.000983 -1.20092 
36532 11751623_s_at 9179 AP4M1 adaptor-related protein complex 4, 
mu 1 subunit 
NM_004722 0.000987 -1.20124 
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36540 11751631_s_at 9179 AP4M1 adaptor-related protein complex 4, 
mu 1 subunit 
NM_004722 0.000987 -1.20124 
49069 11764160_at --- --- --- --- 0.005169 -1.20153 
41283 11756374_a_at 8460 TPST1 tyrosylprotein sulfotransferase 1 NM_003596 0.033913 -1.20214 
6377 11721468_at 114327 EFHC1 EF-hand domain (C-terminal) 
containing 1 
NM_001172420 
/// NM_018100 
/// NR_033327 
0.018092 -1.20227 
48108 11763199_at 5094 PCBP2 poly(rC) binding protein 2 NM_001098620 
/// 
NM_001128911 
/// 
NM_001128912 
/// 
NM_001128913 
/// 
NM_001128914 
/// NM 
0.034997 -1.20228 
22247 11737338_a_at 84503 ZNF527 zinc finger protein 527 NM_032453 0.018612 -1.20246 
40076 11755167_s_at 729678 LOC729678 uncharacterized LOC729678 NR_027183 /// 
NR_045678 /// 
NR_045679 
0.007106 -1.20249 
17601 11732692_at 140711 C20orf118 chromosome 20 open reading frame 
118 
NM_080628 0.029336 -1.20265 
2511 11717602_a_at 79048 SECISBP2 SECIS binding protein 2 NM_024077 0.049288 -1.20265 
24123 11739214_at 79085 SLC25A23 solute carrier family 25 
(mitochondrial carrier; phosphate 
carrier), member 23 
NM_024103 0.029546 -1.20285 
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34300 11749391_x_at 23475 QPRT quinolinate 
phosphoribosyltransferase 
NM_014298 0.006679 -1.20335 
12774 11727865_a_at 9481 SLC25A27 solute carrier family 25, member 27 NM_001204051 
/// 
NM_001204052 
/// NM_004277 
0.022818 -1.20457 
39133 11754224_x_at 100271927 /// 
10156 
RASA4 /// 
RASA4B 
RAS p21 protein activator 4 /// RAS 
p21 protein activator 4B 
NM_001079877 
/// NM_006989 
/// 
XM_003118598 
/// 
XM_003118599 
/// 
XM_003118600 
/// XM_00 
0.006129 -1.20463 
14328 11729419_a_at 489 ATP2A3 ATPase, Ca++ transporting, 
ubiquitous 
NM_005173 /// 
NM_174953 /// 
NM_174954 /// 
NM_174955 /// 
NM_174956 /// 
NM_174957 /// 
NM_ 
0.005561 -1.20467 
22330 11737421_at 345079 SOWAHB sosondowah ankyrin repeat domain 
family member B 
NM_001029870 0.044605 -1.20471 
1021 11716112_at 5284 PIGR polymeric immunoglobulin receptor NM_002644 0.016502 -1.20495 
26052 11741143_x_at 50507 NOX4 NADPH oxidase 4 NM_001143836 
/// 
NM_001143837 
0.020971 -1.20507 
290 
 
/// NM_016931 
/// NR_026571 
2569 11717660_a_at 26051 PPP1R16B protein phosphatase 1, regulatory 
subunit 16B 
NM_001172735 
/// NM_015568 
0.046059 -1.20543 
40431 11755522_a_at 9404 LPXN leupaxin NM_001143995 
/// NM_004811 
0.018913 -1.20549 
2721 11717812_a_at 3797 KIF3C kinesin family member 3C NM_002254 0.011076 -1.20567 
6451 11721542_a_at 92979 Mar-09 membrane-associated ring finger 
(C3HC4) 9 
NM_138396 0.03139 -1.20585 
29723 11744814_a_at 5108 PCM1 pericentriolar material 1 NM_006197 0.039572 -1.20608 
31866 11746957_a_at 8794 TNFRSF10C tumor necrosis factor receptor 
superfamily, member 10c, decoy 
without an intracellular  
NM_003841 0.005701 -1.20612 
35173 11750264_x_at 55266 TMEM19 transmembrane protein 19 NM_018279 0.01368 -1.20624 
31547 11746638_a_at 79154 DHRS11 dehydrogenase/reductase (SDR 
family) member 11 
NM_024308 0.040247 -1.20662 
10073 11725164_at 136895 C7orf31 chromosome 7 open reading frame 
31 
NM_138811 0.008362 -1.20684 
6624 11721715_s_at 546 ATRX alpha thalassemia/mental 
retardation syndrome X-linked 
NM_000489 /// 
NM_138270 /// 
NM_138271 
0.009359 -1.20697 
41186 11756277_a_at 29799 YPEL1 yippee-like 1 (Drosophila) NM_013313 0.006849 -1.20719 
27377 11742468_at 644943 RASSF10 Ras association (RalGDS/AF-6) 
domain family (N-terminal) 
member 10 
NM_001080521 0.022588 -1.20719 
28881 11743972_a_at 54541 DDIT4 DNA-damage-inducible transcript 4 NM_019058 0.023377 -1.20731 
27639 11742730_a_at 828 CAPS calcyphosine NM_004058 /// 0.012728 -1.20756 
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NM_080590 
48285 11763376_s_at 5094 PCBP2 poly(rC) binding protein 2 NM_001098620 
/// 
NM_001128911 
/// 
NM_001128912 
/// 
NM_001128913 
/// 
NM_001128914 
/// NM 
0.035006 -1.20845 
11539 11726630_a_at 27429 HTRA2 HtrA serine peptidase 2 NM_013247 /// 
NM_145074 
0.025179 -1.20892 
14747 11729838_at 54877 ZCCHC2 zinc finger, CCHC domain 
containing 2 
NM_017742 0.036758 -1.20895 
25014 11740105_x_at 200728 TMEM17 transmembrane protein 17 NM_198276 0.016459 -1.209 
37766 11752857_x_at 2875 GPT glutamic-pyruvate transaminase 
(alanine aminotransferase) 
NM_005309 0.019151 -1.2099 
33818 11748909_a_at 665 BNIP3L BCL2/adenovirus E1B 19kDa 
interacting protein 3-like 
NM_004331 0.004611 -1.20994 
38331 11753422_a_at 665 BNIP3L BCL2/adenovirus E1B 19kDa 
interacting protein 3-like 
NM_004331 0.004611 -1.20994 
10162 11725253_at 6928 HNF1B HNF1 homeobox B NM_000458 /// 
NM_001165923 
/// NM_006481 
0.002235 -1.20999 
13604 11728695_at 384 ARG2 arginase, type II NM_001172 0.030119 -1.21058 
166 11715257_x_at 170626 XAGE3 X antigen family, member 3 NM_130776 /// 0.045026 -1.21082 
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NM_133179 
2683 11717774_a_at 58473 PLEKHB1 pleckstrin homology domain 
containing, family B (evectins) 
member 1 
NM_001130033 
/// 
NM_001130034 
/// 
NM_001130035 
/// 
NM_001130036 
/// NM_021200 
0.007767 -1.21093 
46027 11761118_at 56904 SH3GLB2 SH3-domain GRB2-like endophilin 
B2 
NM_020145 0.027158 -1.21112 
21296 11736387_a_at 18 ABAT 4-aminobutyrate aminotransferase NM_000663 /// 
NM_001127448 
/// NM_020686 
0.009395 -1.21135 
1846 11716937_a_at 26471 NUPR1 nuclear protein, transcriptional 
regulator, 1 
NM_001042483 
/// NM_012385 
0.031886 -1.21142 
36077 11751168_s_at 100532746 /// 
80864 /// 9374 
EGFL8 /// 
PPT2 /// PPT2-
EGFL8 
EGF-like-domain, multiple 8 /// 
palmitoyl-protein thioesterase 2 /// 
PPT2-EGFL8 readthr 
NM_001204103 
/// NM_005155 
/// NM_030652 
/// NM_138717 
/// NM_138934 
/// NR_037860 
///  
0.049869 -1.21157 
17348 11732439_a_at 27293 SMPDL3B sphingomyelin phosphodiesterase, 
acid-like 3B 
NM_001009568 
/// NM_014474 
0.046449 -1.21209 
29214 11744305_a_at 79705 LRRK1 leucine-rich repeat kinase 1 NM_024652 0.007476 -1.2121 
37593 11752684_a_at 283461 C12orf40 chromosome 12 open reading frame 
40 
NM_001031748 
/// NM_173599 
0.033035 -1.21296 
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37947 11753038_a_at 27241 BBS9 Bardet-Biedl syndrome 9 NM_001033604 
/// 
NM_001033605 
/// NM_014451 
/// NM_198428 
0.007922 -1.21345 
10381 11725472_a_at 85315 PAQR8 progestin and adipoQ receptor 
family member VIII 
NM_133367 0.019707 -1.21345 
20959 11736050_s_at 619208 C6orf225 chromosome 6 open reading frame 
225 
NM_001033564 0.006055 -1.21369 
16392 11731483_a_at 25927 CNRIP1 cannabinoid receptor interacting 
protein 1 
NM_001111101 
/// NM_015463 
0.047908 -1.21401 
28175 11743266_a_at 6164 RPL34 ribosomal protein L34 NM_000995 /// 
NM_033625 
0.001965 -1.21418 
27525 11742616_at 390148 OR5W2 olfactory receptor, family 5, 
subfamily W, member 2 
NM_001001960 0.043484 -1.21431 
4131 11719222_at 6690 SPINK1 serine peptidase inhibitor, Kazal 
type 1 
NM_003122 0.001685 -1.21453 
31117 11746208_a_at 578 BAK1 BCL2-antagonist/killer 1 NM_001188 0.007218 -1.21486 
23343 11738434_s_at 390443 RNASE9 ribonuclease, RNase A family, 9 
(non-active) 
NM_001001673 
/// 
NM_001110356 
/// 
NM_001110357 
/// 
NM_001110358 
/// 
NM_001110359 
/// NM 
0.040511 -1.21499 
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42458 11757549_s_at 64755 C16orf58 chromosome 16 open reading frame 
58 
NM_022744 0.004109 -1.215 
23029 11738120_x_at 138474 TAF1L TAF1 RNA polymerase II, TATA 
box binding protein (TBP)-
associated factor, 210kDa-like 
NM_153809 0.028277 -1.21572 
17123 11732214_at 7586 ZKSCAN1 zinc finger with KRAB and SCAN 
domains 1 
NM_003439 0.011543 -1.2161 
31463 11746554_a_at 100505813 /// 
6678 
LOC100505813 
/// SPARC 
uncharacterized LOC100505813 /// 
secreted protein, acidic, cysteine-
rich (osteonectin) 
NM_003118 /// 
XR_110317 /// 
XR_110318 /// 
XR_110319 /// 
XR_133410 /// 
XR_133411 /// 
XR_ 
0.023456 -1.2163 
9709 11724800_a_at 23475 QPRT quinolinate 
phosphoribosyltransferase 
NM_014298 0.005231 -1.21631 
8714 11723805_a_at 9590 AKAP12 A kinase (PRKA) anchor protein 12 NM_005100 /// 
NM_144497 
0.046348 -1.21649 
3897 11718988_s_at 6038 RNASE4 ribonuclease, RNase A family, 4 NM_002937 /// 
NM_194430 /// 
NM_194431 
0.008156 -1.21663 
11704 11726795_a_at 3691 ITGB4 integrin, beta 4 NM_000213 /// 
NM_001005619 
/// 
NM_001005731 
0.00242 -1.21681 
40991 11756082_a_at 4281 MID1 midline 1 (Opitz/BBB syndrome) NM_000381 /// 
NM_001098624 
/// 
0.025082 -1.21694 
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NM_001193277 
/// 
NM_001193278 
/// 
NM_001193279 
/// NM_00 
189 11715280_s_at 3728 /// 3872 JUP /// KRT17 junction plakoglobin /// keratin 17 NM_000422 /// 
NM_002230 /// 
NM_021991 
0.007101 -1.21711 
231 11715322_s_at 646486 FABP12 fatty acid binding protein 12 NM_001105281 0.044813 -1.2175 
36793 11751884_s_at 23198 PSME4 proteasome (prosome, macropain) 
activator subunit 4 
NM_014614 0.045089 -1.21759 
30737 11745828_x_at 665 BNIP3L BCL2/adenovirus E1B 19kDa 
interacting protein 3-like 
NM_004331 0.026464 -1.21781 
35309 11750400_a_at 10020 GNE glucosamine (UDP-N-acetyl)-2-
epimerase/N-acetylmannosamine 
kinase 
NM_001128227 
/// 
NM_001190383 
/// 
NM_001190384 
/// 
NM_001190388 
/// NM_005476 
0.01022 -1.21826 
38919 11754010_x_at 2801 GOLGA2 golgin A2 NM_004486 0.030603 -1.2185 
8212 11723303_at 10158 PDZK1IP1 PDZK1 interacting protein 1 NM_005764 0.005362 -1.21855 
15359 11730450_at 140825 NEURL2 neuralized homolog 2 (Drosophila) NM_080749 0.000234 -1.21876 
16204 11731295_at 55064 SPATA6L spermatogenesis associated 6-like NM_001039395 
/// NM_017985 
0.010215 -1.21931 
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33132 11748223_a_at 200879 LIPH lipase, member H NM_139248 0.020476 -1.21945 
20659 11735750_x_at 54960 GEMIN8 gem (nuclear organelle) associated 
protein 8 
NM_001042479 
/// 
NM_001042480 
/// NM_017856 
0.006971 -1.21985 
18034 11733125_a_at 5824 PEX19 peroxisomal biogenesis factor 19 NM_001131039 
/// 
NM_001193644 
/// NM_002857 
/// NR_036492 
/// NR_036493 
9.53E-05 -1.22 
29188 11744279_a_at 83998 REG4 regenerating islet-derived family, 
member 4 
NM_001159352 
/// 
NM_001159353 
/// NM_032044 
0.026264 -1.22012 
17335 11732426_a_at 9630 GNA14 guanine nucleotide binding protein 
(G protein), alpha 14 
NM_004297 0.009822 -1.22036 
431 11715522_a_at 3030 HADHA hydroxyacyl-CoA dehydrogenase/3-
ketoacyl-CoA thiolase/enoyl-CoA 
hydratase (trifunctiona 
NM_000182 0.031358 -1.22095 
39927 11755018_a_at 5501 PPP1CC protein phosphatase 1, catalytic 
subunit, gamma isozyme 
NM_001244974 
/// NM_002710 
4.23E-05 -1.22125 
4585 11719676_s_at 4128 MAOA monoamine oxidase A NM_000240 0.000409 -1.2222 
11192 11726283_s_at 59084 ENPP5 ectonucleotide 
pyrophosphatase/phosphodiesterase 
5 (putative) 
NM_021572 0.021045 -1.223 
43133 11758224_s_at 151887 CCDC80 coiled-coil domain containing 80 NM_199511 /// 
NM_199512 
0.013373 -1.2235 
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12271 11727362_x_at 7846 TUBA1A tubulin, alpha 1a NM_001270399 
/// 
NM_001270400 
/// NM_006009 
0.049391 -1.22382 
26468 11741559_a_at 312 ANXA13 annexin A13 NM_001003954 
/// NM_004306 
0.001654 -1.22403 
34825 11749916_a_at 79841 AGBL2 ATP/GTP binding protein-like 2 NM_024783 0.033135 -1.22414 
44989 11760080_at 634 CEACAM1 carcinoembryonic antigen-related 
cell adhesion molecule 1 (biliary 
glycoprotein) 
NM_001024912 
/// 
NM_001184813 
/// 
NM_001184815 
/// 
NM_001184816 
/// 
NM_001205344 
/// NM 
0.036474 -1.22479 
19063 11734154_a_at 143879 KBTBD3 kelch repeat and BTB (POZ) 
domain containing 3 
NM_152433 /// 
NM_198439 
0.003809 -1.22488 
4323 11719414_a_at 5087 PBX1 pre-B-cell leukemia homeobox 1 NM_001204961 
/// 
NM_001204963 
/// NM_002585 
0.0275 -1.22505 
10989 11726080_a_at 117248 GALNTL2 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 
2 
NM_054110 0.009221 -1.22518 
48627 11763718_x_at 1028 CDKN1C cyclin-dependent kinase inhibitor NM_000076 /// 0.03569 -1.22587 
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1C (p57, Kip2) NM_001122630 
/// 
NM_001122631 
45250 11760341_at 389161 ANKUB1 ankyrin repeat and ubiquitin domain 
containing 1 
NM_001144960 0.010898 -1.22595 
3654 11718745_s_at 57584 ARHGAP21 Rho GTPase activating protein 21 NM_020824 0.018088 -1.22613 
23465 11738556_s_at 100133046 /// 
100287534 /// 
3803 /// 3805 
/// 3813 /// 
553128 /// 
57292 
KIR2DL2 /// 
KIR2DL4 /// 
KIR2DL5A /// 
KIR2DL5B /// 
KIR3DL3 /// 
KIR3DS1 /// 
LOC100287534 
killer cell immunoglobulin-like 
receptor, two domains, long 
cytoplasmic tail, 2 /// kil 
NM_001018081 
/// 
NM_001080770 
/// 
NM_001080772 
/// 
NM_001083539 
/// 
NM_001258383 
/// NM 
0.023448 -1.22624 
1294 11716385_at 7040 TGFB1 transforming growth factor, beta 1 NM_000660 0.010381 -1.22672 
15689 11730780_x_at 126 ADH1C alcohol dehydrogenase 1C (class I), 
gamma polypeptide 
NM_000669 0.010235 -1.22684 
39145 11754236_a_at 5792 PTPRF protein tyrosine phosphatase, 
receptor type, F 
NM_002840 /// 
NM_130440 
0.009022 -1.2269 
32049 11747140_a_at 63027 SLC22A23 solute carrier family 22, member 23 NM_015482 /// 
NM_021945 
0.0003 -1.22703 
16081 11731172_s_at 342035 GLDN gliomedin NM_181789 0.002424 -1.22707 
524 11715615_at 7832 BTG2 BTG family, member 2 NM_006763 0.009668 -1.22718 
45095 11760186_at 59 ACTA2 Actin, alpha 2, smooth muscle, 
aorta 
NM_001141945 
/// NM_001613 
0.00459 -1.22722 
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38230 11753321_a_at 407977 /// 
8741 /// 8742 
TNFSF12 /// 
TNFSF12-
TNFSF13 /// 
TNFSF13 
tumor necrosis factor (ligand) 
superfamily, member 12 /// 
TNFSF12-TNFSF13 readthrough / 
NM_001198622 
/// 
NM_001198623 
/// 
NM_001198624 
/// NM_003808 
/// NM_003809 
/// NM_17208 
0.001394 -1.22778 
20432 11735523_a_at 100129583 /// 
100631383 
FAM47E /// 
FAM47E-
STBD1 
family with sequence similarity 47, 
member E /// FAM47E-STBD1 
readthrough 
NM_001136570 
/// 
NM_001242936 
/// 
NM_001242939 
0.023535 -1.22893 
43255 11758346_s_at 9060 PAPSS2 3'-phosphoadenosine 5'-
phosphosulfate synthase 2 
NM_001015880 
/// NM_004670 
0.039836 -1.229 
10964 11726055_at 8705 B3GALT4 UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypeptide 4 
NM_003782 0.00043 -1.22973 
21972 11737063_a_at 9633 MTL5 metallothionein-like 5, testis-
specific (tesmin) 
NM_001039656 
/// NM_004923 
0.018281 -1.22999 
21470 11736561_a_at 85480 TSLP thymic stromal lymphopoietin NM_033035 /// 
NM_138551 /// 
NR_033425 /// 
NR_045089 
0.049996 -1.23 
16287 11731378_a_at 81857 MED25 mediator complex subunit 25 NM_030973 0.000372 -1.23034 
43290 11758381_s_at 79640 C22orf46 chromosome 22 open reading frame 
46 
NM_001142964 
/// NM_024588 
0.043647 -1.23085 
13680 11728771_a_at 22802 CLCA4 chloride channel accessory 4 NM_012128 /// 
NR_024602 
0.048875 -1.23097 
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45858 11760949_a_at 7389 UROD uroporphyrinogen decarboxylase NM_000374 /// 
NR_036510 
0.034561 -1.23148 
37478 11752569_x_at 3932 LCK lymphocyte-specific protein 
tyrosine kinase 
NM_001042771 
/// NM_005356 
0.018114 -1.23174 
7974 11723065_at 2021 ENDOG endonuclease G NM_004435 0.001787 -1.23218 
32943 11748034_a_at 8418 CMAHP cytidine monophospho-N-
acetylneuraminic acid hydroxylase, 
pseudogene 
NR_002174 /// 
NR_027626 
0.010086 -1.23245 
41718 11756809_a_at 80258 EFHC2 EF-hand domain (C-terminal) 
containing 2 
NM_025184 0.015188 -1.23286 
8830 11723921_at 10324 /// 
129880 
BBS5 /// 
KBTBD10 
Bardet-Biedl syndrome 5 /// kelch 
repeat and BTB (POZ) domain 
containing 10 
NM_006063 /// 
NM_152384 
0.007444 -1.2331 
8982 11724073_a_at 28227 PPP2R3B protein phosphatase 2, regulatory 
subunit B'', beta 
NM_013239 /// 
NM_199326 
0.013236 -1.23367 
19632 11734723_at 10085 EDIL3 EGF-like repeats and discoidin I-
like domains 3 
NM_005711 0.019917 -1.23375 
5424 11720515_s_at 286343 LURAP1L leucine rich adaptor protein 1-like NM_203403 0.045501 -1.23386 
3386 11718477_a_at 6770 STAR steroidogenic acute regulatory 
protein 
NM_000349 /// 
NM_001007243 
0.041029 -1.23387 
38686 11753777_a_at 10242 KCNMB2 potassium large conductance 
calcium-activated channel, 
subfamily M, beta member 2 
NM_005832 /// 
NM_181361 
0.027343 -1.23408 
48626 11763717_a_at 1028 CDKN1C cyclin-dependent kinase inhibitor 
1C (p57, Kip2) 
NM_000076 /// 
NM_001122630 
/// 
NM_001122631 
0.025871 -1.23421 
301 
 
22097 11737188_x_at 165082 GPR113 G protein-coupled receptor 113 NM_001145168 
/// 
NM_001145169 
/// NM_153835 
0.005379 -1.23477 
14813 11729904_at 3268 AGFG2 ArfGAP with FG repeats 2 NM_006076 0.029345 -1.23536 
20718 11735809_a_at 221391 OPN5 opsin 5 NM_001030051 
/// NM_181744 
/// NR_033806 
0.044833 -1.23548 
24764 11739855_a_at 9765 ZFYVE16 zinc finger, FYVE domain 
containing 16 
NM_001105251 
/// NM_014733 
0.031046 -1.23554 
28026 11743117_a_at 22803 XRN2 5'-3' exoribonuclease 2 NM_012255 0.014837 -1.23564 
31855 11746946_a_at 55109 AGGF1 angiogenic factor with G patch and 
FHA domains 1 
NM_018046 0.029804 -1.23608 
34845 11749936_a_at 55869 HDAC8 histone deacetylase 8 NM_001166418 
/// 
NM_001166419 
/// 
NM_001166420 
/// 
NM_001166422 
/// 
NM_001166448 
/// NM 
0.029899 -1.23617 
8276 11723367_a_at 25837 RAB26 RAB26, member RAS oncogene 
family 
NM_014353 0.010147 -1.23648 
43304 11758395_s_at 2153 F5 coagulation factor V (proaccelerin, 
labile factor) 
NM_000130 0.043685 -1.23702 
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10264 11725355_at 9852 EPM2AIP1 EPM2A (laforin) interacting protein 
1 
NM_014805 0.017311 -1.2374 
21765 11736856_at 387496 RASL11A RAS-like, family 11, member A NM_206827 0.000284 -1.23756 
11475 11726566_a_at 1981 EIF4G1 eukaryotic translation initiation 
factor 4 gamma, 1 
NM_001194946 
/// 
NM_001194947 
/// NM_004953 
/// NM_182917 
/// NM_198241 
/// NM_198242 
/ 
0.048389 -1.23763 
1675 11716766_a_at 8826 IQGAP1 IQ motif containing GTPase 
activating protein 1 
NM_003870 0.041029 -1.23771 
45447 11760538_a_at 54534 MRPL50 mitochondrial ribosomal protein 
L50 
NM_019051 0.037577 -1.23779 
31965 11747056_a_at 171023 ASXL1 additional sex combs like 1 
(Drosophila) 
NM_001164603 
/// NM_015338 
0.03195 -1.2379 
13439 11728530_a_at 29760 BLNK B-cell linker NM_001114094 
/// 
NM_001258440 
/// 
NM_001258441 
/// 
NM_001258442 
/// NM_013314 
/// NR_04 
0.002115 -1.23805 
34807 11749898_a_at 9522 SCAMP1 secretory carrier membrane protein 
1 
NM_004866 /// 
NM_052822 
0.035959 -1.23847 
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28709 11743800_a_at 146754 DNAH2 dynein, axonemal, heavy chain 2 NM_020877 0.031707 -1.2385 
12108 11727199_a_at 56134 /// 
56135 /// 
56136 /// 
56137 /// 
56138 /// 
56139 /// 
56140 /// 
56141 /// 
56142 / 
PCDHA1 /// 
PCDHA10 /// 
PCDHA11 /// 
PCDHA12 /// 
PCDHA13 /// 
PCDHA2 /// 
PCDHA3 /// 
PCDHA4 /// 
PCDHA5 /// 
PCDHA6 /// 
PCDHA7 /// 
PCDHA8 /// 
PCDHA9 /// 
PCDHAC1 /// 
PCDHAC2 
protocadherin alpha 1 /// 
protocadherin alpha 10 /// 
protocadherin alpha 11 /// protoca 
NM_014005 /// 
NM_018898 /// 
NM_018899 /// 
NM_018900 /// 
NM_018901 /// 
NM_018902 /// 
NM_ 
0.026203 -1.2386 
5577 11720668_at 8850 KAT2B K(lysine) acetyltransferase 2B NM_003884 0.00451 -1.23864 
11212 11726303_a_at 148808 MFSD4 major facilitator superfamily 
domain containing 4 
NM_181644 0.025465 -1.23888 
48966 11764057_s_at 57035 C1orf63 chromosome 1 open reading frame 
63 
NM_020317 /// 
NM_207035 
0.000121 -1.23893 
42187 11757278_x_at 445 ASS1 argininosuccinate synthase 1 NM_000050 /// 
NM_054012 
0.009249 -1.24044 
37535 11752626_a_at 5087 PBX1 pre-B-cell leukemia homeobox 1 NM_001204961 
/// 
NM_001204963 
/// NM_002585 
0.011712 -1.24106 
8082 11723173_at 54756 IL17RD interleukin 17 receptor D NM_017563 0.003662 -1.2413 
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43900 11758991_at 284069 FAM171A2 family with sequence similarity 
171, member A2 
NM_198475 0.003381 -1.24169 
2762 11717853_at 6366 CCL21 chemokine (C-C motif) ligand 21 NM_002989 0.006669 -1.24311 
25340 11740431_s_at 643836 ZFP62 zinc finger protein 62 homolog 
(mouse) 
NM_001172638 
/// NM_152283 
0.011418 -1.24403 
37133 11752224_a_at 162394 SLFN5 schlafen family member 5 NM_144975 0.017746 -1.24454 
26134 11741225_a_at 57082 CASC5 cancer susceptibility candidate 5 NM_144508 /// 
NM_170589 
0.016498 -1.24472 
16712 11731803_a_at 399948 C11orf92 chromosome 11 open reading frame 
92 
NM_207429 /// 
NR_034154 
0.008069 -1.2453 
6125 11721216_s_at 54664 TMEM106B transmembrane protein 106B NM_001134232 
/// NM_018374 
0.035951 -1.24585 
6627 11721718_a_at 546 ATRX alpha thalassemia/mental 
retardation syndrome X-linked 
NM_000489 /// 
NM_138270 /// 
NM_138271 
0.045416 -1.24606 
45732 11760823_x_at 6324 SCN1B sodium channel, voltage-gated, type 
I, beta subunit 
NM_001037 /// 
NM_199037 
0.045525 -1.24654 
44745 11759836_at 9886 RHOBTB1 Rho-related BTB domain 
containing 1 
NM_001242359 
/// NM_014836 
/// NR_024554 
/// NR_024555 
0.041544 -1.24688 
18642 11733733_a_at 51611 DPH5 DPH5 homolog (S. cerevisiae) NM_001077394 
/// 
NM_001077395 
/// NM_015958 
0.022314 -1.24689 
4601 11719692_a_at 5920 RARRES3 retinoic acid receptor responder 
(tazarotene induced) 3 
NM_004585 0.000751 -1.24696 
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1153 11716244_s_at 10163 WASF2 WAS protein family, member 2 NM_001201404 
/// NM_006990 
0.041973 -1.24753 
29137 11744228_x_at 93129 ORAI3 ORAI calcium release-activated 
calcium modulator 3 
NM_152288 0.007309 -1.24772 
6213 11721304_at 10267 RAMP1 receptor (G protein-coupled) 
activity modifying protein 1 
NM_005855 0.023286 -1.24875 
25751 11740842_at 401145 FAM190A family with sequence similarity 
190, member A 
NM_001145065 
/// NM_207491 
0.005094 -1.24915 
4416 11719507_a_at 57325 CSRP2BP CSRP2 binding protein NM_020536 /// 
NM_177926 /// 
NR_028402 
0.02803 -1.24964 
16566 11731657_s_at 10451 VAV3 vav 3 guanine nucleotide exchange 
factor 
NM_001079874 
/// NM_006113 
0.005075 -1.24991 
15688 11730779_at 126 ADH1C alcohol dehydrogenase 1C (class I), 
gamma polypeptide 
NM_000669 0.000333 -1.25012 
15488 11730579_a_at 57520 HECW2 HECT, C2 and WW domain 
containing E3 ubiquitin protein 
ligase 2 
NM_020760 0.003253 -1.25085 
42842 11757933_s_at 7832 BTG2 BTG family, member 2 NM_006763 0.002055 -1.25124 
41497 11756588_a_at 55808 ST6GALNAC1 ST6 (alpha-N-acetyl-neuraminyl-
2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2 
NM_018414 0.007672 -1.25186 
47438 11762529_at 55612 FERMT1 fermitin family member 1 NM_017671 0.039922 -1.25232 
39769 11754860_a_at 7586 ZKSCAN1 zinc finger with KRAB and SCAN 
domains 1 
NM_003439 0.030506 -1.25359 
37224 11752315_a_at 129563 DIS3L2 DIS3 mitotic control homolog (S. 
cerevisiae)-like 2 
NM_001257281 
/// 
0.021344 -1.25481 
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NM_001257282 
/// NM_152383 
/// NR_046476 
/// NR_046477 
16737 11731828_at 221914 GPC2 glypican 2 NM_152742 0.024006 -1.25497 
37427 11752518_a_at 55102 ATG2B autophagy related 2B NM_018036 0.024243 -1.25518 
3946 11719037_a_at 7405 UVRAG UV radiation resistance associated 
gene 
NM_003369 0.003668 -1.25647 
29228 11744319_a_at 80235 PIGZ phosphatidylinositol glycan anchor 
biosynthesis, class Z 
NM_025163 0.01918 -1.25682 
10335 11725426_a_at 5873 RAB27A RAB27A, member RAS oncogene 
family 
NM_004580 /// 
NM_183234 /// 
NM_183235 /// 
NM_183236 
0.043738 -1.25729 
35951 11751042_a_at 2153 F5 coagulation factor V (proaccelerin, 
labile factor) 
NM_000130 0.009224 -1.25795 
36598 11751689_a_at 10020 GNE glucosamine (UDP-N-acetyl)-2-
epimerase/N-acetylmannosamine 
kinase 
NM_001128227 
/// 
NM_001190383 
/// 
NM_001190384 
/// 
NM_001190388 
/// NM_005476 
0.030207 -1.25848 
42531 11757622_s_at 85453 TSPYL5 TSPY-like 5 NM_033512 0.038948 -1.25874 
44503 11759594_at 100616102 /// 
100862685 
ERVK-19 /// 
ERVK-9 
endogenous retrovirus group K, 
member 19 /// endogenous 
--- 0.048496 -1.25896 
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retrovirus group K, member 9 
28752 11743843_a_at 54943 DNAJC28 DnaJ (Hsp40) homolog, subfamily 
C, member 28 
NM_001040192 
/// NM_017833 
0.005817 -1.26047 
3699 11718790_at 55502 HES6 hairy and enhancer of split 6 
(Drosophila) 
NM_001142853 
/// NM_018645 
0.000136 -1.26062 
48714 11763805_a_at 149986 LSM14B LSM14B, SCD6 homolog B (S. 
cerevisiae) 
NM_144703 0.028343 -1.26131 
42724 11757815_s_at 25840 METTL7A methyltransferase like 7A NM_014033 0.00147 -1.2614 
1748 11716839_a_at 51655 RASD1 RAS, dexamethasone-induced 1 NM_001199989 
/// NM_016084 
0.01462 -1.2623 
29560 11744651_a_at 27035 NOX1 NADPH oxidase 1 NM_007052 /// 
NM_013954 /// 
NM_013955 
0.000814 -1.26244 
39503 11754594_a_at 1836 SLC26A2 solute carrier family 26 (sulfate 
transporter), member 2 
NM_000112 0.030755 -1.26315 
14953 11730044_a_at 84688 C9orf24 chromosome 9 open reading frame 
24 
NM_001252195 
/// NM_032596 
/// NM_147168 
/// NM_147169 
0.045568 -1.26447 
43306 11758397_s_at 81790 RNF170 ring finger protein 170 NM_001160223 
/// 
NM_001160224 
/// 
NM_001160225 
/// NM_030954 
/// NR_027668 
/// NR_02766 
0.010982 -1.26506 
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38320 11753411_a_at 23197 FAF2 Fas associated factor family 
member 2 
NM_014613 0.040681 -1.26559 
30988 11746079_a_at 113 ADCY7 adenylate cyclase 7 NM_001114 0.003523 -1.26587 
41715 11756806_a_at 3669 ISG20 interferon stimulated exonuclease 
gene 20kDa 
NM_002201 2.58E-05 -1.26625 
10912 11726003_a_at 51315 KRCC1 lysine-rich coiled-coil 1 NM_016618 0.001054 -1.26682 
20868 11735959_at 344018 FIGLA folliculogenesis specific basic helix-
loop-helix 
NM_001004311 0.008797 -1.26683 
38104 11753195_a_at 80274 SCUBE1 signal peptide, CUB domain, EGF-
like 1 
NM_173050 0.032757 -1.26762 
48145 11763236_at 149076 ZNF362 Zinc finger protein 362 NM_152493 0.026231 -1.26776 
14349 11729440_at 203562 TMEM31 transmembrane protein 31 NM_182541 0.03059 -1.26808 
39380 11754471_a_at 3109 HLA-DMB major histocompatibility complex, 
class II, DM beta 
NM_002118 0.030613 -1.26829 
42624 11757715_a_at 642587 MIR205HG MIR205 host gene (non-protein 
coding) 
NM_001104548 0.007751 -1.26991 
12939 11728030_a_at 285313 IGSF10 immunoglobulin superfamily, 
member 10 
NM_001178145 
/// 
NM_001178146 
/// NM_178822 
0.005391 -1.27027 
11066 11726157_at 139886 SPIN4 spindlin family, member 4 NM_001012968 0.027853 -1.27111 
8857 11723948_s_at 6519 SLC3A1 solute carrier family 3 (cystine, 
dibasic and neutral amino acid 
transporters, activato 
NM_000341 0.003673 -1.27118 
20409 11735500_a_at 696 BTN1A1 butyrophilin, subfamily 1, member 
A1 
NM_001732 0.022304 -1.27142 
860 11715951_s_at 115207 KCTD12 potassium channel tetramerisation NM_138444 0.021417 -1.27191 
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domain containing 12 
5350 11720441_x_at 25903 OLFML2B olfactomedin-like 2B NM_015441 0.00397 -1.27259 
39793 11754884_s_at 57590 WDFY1 WD repeat and FYVE domain 
containing 1 
NM_020830 0.049915 -1.27348 
12461 11727552_at 2535 FZD2 frizzled family receptor 2 NM_001466 0.007723 -1.27385 
21406 11736497_a_at 23112 TNRC6B trinucleotide repeat containing 6B NM_001024843 
/// 
NM_001162501 
/// NM_015088 
0.007254 -1.27394 
20848 11735939_at 730755 /// 
85294 
KRTAP2-4 /// 
LOC730755 
keratin associated protein 2-4 /// 
keratin associated protein 2-4-like 
NM_001165252 
/// NM_033184 
0.024651 -1.27397 
25489 11740580_at 427 ASAH1 N-acylsphingosine amidohydrolase 
(acid ceramidase) 1 
NM_001127505 
/// NM_004315 
/// NM_177924 
0.016775 -1.27454 
8926 11724017_a_at 127700 OSCP1 organic solute carrier partner 1 NM_145047 /// 
NM_206837 
0.04227 -1.27492 
43591 11758682_s_at 90871 C9orf123 chromosome 9 open reading frame 
123 
NM_033428 0.012916 -1.27527 
27736 11742827_a_at 23469 PHF3 PHD finger protein 3 NM_015153 0.03338 -1.27653 
24789 11739880_a_at 169792 GLIS3 GLIS family zinc finger 3 NM_001042413 
/// NM_152629 
0.02803 -1.27692 
20990 11736081_at 819 CAMLG calcium modulating ligand NM_001745 0.006621 -1.27789 
27738 11742829_x_at 23469 PHF3 PHD finger protein 3 NM_015153 0.018363 -1.278 
1395 11716486_at 8857 FCGBP Fc fragment of IgG binding protein NM_003890 0.034969 -1.27848 
17757 11732848_a_at 153768 PRELID2 PRELI domain containing 2 NM_138492 /// 
NM_182960 /// 
NM_205846 
0.016394 -1.27874 
310 
 
11239 11726330_a_at 9963 SLC23A1 solute carrier family 23 (nucleobase 
transporters), member 1 
NM_005847 /// 
NM_152685 
0.001014 -1.27999 
37982 11753073_a_at 7292 TNFSF4 tumor necrosis factor (ligand) 
superfamily, member 4 
NM_003326 0.02055 -1.28155 
38249 11753340_a_at 3384 ICAM2 intercellular adhesion molecule 2 NM_000873 /// 
NM_001099786 
/// 
NM_001099787 
/// 
NM_001099788 
/// 
NM_001099789 
0.022321 -1.28185 
7747 11722838_a_at 2568 GABRP gamma-aminobutyric acid (GABA) 
A receptor, pi 
NM_014211 0.005674 -1.28205 
6365 11721456_x_at 5265 SERPINA1 serpin peptidase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), 
member 1 
NM_000295 /// 
NM_001002235 
/// 
NM_001002236 
/// 
NM_001127700 
/// 
NM_001127701 
/// NM_00 
0.001629 -1.28231 
9256 11724347_a_at 23245 ASTN2 astrotactin 2 NM_001184734 
/// 
NM_001184735 
/// NM_014010 
/// NM_198186 
0.017982 -1.28324 
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/// NM_198187 
/// NM_198188 
45244 11760335_s_at 10436 EMG1 EMG1 nucleolar protein homolog 
(S. cerevisiae) 
NM_006331 0.032114 -1.28401 
21486 11736577_a_at 134728 IRAK1BP1 interleukin-1 receptor-associated 
kinase 1 binding protein 1 
NM_001010844 0.027579 -1.28421 
42786 11757877_a_at 547 KIF1A kinesin family member 1A NM_001244008 
/// NM_004321 
0.049659 -1.28448 
1134 11716225_a_at 51474 LIMA1 LIM domain and actin binding 1 NM_001113546 
/// 
NM_001113547 
/// 
NM_001243775 
/// NM_016357 
0.020845 -1.28473 
8281 11723372_a_at 139818 DOCK11 dedicator of cytokinesis 11 NM_144658 0.021828 -1.28545 
30333 11745424_a_at 10592 SMC2 structural maintenance of 
chromosomes 2 
NM_001042550 
/// 
NM_001042551 
/// 
NM_001265602 
/// NM_006444 
0.021935 -1.2857 
46384 11761475_x_at 79465 ULBP3 UL16 binding protein 3 NM_024518 0.017126 -1.28672 
18998 11734089_a_at 863 CBFA2T3 core-binding factor, runt domain, 
alpha subunit 2; translocated to, 3 
NM_005187 /// 
NM_175931 
0.018349 -1.28685 
18914 11734005_s_at 201931 TMEM192 transmembrane protein 192 NM_001100389 
/// NM_152681 
0.048167 -1.28847 
40203 11755294_x_at 4703 NEB nebulin NM_001164507 
/// 
0.010163 -1.28987 
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NM_001164508 
/// NM_004543 
43383 11758474_s_at 399948 C11orf92 chromosome 11 open reading frame 
92 
NM_207429 /// 
NR_034154 
0.004775 -1.29007 
6363 11721454_a_at 5265 SERPINA1 serpin peptidase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), 
member 1 
NM_000295 /// 
NM_001002235 
/// 
NM_001002236 
/// 
NM_001127700 
/// 
NM_001127701 
/// NM_00 
0.002156 -1.29052 
37776 11752867_a_at 10908 PNPLA6 patatin-like phospholipase domain 
containing 6 
NM_001166111 
/// 
NM_001166112 
/// 
NM_001166113 
/// 
NM_001166114 
/// NM_006702 
0.036812 -1.29102 
36815 11751906_a_at 5797 PTPRM protein tyrosine phosphatase, 
receptor type, M 
NM_001105244 
/// NM_002845 
0.00182 -1.29125 
9384 11724475_a_at 57509 MTUS1 microtubule associated tumor 
suppressor 1 
NM_001001924 
/// 
NM_001001925 
/// 
NM_001001927 
0.008062 -1.29213 
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/// 
NM_001001931 
/// 
NM_001166393 
/// NM 
30036 11745127_x_at 7138 TNNT1 troponin T type 1 (skeletal, slow) NM_001126132 
/// 
NM_001126133 
/// NM_003283 
0.004097 -1.29326 
15613 11730704_s_at 81285 OR51E2 olfactory receptor, family 51, 
subfamily E, member 2 
NM_030774 0.026457 -1.2935 
45803 11760894_s_at 6430 SRSF5 serine/arginine-rich splicing factor 5 NM_001039465 
/// NM_006925 
0.016484 -1.29479 
36054 11751145_a_at 23376 UFL1 UFM1-specific ligase 1 NM_015323 0.022721 -1.2978 
35770 11750861_x_at 8418 CMAHP cytidine monophospho-N-
acetylneuraminic acid hydroxylase, 
pseudogene 
NR_002174 /// 
NR_027626 
0.032434 -1.29807 
36749 11751840_s_at 255180 FLJ38723 uncharacterized FLJ38723 NM_173805 /// 
XR_132593 /// 
XR_133071 
0.008121 -1.29919 
36240 11751331_a_at 64798 DEPTOR DEP domain containing MTOR-
interacting protein 
NM_022783 0.000199 -1.29997 
46264 11761355_a_at 10084 PQBP1 polyglutamine binding protein 1 NM_001032381 
/// 
NM_001032382 
/// 
NM_001032383 
/// 
0.022616 -1.30309 
314 
 
NM_001032384 
/// 
NM_001032385 
/// NM 
31747 11746838_a_at 26058 GIGYF2 GRB10 interacting GYF protein 2 NM_001103146 
/// 
NM_001103147 
/// 
NM_001103148 
/// NM_015575 
0.005785 -1.3032 
33457 11748548_a_at 5025 P2RX4 purinergic receptor P2X, ligand-
gated ion channel, 4 
NM_001256796 
/// 
NM_001261397 
/// 
NM_001261398 
/// NM_002560 
/// NM_175567 
/// NM_17556 
0.033658 -1.30328 
32040 11747131_at 83998 REG4 regenerating islet-derived family, 
member 4 
NM_001159352 
/// 
NM_001159353 
/// NM_032044 
0.005908 -1.30564 
47143 11762234_a_at 4149 MAX MYC associated factor X NM_002382 /// 
NM_145112 /// 
NM_145113 /// 
NM_145114 /// 
NM_145116 /// 
NM_197957 
0.024282 -1.3077 
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7618 11722709_a_at 54462 FAM190B family with sequence similarity 
190, member B 
NM_018999 0.017885 -1.31036 
1044 11716135_a_at 9961 MVP major vault protein NM_005115 /// 
NM_017458 
0.007348 -1.31096 
23241 11738332_a_at 10317 B3GALT5 UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypeptide 5 
NM_006057 /// 
NM_033170 /// 
NM_033171 /// 
NM_033172 /// 
NM_033173 
0.027184 -1.31194 
34843 11749934_s_at 3323 HSP90AA4P heat shock protein 90kDa alpha 
(cytosolic), class A member 4, 
pseudogene 
NR_036692 4.31E-05 -1.31311 
25821 11740912_a_at 55024 BANK1 B-cell scaffold protein with ankyrin 
repeats 1 
NM_001083907 
/// 
NM_001127507 
/// NM_017935 
0.001232 -1.31351 
8687 11723778_at 113612 CYP2U1 cytochrome P450, family 2, 
subfamily U, polypeptide 1 
NM_183075 0.006067 -1.31428 
28204 11743295_a_at 1063 CENPF centromere protein F, 350/400kDa 
(mitosin) 
NM_016343 0.041141 -1.31452 
9672 11724763_s_at 64798 DEPTOR DEP domain containing MTOR-
interacting protein 
NM_022783 0.002325 -1.31576 
18475 11733566_a_at 26013 L3MBTL1 l(3)mbt-like 1 (Drosophila) NM_015478 /// 
NM_032107 
0.005787 -1.31856 
17083 11732174_a_at 2188 FANCF Fanconi anemia, complementation 
group F 
NM_022725 0.015158 -1.31877 
46640 11761731_x_at 51548 SIRT6 sirtuin 6 NM_001193285 
/// NM_016539 
0.021283 -1.32108 
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6366 11721457_a_at 5265 SERPINA1 serpin peptidase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), 
member 1 
NM_000295 /// 
NM_001002235 
/// 
NM_001002236 
/// 
NM_001127700 
/// 
NM_001127701 
/// NM_00 
0.028544 -1.32316 
21908 11736999_a_at 7592 ZNF41 zinc finger protein 41 NM_007130 /// 
NM_153380 
0.034478 -1.32613 
34889 11749980_x_at 84525 HOPX HOP homeobox NM_001145459 
/// 
NM_001145460 
/// NM_032495 
/// NM_139211 
/// NM_139212 
0.011405 -1.32703 
35827 11750918_a_at 253012 HEPACAM2 HEPACAM family member 2 NM_001039372 
/// NM_198151 
0.013962 -1.32864 
3415 11718506_at 7033 TFF3 trefoil factor 3 (intestinal) NM_003226 0.000792 -1.33201 
26356 11741447_s_at 6038 RNASE4 ribonuclease, RNase A family, 4 NM_002937 /// 
NM_194430 /// 
NM_194431 
0.00244 -1.33863 
6478 11721569_a_at 283 ANG angiogenin, ribonuclease, RNase A 
family, 5 
NM_001097577 
/// NM_001145 
0.027187 -1.33982 
39246 11754337_s_at 10397 NDRG1 N-myc downstream regulated 1 NM_001135242 
/// 
NM_001258432 
0.029326 -1.34082 
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/// 
NM_001258433 
/// NM_006096 
47628 11762719_at 3658 IREB2 iron-responsive element binding 
protein 2 
NM_004136 0.015881 -1.34125 
18269 11733360_x_at 6563 SLC14A1 solute carrier family 14 (urea 
transporter), member 1 (Kidd blood 
group) 
NM_001128588 
/// 
NM_001146036 
/// 
NM_001146037 
/// NM_015865 
0.027089 -1.34247 
9671 11724762_a_at 64798 DEPTOR DEP domain containing MTOR-
interacting protein 
NM_022783 0.001008 -1.34342 
4121 11719212_a_at 388677 NOTCH2NL notch 2 N-terminal like NM_203458 0.026813 -1.34398 
47068 11762159_at 23301 EHBP1 EH domain binding protein 1 NM_001142614 
/// 
NM_001142615 
/// 
NM_001142616 
/// NM_015252 
0.005564 -1.3443 
38679 11753770_a_at 22803 XRN2 5'-3' exoribonuclease 2 NM_012255 0.006529 -1.34525 
15351 11730442_s_at 728215 FAM155A family with sequence similarity 
155, member A 
NM_001080396 0.026916 -1.34558 
27899 11742990_x_at 7430 EZR ezrin NM_001111077 
/// NM_003379 
0.049235 -1.34755 
13730 11728821_a_at 253012 HEPACAM2 HEPACAM family member 2 NM_001039372 
/// NM_198151 
0.002761 -1.35247 
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38229 11753320_s_at 55632 G2E3 G2/M-phase specific E3 ubiquitin 
protein ligase 
NM_017769 0.035822 -1.35578 
10087 11725178_at 147040 KCTD11 potassium channel tetramerisation 
domain containing 11 
NM_001002914 0.007298 -1.36071 
46615 11761706_at 9200 PTPLA protein tyrosine phosphatase-like 
(proline instead of catalytic 
arginine), member A 
NM_014241 0.004611 -1.36145 
42057 11757148_at 619505 SNORA21 small nucleolar RNA, H/ACA box 
21 
NR_002576 0.006612 -1.37038 
18386 11733477_at 56670 SUCNR1 succinate receptor 1 NM_033050 0.0055 -1.37048 
21368 11736459_a_at 27035 NOX1 NADPH oxidase 1 NM_007052 /// 
NM_013954 /// 
NM_013955 
0.008144 -1.37311 
1275 11716366_s_at 10136 /// 
23436 
CELA3A /// 
CELA3B 
chymotrypsin-like elastase family, 
member 3A /// chymotrypsin-like 
elastase family, mem 
NM_005747 /// 
NM_007352 
0.008322 -1.38925 
7326 11722417_a_at 55323 LARP6 La ribonucleoprotein domain 
family, member 6 
NM_018357 /// 
NM_197958 
0.029808 -1.38955 
37120 11752211_a_at 340706 VWA2 von Willebrand factor A domain 
containing 2 
NM_198496 0.007477 -1.39297 
3373 11718464_s_at 54492 NEURL1B neuralized homolog 1B 
(Drosophila) 
NM_001142651 
/// NR_015355 
0.024115 -1.39907 
30297 11745388_x_at 1954 MEGF8 multiple EGF-like-domains 8 NM_001410 /// 
NM_178121 
0.011358 -1.40016 
19110 11734201_s_at 2710 GK glycerol kinase NM_000167 /// 
NM_001128127 
/// 
NM_001205019 
0.023056 -1.43066 
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/// NM_203391 
1507 11716598_a_at 5119 CHMP1A charged multivesicular body protein 
1A 
NM_001083314 
/// NM_002768 
/// NR_046418 
0.018856 -1.43344 
3681 11718772_at 6605 SMARCE1 SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, subfamily e 
NM_003079 0.000268 -1.49914 
13953 11729044_at 143503 OR51E1 olfactory receptor, family 51, 
subfamily E, member 1 
NM_152430 0.008961 -1.50046 
39900 11754991_a_at 6257 RXRB retinoid X receptor, beta NM_001270401 
/// NM_021976 
0.0296 -1.52294 
31787 11746878_s_at 3398 ID2 inhibitor of DNA binding 2, 
dominant negative helix-loop-helix 
protein 
NM_002166 0.037375 -1.53804 
5666 11720757_a_at 10625 IVNS1ABP influenza virus NS1A binding 
protein 
NM_006469 /// 
NM_016389 
1.82E-05 -1.57134 
2483 11717574_s_at 5216 PFN1 profilin 1 NM_005022 1.70E-05 -1.69428 
30219 11745310_s_at 6519 SLC3A1 solute carrier family 3 (cystine, 
dibasic and neutral amino acid 
transporters, activato 
NM_000341 0.004815 -1.74989 
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Appendices 
Appendix B 
Altered miRNA expression profile of EV71 infected and non-infected control colorectal cells, HT29. 
Column # Probeset ID Species Scientific Name p-value(Infected vs. Control) Fold-Change(Infected vs. Control) 
11517 hsa-miR-1975_st Homo sapiens 0.000163 3.94209 
11959 hsa-miR-483-5p_st Homo sapiens 0.024704 2.81949 
12080 hsa-miR-548a-3p_st Homo sapiens 0.010631 2.71964 
11669 hsa-miR-3124_st Homo sapiens 0.047508 2.50557 
11434 hsa-miR-149-star_st Homo sapiens 0.000677 2.23921 
12237 hsa-miR-664-star_st Homo sapiens 0.01227 2.22846 
11617 hsa-miR-2861_st Homo sapiens 0.002286 2.059 
12236 hsa-miR-663b_st Homo sapiens 0.01177 1.99451 
19572 v11_hsa-miR-768-3p_st Homo sapiens 0.000723 1.89955 
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12166 hsa-miR-601_st Homo sapiens 0.046423 1.79713 
12209 hsa-miR-638_st Homo sapiens 0.002766 1.78007 
11499 hsa-miR-1915_st Homo sapiens 0.001266 1.70212 
11710 hsa-miR-3162_st Homo sapiens 0.027274 1.56497 
11874 hsa-miR-4270_st Homo sapiens 0.002332 1.47817 
11486 hsa-miR-1909-star_st Homo sapiens 0.024058 1.46414 
9845 hp_hsa-mir-525_st Homo sapiens 0.017357 1.45682 
11288 hsa-miR-1228-star_st Homo sapiens 0.044908 1.3919 
9062 hp_hsa-mir-1181_st Homo sapiens 0.013386 1.38869 
11522 hsa-miR-199a-3p_st Homo sapiens 0.008481 1.34305 
9576 hp_hsa-mir-320c-2_x_st Homo sapiens 0.031207 1.32182 
9736 hp_hsa-mir-449a_st Homo sapiens 0.025192 1.29993 
9165 hp_hsa-mir-1282_st Homo sapiens 0.045774 1.26961 
9066 hp_hsa-mir-1184-2_s_st Homo sapiens 0.019358 1.2661 
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9507 hp_hsa-mir-3154_st Homo sapiens 0.047258 1.25549 
10006 hp_hsa-mir-620_x_st Homo sapiens 0.014759 1.24735 
9270 hp_hsa-mir-15b_st Homo sapiens 0.001623 1.23691 
9136 hp_hsa-mir-1263_st Homo sapiens 0.015698 1.23327 
11785 hsa-miR-33a_st Homo sapiens 0.015369 1.22434 
9618 hp_hsa-mir-372_st Homo sapiens 0.024112 1.20353 
10020 hp_hsa-mir-631_x_st Homo sapiens 0.000101 1.20226 
9807 hp_hsa-mir-516b-2_x_st Homo sapiens 0.013246 1.20032 
12294 hsa-miR-922_st Homo sapiens 0.029909 -1.20845 
11495 hsa-miR-1913_st Homo sapiens 0.049946 -1.21026 
11546 hsa-miR-205_st Homo sapiens 0.007349 -1.21409 
9598 hp_hsa-mir-339_st Homo sapiens 0.019065 -1.21441 
12204 hsa-miR-633_st Homo sapiens 0.005741 -1.21803 
11246 hsa-miR-103-2-star_st Homo sapiens 0.000123 -1.22043 
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9174 hp_hsa-mir-1288_st Homo sapiens 0.031884 -1.22398 
11540 hsa-miR-203_st Homo sapiens 0.011568 -1.22787 
12172 hsa-miR-607_st Homo sapiens 0.01372 -1.22914 
9178 hp_hsa-mir-1289-2_x_st Homo sapiens 0.041897 -1.22958 
9707 hp_hsa-mir-4304_st Homo sapiens 0.02584 -1.24091 
11489 hsa-miR-190b_st Homo sapiens 0.037805 -1.24125 
12211 hsa-miR-640_st Homo sapiens 0.014434 -1.24236 
10128 hp_hsa-mir-941-3_s_st Homo sapiens 0.001341 -1.2437 
11763 hsa-miR-323b-3p_st Homo sapiens 0.025807 -1.25967 
12182 hsa-miR-616-star_st Homo sapiens 0.03395 -1.26134 
9895 hp_hsa-mir-548i-4_st Homo sapiens 0.003498 -1.26684 
11425 hsa-miR-146b-5p_st Homo sapiens 0.008528 -1.26984 
11822 hsa-miR-375_st Homo sapiens 0.038667 -1.27214 
12084 hsa-miR-548c-3p_st Homo sapiens 0.014034 -1.27284 
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11797 hsa-miR-34b_st Homo sapiens 0.01083 -1.27311 
11672 hsa-miR-3126-5p_st Homo sapiens 0.046993 -1.27517 
12208 hsa-miR-637_st Homo sapiens 0.039124 -1.28712 
9214 hp_hsa-mir-1321_st Homo sapiens 0.01516 -1.29294 
11691 hsa-miR-3144-3p_st Homo sapiens 0.04497 -1.30681 
11578 hsa-miR-219-5p_st Homo sapiens 0.003858 -1.31686 
12087 hsa-miR-548d-5p_st Homo sapiens 0.022997 -1.31845 
9221 hp_hsa-mir-133a-1_x_st Homo sapiens 0.044891 -1.32283 
9307 hp_hsa-mir-1911_st Homo sapiens 0.020344 -1.32376 
12102 hsa-miR-548t_st Homo sapiens 0.043826 -1.33336 
11726 hsa-miR-3178_st Homo sapiens 0.016713 -1.35363 
11963 hsa-miR-486-3p_st Homo sapiens 0.009167 -1.35607 
12184 hsa-miR-617_st Homo sapiens 9.54E-05 -1.35717 
11458 hsa-miR-181a-2-star_st Homo sapiens 0.047522 -1.35906 
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11770 hsa-miR-329_st Homo sapiens 0.006891 -1.39187 
11279 hsa-miR-1208_st Homo sapiens 0.046593 -1.40286 
12155 hsa-miR-590-5p_st Homo sapiens 0.007432 -1.48358 
11566 hsa-miR-212_st Homo sapiens 0.036881 -1.52046 
11473 hsa-miR-185-star_st Homo sapiens 0.031342 -1.5402 
11890 hsa-miR-4286_st Homo sapiens 0.011371 -1.57105 
11395 hsa-miR-134_st Homo sapiens 0.011043 -1.66762 
11331 hsa-miR-1266_st Homo sapiens 0.035153 -1.6898 
11256 hsa-miR-10a-star_st Homo sapiens 0.015768 -1.74491 
11960 hsa-miR-484_st Homo sapiens 0.039047 -1.76997 
11923 hsa-miR-4317_st Homo sapiens 0.034233 -1.80619 
11786 hsa-miR-33b-star_st Homo sapiens 0.011657 -2.05341 
11724 hsa-miR-3176_st Homo sapiens 0.037357 -2.16789 
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Characterisation of enterovirus 71 replication
kinetics in human colorectal cell line, HT29
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Abstract
Hand, Foot and Mouth Disease (HFMD), a contagious viral disease that commonly affects infants and children with
blisters and flu like symptoms, is caused by a group of enteroviruses such as Enterovirus 71 (EV71) and
coxsackievirus A16 (CA16). However some HFMD caused by EV71 may further develop into severe neurological
complications such as encephalitis and meningitis. The route of transmission was postulated that the virus transmit
from one person to another through direct contact of vesicular fluid or droplet from the infected or via faecal-oral
route. To this end, this study utilised a human colorectal adenocarcinoma cell line (HT29) with epithelioid
morphology as an in vitro model for the investigation of EV71 replication kinetics. Using qPCR, viral RNA was first
detected in HT29 cells as early as 12 h post infection (hpi) while viral protein was first detected at 48 hpi. A
significant change in HT29 cells’ morphology was also observed after 48 hpi. Furthermore HT29 cell viability also
significantly decreased at 72 hpi. Together, data from this study demonstrated that co-culture of HT29 with EV71 is
a useful in vitro model to study the pathogenesis of EV71.
Keywords: Hand, Foot and mouth disease, Enterovirus 71, Virus replication kinetics, Colorectal cell
Background
Hand, Foot and Mouth Disease (HFMD), a contagious
viral disease that commonly affects infants and children,
are caused by a group of enteroviruses such as Entero-
virus 71 (EV71) and coxsackievirus A16 (CA16) (Brown
et al. 1999; Cardosa et al. 2003; Lee et al. 2009; Prager
et al. 2003). This self-limiting disease is characterised by
fever, rashes, poor appetite and multiple ulcers in mouth
(Brown et al. 1999; Cardosa et al. 2003; Lee et al. 2009;
Prager et al. 2003). However, patients infected with
EV71 may further develop severe neurological complica-
tion such as aseptic meningitis and brainstem/cerebellar
encephalitis (Lee and Chang 2010; Lee et al. 2009; Singh
et al. 2002; Solomon et al. 2010; McMinn 2002).
EV71, a member from the Enterovirus genus of the
Picornaviridae family, is a non-enveloped, positive sense,
single stranded, RNA virus with genomic RNA of ap-
proximately 7400 bp in length (Lee and Chang 2010;
Oberste et al. 1999a, b). EV71 was first isolated from
HFMD patients with central nervous system disease in
1969 (Schmidt et al. 1974). Large fatal EV71 outbreaks
of HFMD first appeared in Bulgaria in 1975, and disease
outbreaks were subsequently identified in Hungary in
1978 and re-emerged in Malaysia in 1997 and Taiwan in
1998 (Chumakov et al. 1979; Nagy et al. 1982; Ho et al.
1999; Lu et al. 2002; Solomon et al. 2010). HFMD epi-
demics and pandemics have been periodically reported
worldwide with outbreaks occurring every two to three
years in countries including Australia, China, Taiwan,
Japan, Korea, Malaysia, Vietnam, Thailand and Singapore
(Schmidt et al. 1974; Chumakov et al. 1979; McMinn
et al. 2001; Huang et al. 2012). Although the consistent
presences and outbreaks of HFMD push for an urgent
need to develop a vaccine or antiviral therapies against
enteroviruses (Pourianfar et al. 2012; McMinn et al.
2001; Tan et al. 2007a,b; Tan et al. 2010). Currently,
there are no available antiviral therapies or vaccines ap-
proved by the United States Food and Drug Administra-
tion (FDA) to prevent HFMD infections (Li et al. 2007).
The route of transmission of EV71 was postulated to
happen via direct contact of vesicular fluid or droplet
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from the infected or via faecal-oral route (Wong et al.
2010; Lee et al. 2009; Liu et al. 2000; Brown et al. 1999).
EV71 was shown to replicate within the gastrointestinal
tract, bypass the gut barrier and infect into the skeletal
muscle cell before entering into the bloodstream and the
central nervous system (Wong et al. 2010; Lee et al.
2009; Liu et al. 2000; Brown et al. 1999). Indeed various
studies had shown in in vivo model such as mouse that
the intestine was the initial site of infection for EV71 in-
fection with the muscle cells responsible for persistent
infection supporting efficient virus replication (Chen
et al. 2007; Chen et al. 2004; Khong et al. 2012). There-
fore we hypothesised that it is relevant to study EV71
using an in vitro model of a human gastrointestinal cell
type origin during the initial stages of infection.
In this study, we used a human colorectal adenocar-
cinoma cell line (HT29) with epithelioid morphology as
an in vitro model for the investigation of EV71 replica-
tion kinetics. To characterise the virus replication in
HT29 cells, the viral VP1 RNA and protein were moni-
tored using qPCR and western blot respectively. In
addition, the cell viability of HT29 to EV71 infection
was monitored throughout the time course of 72 hours
posts infection (hpi).
Results
This study aims to characterise the viral replication in
an in vitro model of HFMD for EV71 pathogenesis
study. To this end a human colorectal adenocarcinoma
cell line (HT29) with epithelioid morphology was
infected with EV71 over the time course of 72 h.
Cytopathic effects and cell viability of HT29 cells during
EV71 infection
There are no changes between control and infected cells
at 12 hpi, 24 hpi and 48 hpi (Figure 1). However at
72 hpi there was a statistically significant decrease of
approximately 60% of the infected cells (17.6%) as com-
pared to control (77.5%). There are no apparent change
in morphology between infected and control cells at
12 hpi and 24 hpi. However, at 48 hpi and 72 hpi, cells
were observed to lose its adherence and round up which
suggest cells are under stress conditions (Figure 1) with
cytopathic effect observed. At 72 hpi, in comparison
with the control and infected cells, there was a higher
number of floating cells in the media which correlate to
the decrease in live cells count (Figure 1).
Viral kinetics of EV71 replication
To further study EV71 replication kinetics in HT29 cells,
the viral RNA and protein synthesis was monitored over
72 h. Using established protocols, the kinetics of EV71
RNA synthesis in infected HT29 cells were examined
quantitatively using qPCR at various time points (12 hr,
24 hr, 48 hr and 72 hr) (Tan et al. 2008b). Control cells
show no viral RNA presents (Figure 2). There was an
expected exponential increase in viral RNA copy number
of the infected cells as measured by qPCR. Viral RNA
was first detected at 12 hpi. Approximately 5 million
virus copy number was detected at 12 hpi, which then
doubles at 24 hpi to approximately 10 million virus copy
number. Subsequently at 48 hpi, it increases 20 folds to
approximately 200 million virus copy number. Finally at
72 hpi, it increases 5 folds to 1000 million virus copy
number. The viral copy number quantitated had expo-
nential increase at every time points except 72 hpi where
there was only 5 folds increase in virus copy number
(Figure 2).
Viral kinetics of EV71 VP1 protein synthesis
In addition to the detection of viral RNA, the kinetics of
EV71 VP1 protein synthesis in infected HT29 cells was
monitored using western blot specific to EV71 (Figure 3).
Relative expression of EV71 VP1 protein of infected and
control cells were analysed using Image J and statistical
significant amount of virus protein were only detected at
48 hpi and 72 hpi.
Cellular receptor SCARB2 is present in both HT29 and RD
cells
Receptor binding is an essential and vital process during
virus infection of the cells (Patel and Bergelson 2009;
Yamayoshi et al. 2012). Cellular receptor plays an im-
portant role in the pathogenicity of viruses particularly
during the internalisation of virus during infection. As
such we quantified the relative expression of a functional
receptor, Scavenger receptor class B, member 2
(SCARB2) based on the formula: 2(Ct of gene−Ct of ACT).
Primers for SCARB2 and ACT were designed to span
exon-exon boundaries to give a single PCR product of
89 bp and 198 bp respectively (Figure 4). HT29 was
found to express SCARB2 at the expression level of ap-
proximately 20.2 as compared with RD cells of approxi-
mately 26.9. The presence of SCARB2 in HT29 further
supports HT29 cells as a viable in vitro model to study
EV71 pathogenesis.
Discussion
Viral replication kinetics plays an important role in the
understanding of virus pathogenesis (Baccam et al. 2006;
Chang et al. 2006; Major et al. 2004). The kinetics of
various viruses such as hepatitis C, Nipah virus and in-
fluenza virus have been reported in various studies and
have provided valuable information particularly in re-
sponse to antiviral therapeutics which aid in the under-
standing the host pathogen interaction (Baccam et al.
2006; Chang et al. 2006; Major et al. 2004). In compa-
rison, the only information reported for EV71 virus
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kinetics was by Lu et al. (2011) who demonstrated EV71
proliferation in rhabdomyosarcoma (RD) cells, of muscle
cells origin as an in vitro model (Lu et al. 2011). In a
clinical context, this may not be a good representative
model during EV71 infection of a human host. Various
studies have demonstrated in animal model that the
gastrointestinal tract such as the intestine was the first
site for EV71 proliferation (Chen et al. 2007; Chen et al.
2004; Khong et al. 2012). Furthermore, Khong et al.
(2012) reported that mice that were administrated with
EV71 via the intraperitoneal route exhibits 100% morta-
lity as compared to mice that were administrated with
EV71 via the oral route which shows 10-30% mortality
(Khong et al. 2012). Interestingly, the mortality result of
mice administrated with EV71 via the oral route (gastro-
intestinal tract) reported by Khong et al. (2012)
corresponded to the percentage of EV71 infected human
patient with central nervous system complications. This
Figure 1 Cell viability of HT29 cells following EV71 infection. Confluent HT29 cells were infected with or without EV71 (MOI of 1). (A) HT29
cell harvested at different time points and cell viability assessed using vital dye trypan blue. (n = 3, * = p values of < 0.05) (B) Micrograph of
confluent HT29 cell cultures were taken at a magnification of 20× at different time points for 72 h.
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suggests the relevant of studying EV71 in colorectal cell
line (oral route), HT29 as an in vitro model (Ooi et al.
2010; Ooi et al. 2009; Ooi et al. 2007).
In this study, we have demonstrated that upon EV71
infection in human epithelial colorectal cell line (HT29),
significant cell death only occurs at 72 hpi. This was var-
ies from the rhabdomyosarcoma (RD) cells previously
reported by Lu et al. (2011) where most cell death
occurs within 24 hpi. Similarly Chen et al. (2007) and
Khong et al. (2012) proposed that skeletal muscle cells
such as RD cells are more effective in supporting viral
replication which allow persistent enterovirus infection
to represent viral source of entry into the central ner-
vous system (CNS) (Chen et al. 2007; Khong et al. 2012).
In comparison with EV71 RNA synthesis, RNA was first
detected at 12 hpi. Viral protein synthesis was only ob-
served at a later stage during the infection possibly due
to translational time required. Lu et al. (2011) showed a
similar trend that virus RNA was first detected at 3 hpi
while virus protein was observed at 6 hpi. We reckon
Figure 3 Kinetics of EV71 VP1 protein synthesis in HT29 cells. Confluent HT29 cells were infected with or without EV71 (MOI of 1). Total
intracellular protein were harvested at various time points and measured by western blot captured using Quantity One software. (n = 3, * = p values
of < 0.05) The results were then analysed using Image J. As observed, it trends the results we observed by viral RNA amplification. (A) Intracellular viral
VP1 measured by Western blotting with Ponceau S staining control of membrane (B) Relative expression of viral VP1 protein.
Figure 2 Kinetics of EV71 replication in HT29 cells. Confluent
HT29 cells were infected with or without EV71 (MOI of 1). Total
intracellular RNA were harvested at various time points, converted to
cDNA and measured by quantitative real time polymerase chain reaction
(qRT-PCR) with primers specific to viral VP1. (n = 3, * = p values of < 0.05)
As observed, there was an increase in viral copy number through
increasingly time points.
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that such differences could be due to the fact that it
takes three times longer for the virus to kill HT29 cells
in comparison with RD cells Additional file 1: Table S1.
Receptor binding is an essential and vital process dur-
ing virus infection of the cells (Patel and Bergelson 2009;
Tan et al. 2013; Yamayoshi et al. 2012). Cellular recep-
tors therefore play an important role in the pathogen-
icity of viruses. Notwithstanding, viruses have been
found to utilise multiple receptors for the facilitation of
entry into susceptible cells (Patel and Bergelson 2009;
Hayes et al. 2006; Yamayoshi et al. 2009). Thus the iden-
tification and characterisation of cellular receptors plays
a critical role in the understanding of EV71 pathogen-
esis. Scavenger receptor class B, member 2 (SCARB2)
was first reported by Yamayoshi et al. (2009) to be a re-
ceptor for all EV71 strains and expressed in the sites of
EV71 replication in vivo (Hayes et al. 2006; Yamayoshi
et al. 2009). It is composed of 478 amino acids and
belongs to the CD36 family (Yamayoshi et al. 2012).
SCARB2 is commonly found in abundant in the lyso-
somal membrane of the cell and assist in the internalisa-
tion of EV71 into the host cell via clathrin mediated
endocytosis (Hussain et al. 2011; Lui et al. 2013;
Yamayoshi et al. 2012). The presence of SCARB2 in
HT29 further supports HT29 cells as a viable in vitro
model to study EV71 pathogenesis.
Considering that different cell types have varying cel-
lular content such as cytoskeleton and endoplasmic
reticulum network which would potentially plays a role
in virus replication, it is therefore the virus replication
kinetics may differs from cell types to cell types. Indeed,
Hussain et al. (2011) has demonstrated that the cytoskel-
etal system comprising of both actin and microtubules
were involved endocytic kinetics (Buss et al. 2001;
Durrbach et al. 1996; Flanagan and Lin 1980; Hussain
et al. 2011). The knockdown of genes involves in
cytoskeleton formation such as ARPC5, ARRB1, and
WASF1 and the use of drug disrupting the cytoskeleton
network such as cytochalasin B, have resulted in the de-
crease in EV71 replication kinetics (Hussain et al. 2011;
Lui et al. 2013).
Furthermore, the incubation period for HFMD is be-
tween three to seven days (Khong et al. 2012; Ooi et al.
2010; Ooi et al. 2009; Ooi et al. 2007). This may corres-
pond to the number of days the virus requires to pass
through the gastrointestinal tract before spreading it
throughout the body Khong et al. 2012; Ooi et al. 2010;
Ooi et al. 2009; Ooi et al. 2007). Therefore the in vitro
Figure 4 Expression SCARB2 in RD and HT29 cells. Total intracellular RNA were harvested from RD and HT29 cells, converted to cDNA and
measured by quantitative real time polymerase chain reaction (qRT-PCR) with primers specific to SCARB2 and ACT. Primers for SCARB2 and ACT
were designed to span exon-exon boundaries to give a single PCR product of 89 bp and 198 bp respectively. The presence of SCARB2 in HT29
further supports HT29 cells as a viable in vitro model to study EV71 pathogenesis.
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model of human epithelial colorectal cell line (HT29)
and EV71 may be more clinically relevant and mimics
the mechanism of pathogenesis of EV71 closer.
Conclusions
In conclusion, we have established the use of HT29 cells
as a clinically relevant in vitro model of EV71 repli-
cation. We have demonstrated for the first time an
increase of viral concentration in a time course of
72 hours upon infection with the use of cell viability,
qPCR and western blot. In addition, this is the first
report on the presence of SCARB2 on HT29 cells, an
essential receptor for all EV71 strains which established
HT29 cells as a viable in vitro model to study EV71
pathogenesis. Our study has provide valuable knowledge
toward the study of EV71 pathogenesis, virus-host inter-
action and this could lead to future investigation for the
development of antiviral therapeutics against EV71.
Therapeutic agents against EV71 could be developed by
potentially inhibit several key stages of the viral life cycle
such as viral attachment, translation, polyprotein pro-
cessing and RNA replication with the use of HT29 as an
in vitro model for EV71 replication (Chen et al. 2008).
Methods
Cell culture and virus propagation
Human colorectal cell line (HT29) (ATCCW catalog no.
HTB-38™) was maintained in Roswell Park Memorial In-
stitute medium (RPMI) (PAA Laboratories, Austria)
supplemented with 10% (v/v) Fetal Bovine Serum (FBS)
(PAA Laboratories, Austria) and 2% penicillin–strepto-
mycin (PAA Laboratories, Austria) at 37°C with 5% CO2.
The EV71 strain used in this study was isolated from a
fatal case of HFMD during October 2000 outbreak in
Singapore, Enterovirus 5865/sin/000009 strain (accession
number 316321; hereby designated as Strain 41) from
subgenogroup B4. The virus stock was prepared by
propagation of viruses using 90% confluent HT29 cells
monolayer in RPMI with 10% FBS and 2% penicillin–
streptomycin at 37°C with 5% CO2. The virus titres were
determined using 50% tissue culture infective dose
(TCID50) per millilitre (mL) according to Reed and
Muench method (Reed and Muench 1938).
Viral infection
HT29 cells were seeded at a concentration of 2 × 106 cells/ml
in 6-well plates and incubated for 24 h at 37°C with 5%
CO2. Cells were washed twice with phosphate buffered sa-
line (PBS) and infect with EV71 at multiplicity of infection
(MOI) of 1 or nil respectively. Following infection for 1 h,
the culture media were removed and replaced with 2 mL
of fresh RPMI medium. Micrograph was then taken using
phase contrast microscopy at different time points after
which the cells were trypsinised and harvested at 12 h,
24 h, 48 h and 72 h to isolate RNA and proteins for qPCR
reactions and western blots respectively.
Cell viability and counts
Cell count and viability was performed on the Luna™
Automated Cell Counter system (Logos Biosystem,
USA) in accordance to the manufacturer’s instructions.
Briefly, the cells were trypsinised at different time points
(12 h, 24 h, 48 h and 72 h). The trypsinised cells were
then topped up with fresh media to a total volume of
1000 μl of media and 10 μl of this cell suspension were
mixed with 10 μl of tryphan blue. 10 μl of this diluted
cell suspension were then loaded onto the Luna™
counting slide for analysis.
RNA isolation and cDNA synthesis
The total cellular RNA of HT29 cells were extracted
using the miRNeasy mini kit (Qiagen, Hilden, Germany)
in accordance to the manufacturer’s instructions. Briefly,
the cells were lysed and homogenise using lyses solution
provided (Qiagen, Hilden, Germany). Total RNA were
harvested using the RNeasy spin column and wash twice
before elution (Qiagen, Hilden, Germany). Harvested
total RNA was quantitated using Nanodrop 100 spectro-
photometer (Thermo Scientific, Waltham, USA) and
1 ng of the total RNA was then reverse transcripted
using the iScript™ cDNA Synthesis Kit (Bio-Rad Labora-
tories, CA, USA) in accordance to the manufacturer’s in-
structions. Briefly, 1 ng of the extracted RNA was mixed
with enzyme reverse transcriptase and buffer to a vol-
ume of 20 ul and subjected to thermal profile of 25°C
for 5 m, 42°C for 30 m followed by 85°C for 5 m in ac-
cordance to the manufacturer’s instructions.
Quantitative real time polymerase chain reaction
The EV71 specific primers targeting the conserve VP1
regions were 5′-GCTCTATAGGAGATAGTGTGAGTA
GGG-3′ and the reverse primer 5′-ATGACTGCTCAC
CTGCGTGTT-3′ (Tan et al. 2008a). Primers for
SCARB2 receptors were 5′- CCAATACGTCAGACAAT
GCC-3′ and the reverse primer 5′-ACCATTCTTGCA
GATGCTGA-3′ were designed to span exon-exon
boundaries. The primers for the house keeping gene
actin (ACT) used were 5′- ACCAACTGGGACGACAT
GGAGAAA-3′ and the reverse primer 5′-TAGCA
CAGCCTGGATAGCAACGTA-3′. The quantitative real
time polymerase chain reaction (qRT-PCR) was per-
formed using the iQ™ SYBRW Green Super mix (Bio-Rad
Laboratories, CA, USA) on the Bio-Rad CFX96™ Real-
Time PCR system (Bio-Rad Laboratories, CA, USA).
Briefly, 1 μl of cDNA and 1 μl of the forward and the re-
verse primers were added to iQ™ SYBRW Green Super
mix. The reaction mix was then subjected to thermal
profile of denaturation at 95°C for 10 m, followed by
Lui et al. SpringerPlus 2013, 2:267 Page 6 of 8
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amplification and quantification in 40 cycles at 95°C for
10 s, 60°C for 30 s followed by 50°C for 30 s. At the end of
amplification cycles, melting temperature analysis was
performed by the Bio-Rad CFX96™ Real-Time PCR system
(Bio-Rad Laboratories, CA, USA). Relative gene expression
was quantified based on the formula: 2(Ct of gene−Ct of ACT).
Western blot
Total cellular protein extraction for HT29 cells and con-
trol cells were performed using a lysis mix in mamma-
lian cell lysis solution – CelLytic M (Sigma-Aldrich Pte
Ltd, USA) in accordance with manufacturer’s instruc-
tions. Equal protein concentration (20 μg) from each
samples were added into SDS PAGE, 10% Mini-
PROTEANW TGX™ (Bio-Rad Laboratories, CA, USA)
and separated by electrophoresis. Separated proteins
were transferred onto polyvinylidene diflouride mem-
branes (Invitrogen, California, USA) using iBlotW
Western Detection kit (Invitrogen, California, USA) in
accordance to manufacturer instructions. Ponceau S
staining was performed to ensure equal level of protein
present in all lanes according to Romero-Calvo et al.
(2010) (Romero-Calvo et al. 2010). Briefly, membranes
were stained with Ponceau S (Sigma-Aldrich Pte Ltd,
USA) for 1 m and washed three times with water to
remove stain. Western blot was then performed
using Western BreezeW Chromogenic Kit–Anti-Mouse
(Invitrogen, California, USA) in accordance to manufac-
turer instructions. Briefly, the membranes were incu-
bated with mouse anti EV71 antibody (AbD serotech,
Oxford, UK) or anti Tubulin antibody (Santa Cruz
Biotechnology inc, California, USA) respectively in
shaker for an hour. The membranes were washed three
times before and incubating with secondary antibodies
(Invitrogen, California, USA) for 30 m. The membranes
were washed three times and incubated with chromogen
substrate till purple bands were developed in 1 h. The
membranes were left to air dry then placed into the
densitometer and scanned using the Quantity One soft-
ware (Bio-Rad Laboratories, CA, USA). The picture
was analysed using Image J (National Institutes of
Health, USA).
Statistical analysis
All statistical analysis was performed on Graph Pad
Prism Version 6.0c (Graph Pad Software, USA). Student
t test was used to compare two groups. p values of < 0.05
were considered statistically significant.
Additional file
Additional file 1: Table S1. Proposed timeline of EV71 replication
kinetics in HT29 cells.
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Hand, Foot and Mouth DiseaseEnterovirus 71 (EV71) is one of the main etiological agents for Hand, Foot and Mouth Disease
(HFMD) and has been shown to be associated with severe clinical manifestation. Currently, there
is no antiviral therapeutic for the treatment of HFMD patients owing to a lack of understanding
of EV71 pathogenesis. This study seeks to elucidate the transcriptomic changes that result from
EV71 infection. Human whole genome microarray was employed to monitor changes in genomic
profiles between infected and uninfected cells. The results reveal altered expression of human genes
involved in critical pathways including the immune response and the stress response. Together, data
from this study provide valuable insights into the host–pathogen interaction between human colo-
rectal cells and EV71.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Enterovirus 71 (EV71) is a positive sense, single stranded, non-
enveloped RNA virus belonging to Enterovirus genus of the Picor-
naviridae family [1–4]. It is one of the main etiological agents for
Hand, Foot and Mouth Disease (HFMD) which commonly affects
infants and children. This disease is usually self-limiting, charac-
terised by various symptoms such as fever, rashes, poor appetite
and multiple ulcers in mouth [5–7]. The route of transmission of
EV71 was postulated to happen via direct contact of vesicular fluid
or droplet from the infected or via faecal-oral route [5,8–10]. EV71
was shown to replicate within the gastrointestinal tract, bypass thegut barrier and infect into the skeletal muscle cell before entering
into the bloodstream and the central nervous system [5,8–10].
However, unlike other HFMD causing enteroviruses, EV71 have
been commonly associated with severe clinical diseases, including
neurological diseases leading to cardiopulmonary failure and
death.
EV71 was first described in 1974 in CA (USA) after it was iso-
lated from patients with central nervous system disease in 1969
[11]. Recent molecular evolution studies have predicted that
EV71 could have emerged in the human population as early as
1941 [12–14]. Large fatal outbreaks of HFMD first appeared in Bul-
garia in 1975, and disease outbreaks were subsequently identified
in Hungary in 1978 and re-emerged after two decades in Malaysia
in 1997 and Taiwan in 1998 [15–19]. Since then, there have been
various outbreaks, epidemics and pandemics that have periodically
been reported worldwide with outbreaks occurring every two to
three years in countries including Australia, China, Taiwan, Japan,
Korea, Malaysia, Vietnam, Thailand and Singapore [7,11,15,20].
Currently and due in part to a lack of understanding of viral
pathogenesis of EV71 causing HFMD, there are no effective antivi-
ral therapies or vaccines approved by the United States Food and
Table 1
Primers used in this study.
Primers 50–30
EV71-VP1-reverse GCTCTATAGGAGATAGTGTGAGTAGGG
EV71-VP1-forward ATGACTGCTCACCTGCGTGTT
IL29/IFN lambda1-forward ACCGTGGTGCTGGTGACTT
IL29/IFN lambda1-reverse CTAGCTCCTGTGGTGACAGA
IFN beta1-forward ATGACCAACAAGTGTCTCCTCC
IFN beta1-reverse GGAATCCAAGCAAGTTGTAGCTC
IFN gamma1-forward TCTTTGGGTCAGAGTTAAAGCCA
IFN gamma1-reverse TTCCATCTCGGCATACAGCAA
ISG54-forward AAGCACCTCAAAGGGCAAAAC
ISG54-reverse TCGGCCCATGTGATAGTAGAC
ISG56-forward TTGATGACGATGAAATGCCTGA
ISG56-reverse CAGGTCACCAGACTCCTCAC
b-Actin forward ACCAACTGGGACGACATGGAGAAA
b-Actin reverse TAGCACAGCCTGGATAGCAACGTA
Y.L.E. Lui et al. / FEBS Open Bio 4 (2014) 426–431 427Drug Administration (FDA) to prevent HFMD. There is therefore a
need to gain a better understanding of the mechanism of EV71
pathogenesis. The ability to cause infection directly correlates to
the interaction between the host and pathogen. In order to survive
and proliferate during infection, the pathogen must be able to
sense, react and adapt to the ever-changing microenvironment
within the host. Such adaptations and the use of the host resources
to proliferate are prerequisites for the successful colonisation of
the host and establish disease. Viruses, being obligate intracellular
parasites have developed highly sophisticated mechanisms not
only to exploit the biosynthetic machinery for replication, but also
to specifically evade the host immune system.
During infection, viruses regulate host gene expression to
enhance their survival. Such activities include altering the cellular
microenvironment to allow successful virus replication and evasion
of the host immune system [21–23]. Elucidating the mechanism
that the virus uses to bypass host defence systems and establish
infections will provide us with a better understanding of the path-
ogenesis mechanism of the EV71 virus and will thus aid in the
development of potential antiviral therapeutics for HFMD patients.
In this study, transcriptomics profiling was performed using colo-
rectal cells infected with EV71 using mRNA microarray.
2. Materials and methods
2.1. Cell culture and virus propagation
Human colorectal cell line (HT29) (ATCC Catalog No. HTB-
38™) was maintained in Roswell Park Memorial Institute medium
(RPMI) (PAA Laboratories, Austria) supplemented with 10% (v/v)
Fetal Bovine Serum (FBS) (PAA Laboratories, Austria) and 2%
penicillin–streptomycin (PAA Laboratories, Austria) at 37 C with
5% CO2. The EV71 strain used in this study was isolated from a fatal
case of HFMD during October 2000 outbreak in Singapore, Entero-
virus 5865/sin/000009 strain from subgenogroup B4 (accession
number 316321; hereby designated as Strain 41). The virus stock
was prepared by propagation of viruses using 90% confluent
HT29 cells monolayer in RPMI with 10% FBS at 37 C with 5%
CO2. The virus titres were determined using 50% tissue culture
infective dose (TCID50) per millilitre (mL) according to Reed and
Muench method [24].
2.2. EV71 infection for mRNA profiling
HT29 cells were seeded at a concentration of 5  105 cells/mL in
each well of a 6-well plate and incubated for 24 h at 37 C with 5%
CO2. Cells were washed twice with phosphate buffered saline (PBS)
and infected with EV71 at multiplicity of infection (MOI) of 1 or nil
respectively. The culture media were removed and replaced with
2 mL of fresh RPMI medium after 1 h of incubation at 37 C with
5% CO2. The respective infected cells were harvested at 36 h posts
infection (hpi). The total cellular RNA of HT29 cells were extracted
using the miRNeasy mini kit (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions. Briefly, the cells were lysed and
homogenise using lyses solution provided (Qiagen, Hilden, Ger-
many). Total RNA were purified using the RNeasy spin column
and eluted (Qiagen, Hilden, Germany). Harvested total RNA was
quantitated using Nanodrop 100 spectrophotometer (ThermoSci-
entific, Waltham, USA).
2.3. mRNA microarray analysis
Extracted total RNA were labelled with GeneChip HT 30 IVT
Express Kit following manufacturer’s instruction. Hybridization
to GeneChip PrimeView Human Gene Expression Array was
performed in accordance to manufacturer’s recommendations.Every chip was scanned at a high resolution by the Affymetrix
GeneChip Scanner 3000 according to the GeneChip Expression
Analysis Technical Manual procedures (Affymetrix, Santa Clara,
CA). Briefly, total extracted RNA undergo two rounds of cDNA syn-
thesis prior to in vitro transcription to synthesise biotin modified
amplified RNA (Affymetrix, Santa Clara, CA). The amplified RNA
was purified and fragment for the hybridisation onto the GeneChip
PrimeView Human Gene Expression Array (Affymetrix, Santa Clara,
CA). Raw data for the microarray were analysed with the Partek
Genomics Suite (Partek Incorporated, Saint Louis, USA) where
p < 0.05 is considered significant.
2.4. cDNA synthesis and quantitative real time polymerase chain
reaction
For the conversion of mRNA to cDNA, 1 lg of the total RNA was
reverse transcripted using using the iScript™ cDNA Synthesis Kit
(Bio-Rad Laboratories, CA, USA) in accordance to the manufac-
turer’s instructions. Briefly, 1 lg of the extracted RNA was mixed
with enzyme reverse transcriptase and buffer to a volume of
20 ll and subjected to thermal profile of 25 C for 5 min, 42 C
for 30 min followed by 85 C for 5 min in accordance to the manu-
facturer’s instructions.
The quantitative real time polymerase chain reaction (qPCR)
was performed using the iTaq™ Universal SYBR Green Supermix
(Bio-Rad Laboratories, CA, USA) on the BioRad CFX96™ Real-Time
PCR system (Bio-Rad Laboratories, CA, USA). The primers used in
this study are listed in Table 1. Briefly, 1 ll of cDNA and 1 ll of
the forward and the reverse primers were added to iTaq™ Univer-
sal SYBR Green Supermix. The reaction mix was then subjected to
thermal profile of denaturation at 95 C for 30 s, followed by ampli-
fication and quantification in 40 cycles at 95 C for 5 s followed by
60 C for 30 s. At the end of amplification cycles, melting tempera-
ture analysis was performed by the BioRad CFX96TM Real-Time
PCR system (Bio-Rad Laboratories, CA, USA). Relative gene expres-
sion was quantified based on 2DDCT method using the housekeep-
ing gene b-actin as the reference gene [25].
2.5. Data analysis
All statistical analysis was performed on GraphPad Prism Ver-
sion 6.0c (GraphPad Software, USA). Student’s t test was used to
compare two groups. p values of <0.05 were considered statisti-
cally significant.
3. Result and discussion
Systemic analyses of host response to EV71 provide critical clues
to understand the molecular mechanism of EV71 pathogenesis
428 Y.L.E. Lui et al. / FEBS Open Bio 4 (2014) 426–431during infection of a human host. Regulation and alteration of the
host cellular system can also bemonitored by studying the host cel-
lular transcriptomics change following enterovirus infection. Trans-
criptomics analysis via RNA-sequencing, mRNAmicroarray and PCR
array have been previously used to analyse host gene expression
[26–28]. However, these studies have been performed on rhabdo-
myosarcoma (RD) cells or SH-SY5Y cells, of muscle cells or neuronal
origin respectively. In a clinical context, this may not be a goodFig. 1. Heat map of the microarray mRNA expression profile of EV71 infected and non-
showed differential expressed mRNAs of two groups of samples. The mRNAs were chos
expression and red represent mRNAs with increased expression. (n = 3, ⁄p values of <0.0
Fig. 2. Pathway analysis of differentially expressed genes of EV71 infected and non-in
generated using Partek Genomics Suite (Partek Incorporated, Saint Louis, USA) (n = 3).representative model during EV71 infection of a human host as
various studies have demonstrated that the gastrointestinal tract
was the first site for EV71 proliferation [29–31]. Considering that
different cell types have varying cellular content, host–pathogen
interaction may differ from cell types to cell types [1,32,33]. We
have previously reported a human colorectal adenocarcinoma cell
line (HT29) with epithelioid morphology as a useful in vitro model
to study the pathogenesis of EV71 [33]. To this end, this studyinfected control colorectal cells, HT29. The two-way hierarchical cluster heat map
en according to the cut off p < 0.05 where blue represents mRNAs with decreased
5).
fected control colorectal cells, HT29. Pathways with enrichment score of <2 was
Y.L.E. Lui et al. / FEBS Open Bio 4 (2014) 426–431 429utilised HT29 as a model for the transcriptomics analysis of host
response to EV71 infection.
3.1. Identification of deregulated mRNAs during EV71 infection
To identify the differentially transcribed mRNAs in HT29 during
EV71 infection, we perform mRNAs profiling using GeneChip
PrimeView Human Gene Expression Array. Comparative mRNAs
expression between EV71 infected cells and control non-infected
cells were performed. Microarray hybridisation identified 699
genes being differentially expressed significantly during EV71Fig. 3. Expression level of types I, II and III IFN signalling pathways in response to
EV71 infection. Confluent HT29 cells were infected with or without EV71 (MOI of 1).
Total intracellular RNA were harvested 36 hpi, converted to cDNA and measured by
quantitative real time polymerase chain reaction (qPCR). (A) Expression of IL29/IFN-
k1; (B) expression of IFN-b1; (C) expression of IFN-c1 (n = 3, ⁄p values of <0.05).infection (p < 0.05) (Fig. 1 and Supplementary Table 1). Using
Partek Genomics Suite, 699 differentially transcribed genes
between EV71 infected and control non-infected HT29were further
analyses to generate pathways with enrichment score of <2 (Fig. 2).
These differentially transcribed genes were involved in critical
pathways including the immune response, the stress response,
metabolism, cytotoxicity, cytokines and the cytoskeleton network
(Fig. 2).
In response to viral infection, cells were known to induce an
immunological response to combat against invading pathogens.
In particular, immune response cytokines IL29/interferon (IFN)-
k1 and IFN-b1 were significantly up-regulated in EV71 infected
cells (Supplementary Table 1). The microarray results were vali-
dated using qPCR. In line with the microarray findings, qPCR
revealed that both IL29 and IFN-b1 were significantly up-regulated
by approximately 20 fold and 3 fold in EV71 infected cells respec-
tively (Fig. 3a and b). This is not surprising as that both IL29 and
IFN-b1 are cytokines which play important roles in host antiviral
response [34–36]. In addition, IL29 has been previously reported
to be up regulated during viral infection such as influenza A, hep-
atitis C virus and Sendai viruses [34–36]. A key characteristic of
cytokines is the ability to interact with one another to establish
coordinated defence mechanism against invading pathogens. IL29
functions by binding to a unique receptor through a pathway iden-
tical to IFN-b1 and IFN-c1 receptors inducing cellular antiviral
activity to inhibit virus replication [34–36]. Synergetic effect
between IL29, IFN-b1 and IFN-c1 were shown to promote cellularFig. 4. Expression level of interferon stimulated genes in response to EV71
infection. Confluent HT29 cells were infected with or without EV71 (MOI of 1).
Total intracellular RNA were harvested 36 hpi, converted to cDNA and measured by
quantitative real time polymerase chain reaction (qPCR). (A) Expression of ISG54;
(B) expression of ISG56 (n = 3, ⁄p values of <0.05).
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IFN-c1 as antiviral treatment has been shown to inhibit various
viruses including herpes simplex-1 virus, mouse hepatitis virus
type 2, human T-lymphotropic virus-1, cytomegalovirus and hepa-
titis C virus [37–43]. As such during EV71 infection, HT29 may up
regulate cytokines such as IL29, IFN-b1 and IFN-c1 (types I, II and
III IFN) to induce interferon stimulated genes (ISG) as part of
cellular antiviral response to slow down virus replication.
To further verify this reasoning, we performed qPCR on IFN-
gamma1 receptor, ISG54 and ISG56 to investigate if these genes
have been up regulated during EV71 infection. In agreement with
our hypothesis, our qPCR results show significant up regulation
of these cytokines in response to EV71 infection (Figs. 3c and 4a,
b). This support notion that the host colorectal cells up-regulate
cytokines such as IL29, IFN-b1 and IFN-c1 (types I, II and III IFN)Fig. 5. Schematic illustration of the interplay between types I, II and III IFN
pathways and invading viral pathogen-EV71. Following EV71 infection, host
activate types I, II and III IFN pathways through a series of JAK-STAT signalling
cascade to mobilise interferon stimulated genes such as ISG54 and ISG56 in attempt
to slow down virus replication.possibly by a series of JAK-STAT signalling pathways to induce
ISG such as ISG54 and ISG56 (Fig. 5). However, Lei et al. (2010,
2011, 2013) previously reported that EV71 3C protein suppressed
the host immune system, for example type I interferon, during
infection in RD cells (muscle cells) [44–46]. As such, the mecha-
nism whereby EV71 mediate host immune system may differ from
cell type to cell types. To support this hypothesis, Chi et al. (2013)
have compared the expression of IFN-signalling pathway between
intestinal epithelial cells and muscle cells, which demonstrates
that intestinal cells have indeed a significant higher expression of
cytokines response in comparison with muscle cells [47]. This
may explain the fact it takes three times longer for the virus to kill
HT29 cells in comparison with RD cells [32,33]. In addition, IFN sig-
nalling pathways such as type I interferon was previously demon-
strated to play an important role during EV71 pathogenesis [48].
Effectively, the intestinal epithelial immune system, being the
initial site of infection, plays a critical role in the disease progres-
sion and clinical prognosis. Impaired or immature immunity has
previously been associated with increased morbidity and mortality
in EV71 of young children and immune deficient adults [48].The
ability to eliminate viral pathogen such as EV71 at the initial site
of infection is critical as a weaker immune response results in a
higher viral titre leading to a systemic spread with more serve
complications [47]. One of the key antiviral responses that the
intestinal epithelial immune system utilises may be the types I, II
and III IFN to eliminate invading EV71 (Fig. 5).
4. Conclusion
In conclusion, this study utilised HT29 as an in vitro model to
investigate on the transcriptomic changes in human colorectal
cells in response to EV71 infection. Human whole genome micro-
array was employed to monitor changes in profiles between
EV71 infected cells and uninfected control cells. The result reveals
altered expression of human mRNAs in selected pathways includ-
ing the immune response, the stress response, metabolism, cyto-
toxicity, cytokines and the cytoskeleton network. Interestingly,
our results shows significant up regulation of types I, II and III
IFN which suggests that during EV71 infection, this may be the
key antiviral response HT29 cells undertake to eliminate invading
EV71. Taken together, data from this study provide valuable funda-
mental information toward understanding of host–pathogen inter-
action between human colorectal cells and invading EV71.
Elucidating the mechanism that the virus uses to bypass host
defence systems and establish infections will provide us with a
better understanding of the pathogenesis mechanism of the EV71
virus and will thus aid in the development of potential antiviral
therapeutics for HFMD patients.
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Abstract
Hand, Foot and Mouth Disease (HFMD) is a self-limiting viral disease that mainly affects infants and children. In contrast with
other HFMD causing enteroviruses, Enterovirus71 (EV71) has commonly been associated with severe clinical manifestation
leading to death. Currently, due to a lack in understanding of EV71 pathogenesis, there is no antiviral therapeutics for the
treatment of HFMD patients. Therefore the need to better understand the mechanism of EV71 pathogenesis is warranted.
We have previously reported a human colorectal adenocarcinoma cell line (HT29) based model to study the pathogenesis of
EV71. Using this system, we showed that knockdown of DGCR8, an essential cofactor for microRNAs biogenesis resulted in a
reduction of EV71 replication. We also demonstrated that there are miRNAs changes during EV71 pathogenesis and EV71
utilise host miRNAs to attenuate antiviral pathways during infection. Together, data from this study provide critical
information on the role of miRNAs during EV71 infection.
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Introduction
Hand, Foot and Mouth Disease (HFMD) is a contagious viral
disease that commonly affects infants and children, with blisters
and flu like symptoms [1–6]. HFMD is caused by a group of
enteroviruses such as enterovirus 71 (EV71) and coxsackievirus
A16 (CA16) [7–9]. However, unlike other HFMD causing
enteroviruses, EV71 is also commonly associated with severe
clinical diseases, including neurological diseases such as aseptic
meningitis, brainstem and cerebellar encephalitis leading to
cardiopulmonary failure and death [3,10–13]. Due in part to a
lack of understanding of viral pathogenesis of EV71 causing
HFMD, there are no antiviral therapies or vaccines approved by
the United States Food and Drug Administration (FDA) to prevent
HFMD infections. There is therefore a need to gain a better
understanding of the mechanism of EV71 pathogenesis. During
infection, viruses attenuate host gene expression to enhance their
survival [14–18]. Such activities include altering the cellular
microenvironment to allow successful virus replication and evasion
of the host immune system [19].
The host innate system is the first line of defence with the
interferon (IFNs) being a key component against viral infection
[17,18,20–25]. The release of IFNs begins with the recognition of
pathogen-associated molecular patterns (PAMPs) which include
Toll like receptors (TLRs), NOD like receptors (NLRs), retinoic
acid-inducible gene I (RIG-I) like receptors [24,26]. This family of
cytokines act in an autocrine and paracrine manner to induce
expression of transcription factors, gamma activated sequence and
IFN stimulated response element and the consequent induction of
IFN-stimulated genes (ISGs) which function to slow down viral
infection [20–22]. Antiviral pathways such as the programmed cell
death or apoptosis could also be activated by the host cells in
attempt to control the infection by limiting viral replication [19].
Many viruses have evolved to counteract with strategies by host
cells to establish infection. One of the mediators for such
regulation includes genes that encode for microRNA (miRNAs).
microRNAs are small single-stranded RNA species of approxi-
mately 20–24 bases in length that play a pivotal role in the post
transcriptional regulation of gene expression [27,28]. These small
RNA are first discovered in Caenorhabditis elegans but was later
discovered in a wide range of organisms from uni to multicellular
eukaryotes [29–31]. miRNAs are found to regulate many cellular
functions including cell proliferation, differentiation, homeostasis,
immune activation and apoptosis [28,29,32–34]. As such,
miRNAs can contribute to the repertoire of host-pathogen
interactions during infection by modulating and directing host
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and viral gene expression thereby playing a pivotal role during
infection. Elucidating the mechanism that the virus uses to bypass
host defence systems and establish infections will provide us with a
better understanding of the pathogenesis mechanism of the EV71
virus, allowing development of potent antiviral therapeutics for
HFMD patients.
In this study, we explore the role of miRNAs in the pathogenesis
of EV71 infected HT29 cells and identified key miRNA changes
due to EV71 infection which might play a key role during EV71
pathogenesis.
Results
We have previously reported a human colorectal adenocarci-
noma cell line (HT29) with epithelioid morphology as a useful
model to study the pathogenesis of EV71 [35]. Utilising the HT29
as a model, this study further elucidate the role of miRNAs during
EV71 infection.
Knockdown of DGCR8 resulted in the reduction of EV71
replication
In order to characterise the role of miRNAs during EV71
pathogenesis, DGCR8 was knocked down prior to infection.
HT29 cells were transfected with DsiRNA specific to DGCR8, an
essential cofactor for miRNAs biogenesis. As control, HT29 cells
were transfected with NC1, negative control duplex-scrambled
DsiRNA. Knockdown of DGCR8 was verified using qPCR
(Figure 1a). Transfection was shown to be successful using TYE
563 DS Transfection Control, fluorescent-labelled transfection
control duplex (Figure 1b).
miRNAs is essential for EV71 replication
To investigate the role of miRNAs in EV71 infection, we
compare EV71 replication in miRNAs depleted HT29 cells
against control cells (scrambled DsiRNA). Using established
protocols, the kinetics of EV71 RNA synthesis in both infected
DGCR8 knockdown cells and control cells were examined
quantitatively using real time quantitative polymerase chain
reaction (qPCR) at 36 h post infection (hpi). Interestingly, DGCR8
knockdown (miRNAs depleted) HT29 cells were unable to support
EV71 proliferation compared to control cells (Figure 2). There is a
significant decrease in viral RNA between DGCR8 knockdown
HT29 cell in contrast with control cells (scrambled DsiRNA)
(Figure 2a). Consistent with our qPCR analysis, protein analysis of
viral VP1 protein representation of EV71 replication, were shown
to be highly downregulated in EV71 infected DGCR8 knockdown
cells (Figure 2b). To further elucidate the effect of miRNAs during
EV71 infection, we asked if the host cells survivability was
enhanced in EV71 infected miRNAs depleted cells. Indeed, it was
observed that at 72 hpi, there was a statistically significant
percentage of living cells in EV71 infected DGCR8 knockdown
cells compared to control cells infected with EV71 (Figure 2c and
Figure S1). In order to validate our findings in HT29 cells, we
further test this on another colorectal cell line (RKO) and skeleton
muscle cell line (RD) where we knock down DGCR8 and examine
the effect on EV71 replication (Figure 3). Consistent with our
findings in HT29 model, EV71 is unable to establish infection in
miRNAs depleted cells (HT29, RKO and RD cells) (Figure 2 and
3).
Taken together, DGCR8 or rather miRNAs affects EV71
replication and recused its detrimental phenotype.
Identification of deregulated miRNAs during EV71
infection
To pinpoint on the differentially transcribed miRNAs used by
EV71 during infection, we perform miRNAs profiling using
Affymetrix GeneChip miRNA array. Specifically, comparative
miRNAs expression between EV71 infected cells and control non-
infected cells were performed. Microarray hybridisation identified
78 miRNAs being differentially expressed during EV71 infection
(p,0.05) (Figure 4 and Table S1). To confirm the microarray
results, relative abundance of the selected miRNAs were assayed
using qPCR. The expression pattern from 10 selected miRNAs
qPCR data showed similar direction of response in microarray
analysis data with both methodologies showing similar trends
(Figure 5 and 6). This indicates high quality and reliability of the
microarray data analysis.
EV71 down regulate host immune system using host
miRNAs during infection
To understand why miRNAs depleted cells resulted in the
inability of EV71 to established infection; we examine the
expression of 84 key genes involved in the innate antiviral immune
response between EV71 infected miRNAs depleted HT29 cells in
comparison with control cells (scrambled DsiRNA). In particular,
we examine the host antiviral expression profile between infected
DGCR8 knockdown cells against control cells. Using qPCR,
quantitative expression of 52 antiviral genes from various antiviral
signalling pathways such as Toll-like receptor signalling, Nod-like
receptor signalling, RIG-1-like receptor signalling and type 1
interferon signalling were statistically up regulated in DGCR8
knockdown cells (Figure 7a, 7b, 7c, 7d). Noteworthy, CASP1,
OAS2, DDX58, DHX58, CCL5, CXCL10, CXCL11, IRF7,
IFBB1, ISG15, MX1 and STAT1 have at least 10–550 fold
increase (Figure 7a, 7b, 7c, 7d).
Discussion
Viruses have developed highly sophisticated gene-silencing
mechanisms to evade host-immune response in order to establish
infection. One of such mediators used by viruses is miRNAs.
miRNAs is a new paradigm of RNA-directed gene expression
regulation which contribute to the repertoire of host-pathogen
interactions during viral infection. Cellular miRNAs could be
involved during viral infection with either positive or negative
effects on viral replication kinetics [36,37]. Indeed, computational
prediction reveal that one miRNAs may regulate hundreds of
genes while one gene may be in turn regulated by hundreds of
miRNAs [38]. However, the role of cellular miRNAs in the
defence against viral infection has thus remained elusive. Given
the scope of miRNA-mediated gene regulation in the mammalian
system, cellular miRNAs may directly or indirectly affect virus
pathogenesis. Cellular miRNA expression could be remodelled by
viral infection, which can alter the host cellular microenvironment
and attributing to both host antiviral defence and viral factors
[25,32,36,39,40].
The biogenesis of miRNAs begins with the transcription of a
long primary transcript known as pri-miRNA by RNA polymerase
II [27–29,32,39,41]. Pri-miRNAs are cleaved/processed by
Figure 1. Knockdown of DGCR8 using DsiRNA. (A) Relative expression of DGCR8 gene measured by qPCR verifying knockdown. (n = 3, **** = p
values of ,0.0001) (B) Transfection Control using fluorescent-labeled transfection control duplex TYE 563 DS to monitor transfection efficiency.
doi:10.1371/journal.pone.0102997.g001
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RNase III enzyme (Drosha), double-stranded-RNA-binding pro-
tein, (DiGeorge Syndrome Critical Region; DGCR8) and RNAse
III-like Dicer to become functional miRNAs. In this study, we
have demonstrated that abolishing functional miRNAs in human
epithelial colorectal cell line (HT29) impair EV71 replication while
this was not observed in control cells treated with scrambled
DsiRNA. On the contrary, global knockdown of miRNAs have
been previously shown to have enhance HIV-1 infection [42,43].
Knock down of DGCR8, a precursor to miRNAs biogensis were
shown to enhance human immunodeficiency virus (HIV) replica-
tion [42,43]. This implies that EV71 utilise miRNAs during
infection and in the absent of miRNAs, EV71 was unable to
successfully mount the infection.
Another study reported by Otsuka and colleagues showed a
similar finding in Vesicular stomatitis virus (VSV) infection [44].
Otsuka and colleagues observed that impaired miRNA production
in mice with dicer deficient mice resulted in the hypersensitivity
toward infection by VSV [44]. It was observed there is no
alternation of interferon-mediated antiviral response by dicer
deficiency instead the change in virus replication is due to miR-24
and miR-93 [44]. Otsuka and colleagues shown that miR-24 and
miR-93 could target VSV viral protein and thus in miRNA
depleted cells, VSV replication was enhanced in the absence of
miR-24 and miR-93 [44].
In recent years, there are reported evidences of specific host-
cellular miRNAs modulating host-pathogen interaction [44–51].
Cytomegalovirus (CMV) for example was observed to down
regulate miR-27a [45]. Overexpression of miR-27a using miRNAs
mimics was shown to inhibit CMV proliferation and virus titres
suggesting that miR-27a or miR-27a-regulated genes plays a role
during CMV infection [45,52]. Hepatitis C virus (HCV), an
enveloped RNA virus of the Flavivirus family, responsible for both
acute and chronic hepatitis in humans induced a liver-specific
cellular miRNA, miR-122 for the facilitation of HCV replication
[17,48,51,53–55]. It was suggested that miR-122 is a valuable
target for antiviral intervention and therapeutics. In vivo
treatment of HCV-infected chimpanzees with antisense miR-122
successfully reduced HCV virus titres demonstrating promising
antiviral treatment against virus induced diseases [48,49,53,54].
Indeed, various miRNAs have been identified to play a role
during EV71 pathogenesis. Recent publications of investigations
into the role of miRNA in enterovirus infection have reported that
enterovirus-induced miRNAs such as miR-23b, miR-296-5p,
miR-141 and miR-146a play a role in EV71 replication [8,56–
58]. The use of miRNA inhibitors or mimics have demonstrated
that miRNAs plays an important role in EV71 pathogenesis.
miRNA inhibitors or mimics on these miRNAs either inhibited or
enhanced EV71 replication during infection.
In particular, our results revealed miR-548 to be significantly up
regulated in EV71 infected cells at 36 hpi in comparison with
control non infected cells. Further bioinformatics analysis revealed
that miR-548 was involved in antiviral response during infection
[17,23,25,38,59]. Consistent with our findings, Li and colleagues
have recently identified the involvement of miR-548 in IFN
signalling pathways during viral infection [59]. Li and colleagues
demonstrated that miR-548 down-regulates host antiviral response
via direct targeting of IFN-l1 [59]. In contrast, in EV71 infected
rhabdomyosarcoma (RD) cells, miR-548 was observed to decrease
in a time dependent manner [59]. In view that the host innate
system is the first line of defence with IFNs being a key player
during viral infection, it is atypical that miR-548 was up regulated
to down regulate the host immune system [17,18,20–25]. The use
of miR-548 mimics and inhibitors were shown to enhance or
inhibit EV71 replication in RD cells respectively [59].
The innate immune system has evolved an arsenal of
mechanism to sense and destroy invading pathogen. An interesting
question that arises is whether EV71 is able to regulate host
cellular miRNA transcription and processing during infection
thereby leading to the down-regulation of deleterious cellular
miRNA and/or the up-regulation of advantageous cellular
miRNAs to enhance its replication in the host cells. To add to
this intriguing interplay between cellular miRNAs and viral
pathogens, Huang and colleagues has demonstrated that HIV, an
enveloped RNA virus of the Retreoviridae family utilise host
cellular miR-28, miR-125b, miR-150, miR-223 and miR-382 to
control viral protein synthesis in order to evade host immune
system [47]. Epstein-Barr virus (EBV), a DNA virus of the Herpes
family, for example induce the expression of miR-29b, miR-155
and miR-146a to mediate the down regulation of innate immune
response and IFN signalling pathways to enhances its survival
[46,60,61]. Lecellier and colleagues have shown that in primate
foamy virus type 1 (PFV-1), overexpression of cellular miRNA
miR-32 could induce an antiviral response to inhibit virus
replication [37].
To test this reasoning that EV71 down regulate host miRNAs
during infection to enhance its survival, we next ask if the innate
response and signalling pathways were altered in EV71 infected
miRNA-depleted cells. Therefore, we analysed the expression of
84 key genes involved in the innate antiviral immune response
between EV71 infected miRNAs depleted HT29 cells in
comparison with control cells (scrambled DsiRNA). Quantitative
analysis\revealed 52 antiviral genes from various antiviral
signalling pathways such as Toll-like receptor signalling, Nod-like
receptor signalling, RIG-1-like receptor signalling and type 1
interferon signalling were significantly up regulated in EV71
infected miRNAs depleted HT29 cells. In particular, CASP1,
OAS2, DDX58, DHX58, CCL5, CXCL10, CXCL11, IRF7,
IFBB1, ISG15, MX1 and STAT1 have at least 10–550 fold
increase. The enhanced host antiviral response in miRNA-
depleted cells during EV71 infection may result in the inability
for EV71 to replicate during infection (Figure 8).
The host immune response is responsible for the eradication of
invading pathogens, as such viruses has developed means to
counteract with the induction, signalling and antiviral pathways
[16,20,21,25,40]. RNA viruses generally block and inhibit IFN
and antiviral molecules detrimental to virus replication [20,24].
Despite all the sophisticated mechanism used by viruses to inhibit
host immune system, host has been under evolutionary pressure
against viral antagonism of IFN system [20,21,24,40]. Our result
suggests that EV71 attenuate host miRNAs to mediate host
immune system during infection (Figure 8). As a result of DGCR8
knockdown, EV71 is unable to regulate host miRNAs to enhance
cellular microenvironment leading to the inability to establish
infection (Figure 8). Notwithstanding, IFN signalling pathways
Figure 2. miRNA depleted HT29 cells is not able to support EV71 replication. DGCR8 knockdown HT29 cells and control HT29 cells
(scrambled DsiRNA) were infected with EV71 (MOI of 1). Total intracellular RNA were harvested at 36 hpi, converted to cDNA and measured by qPCR
with primers specific to viral VP1. Total intracellular protein were harvested at at 36 hpi and measured by western blot (A) Relative expression of EV71
viral RNA measured by qPCR. (n = 3, **** = p values of,0.0001) (B) Western blot analysis for EV71 VP1 viral protein. (C) Cell viability assessed at 72 hpi
using vital dye trypan blue. (n = 3, ** = p values of ,0.01).
doi:10.1371/journal.pone.0102997.g002
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such as type I interferon was previously demonstrated to play an
important role during EV71 pathogenesis [62,63]. These results
warrant further studies for the identification of specific miRNAs
which play a pivotal role during EV71 pathogenesis specifically
targeting the host antiviral signalling pathway.
Conclusion
In conclusion, we provided evidence for an intricate physiolog-
ical interplay between host miRNAs machinery and invading
pathogen, EV71. We reported three salient findings. First,
DGCR8, an essential cofactor for microRNAs biogenesis contrib-
ute to a central role during EV71 pathogenesis. We have shown
that EV71 is not able to replicate efficiently in miRNAs depleted
cells. Secondly, our results suggest that EV71 may remodel the
cellular miRNAs composition thereby utilising the host cellular
miRNAs to enhance cellular microenvironment for viral replica-
tion. Specifically, our result suggests that EV71 may be at least
partially responsible for the up regulation of host miR-548 to
enhance cellular microenvironment for viral replication. Thirdly,
remodelling of miRNAs during EV71 infection plays a significant
role specifically in antiviral response. We have demonstrated that
in EV71 infected miRNAs depleted cells, host antiviral responses
from various antiviral signalling pathways such as Toll-like
receptor signalling, Nod-like receptor signalling, RIG-1-like
receptor signalling and type 1 interferon signalling were signif-
icantly higher in comparison with EV71 infected control cells.
This may explain our result on the inability for EV71 to infect
miRNAs depleted cells given the enhanced host antiviral response.
Taken together, our study has provide valuable knowledge toward
the study of host-pathogen interaction during EV71 pathogenesis
and this could lead to future investigation for the development of
Figure 3. EV71 is unable to establish infection in both RKO and RD miRNAs depleted cells. DGCR8 knockdown cells and control cells
(scrambled DsiRNA) in both RKO and RD cell line were infected with EV71 (MOI of 1). Total intracellular RNA were harvested at 12 hpi, converted to
cDNA and measured by qPCR with primers specific to viral VP1. (A) Relative expression of DGCR8 gene in miRNAs depleted RKO cells measured by
qPCR verifying knockdown. (n = 3, * = p values of ,0.05) (B) Relative expression of DGCR8 gene in miRNAs depleted RD cells measured by qPCR
verifying knockdown. (n = 3, * = p values of ,0.05) (C) Relative expression of EV71 viral RNA in miRNAs depleted RKO cells measured by qPCR. (n = 3,
* = p values of ,0.05) (D) Relative expression of EV71 viral RNA in miRNAs depleted RKO cells measured by qPCR. (n = 3, * = p values of ,0.05).
doi:10.1371/journal.pone.0102997.g003
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antiviral therapeutics using miRNAs inhibitors against EV71. This
will open the door toward novel host-defence mechanism that
exists in mammalian cells as well as to the antiviral mechanisms
employed during EV71 pathogenesis.
Materials and Methods
Cell culture and virus propagation
The EV71 strain used in this study was isolated from a fatal case
of HFMD during October 2000 outbreak in Singapore, Entero-
virus 5865/sin/000009 strain from subgenogroup B4 (accession
number 316321; hereby designated as Strain 41) (a gift from Mrs
Phoon Meng Chee, Department of Microbiology, National
University of Singapore). Human colorectal cell line (HT29)
(ATCC catalog no. HTB-38) was maintained in Roswell Park
Memorial Institute medium (RPMI) (PAA Laboratories, Austria)
supplemented with 10% (v/v) Fetal Bovine Serum (FBS) (PAA
Laboratories, Austria) and 2% penicillin–streptomycin (PAA
Laboratories, Austria) at 37uC with 5% CO2. Human skeleton
muscle cell line (RD) (ATCC catalog no. CCL-136) and Human
colorectal cell line (RKO) (ATCC catalog no. CRL-2577) were
maintained in Eagle’s minimum essential medium (EMEM) (PAA
Laboratories, Austria) supplemented with 10% (v/v) Fetal Bovine
Serum (FBS) (PAA Laboratories, Austria) and 2% penicillin–
streptomycin (PAA Laboratories, Austria) at 37uC with 5% CO2.
The virus stock was prepared by propagation of viruses using 90%
confluent HT29 cells monolayer in RPMI with 10% FBS at 37uC
with 5% CO2. The virus titres were determined using 50% tissue
culture infective dose (TCID50) per millilitre (mL) according to
Reed and Muench method [64].
DsiRNA transfection and EV71 infection
HT29, RD and RKO cells were seeded at a concentration of
26105 cells/ml in 6-well plates and incubated for 8 h at 37uC with
5% CO2. Cells were washed twice with phosphate buffered saline
(PBS) and transfected using Lipofectamine RNAiMAX (Invitrogen
Corporation, CA, USA) with TriFECTa Dicer-Substrate RNAi
KIT (Integrated DNA Technology, Coralville, IA, USA). Briefly,
10 nM of DGCR8 DsiRNA (NM_001190326 duplex 2), NC1,
negative control duplex-scrambled DsiRNA (NM_001190326)
and TYE 563 DS Transfection Control, fluorescent-labeled
transfection control duplex (NM_001190326) were used to
transfect the cells respectively (Integrated DNA Technology,
Coralville, IA, USA). Following 24 h after transfection, cells were
washed twice with PBS and infected with EV71 at multiplicity of
infection (MOI) of 1. The culture media were removed and
replaced with 2 mL of fresh RPMI medium after 1 h of incubation
at 37uC with 5% CO2.
EV71 infection for miRNA profiling
HT29 cells were seeded at a concentration of 56105 cells/ml in
6-well plates and incubated for 24 h at 37uC with 5% CO2. Cells
were washed twice with phosphate buffered saline (PBS) and
infected with EV71 at multiplicity of infection (MOI) of 1 or nil
respectively. The culture media were removed and replaced with
2 mL of fresh RPMI medium after 1 h of incubation at 37uC with
5% CO2.
Total cellular RNA extraction
The respective infected cells were harvest at 12 or 36 hours
posts infection (hpi) respectively. The total cellular RNA of HT29,
Figure 4. Heat map of the microarray miRNA expression profile of EV71 infected and non-infected control colorectal cells, HT29.
The two-way hierarchical cluster heat map showed differential expressed miRNAs of two groups of samples. The miRNAs were chosen according to
the cut off p,0.05 where blue represents miRNAs with decreased expression and red represent miRNAs with increased expression. (n = 3, * = p values
of ,0.05).
doi:10.1371/journal.pone.0102997.g004
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RD and RKO cells were extracted using the miRNeasy mini kit
(Qiagen, Hilden, Germany) in accordance to the manufacturer’s
instructions. Briefly, the cells were lysed and homogenise using
lyses solution provided (Qiagen, Hilden, Germany). Total RNA
were harvested using the RNeasy spin column and wash twice
before elution (Qiagen, Hilden, Germany). Harvested total RNA
was quantitated using Nanodrop 100 spectrophotometer (Ther-
moScientific, Waltham, USA).
miRNA microarray analysis
The extracted total RNA was labelled with FlashTag Biotin
HSR RNA Labeling Kits for the Affymetrix GeneChip miRNA
array according to manufacturer’s instruction. Briefly, one
microgram of total RNA will be incubated with ATP and Poly
A polymerase at 37uC for 15 m to add a 39 polyA tail. A ligation
reaction will then be performed to covalently attach to the miRNA
population a multiple-biotin molecule containing a 3DNA
dendrimer. Labelled samples will subsequently be processed
according to manufacturer’s instructions for the Affymetrix
miRNA Array 2.0 (Affymetrix, Santa Clara, CA). After hybrid-
isation for 16 h at 48uC, the arrays will be washed and stained in
an Affymetrix Fluidics station 450, then scanned in an Affymetrix
Figure 5. Validation of differential expression of selected miRNAs by qPCR. Ten expression levels of selected miRNAs from microarray assay
were validated using qPCR. U6snRNA was used as reference RNA for the normalization of miRNAs and relative gene expression was quantified based
on 22DDCT. (n = 3, * = p values of ,0.05).
doi:10.1371/journal.pone.0102997.g005
Figure 6. Heat map of differential expression of selected
miRNAs by microarray. The two-way hierarchical cluster heat map
showed differential expressed selected miRNAs of two groups of
samples. The miRNAs from both methodology qPCR data showed
similar direction of response in microarray analysis data with both
methodologies showing similar trends where blue represents miRNAs
with decreased expression and red represent miRNAs with increased
expression.
doi:10.1371/journal.pone.0102997.g006
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3000 7G scanner. Raw data for the microarray (GSE57372) was
analysed with Partek Genomics Suite (Partek Incorporated, Saint
Louis, USA) where p,0.05 is considered significant.
cDNA synthesis
For the conversion of mRNA to cDNA, 1 mg of the total RNA
was reverse transcripted using RT2 First Strand kit (Qiagen,
Hilden, Germany) in accordance to the manufacturer’s instruc-
tions. Briefly, 1 mg of the extracted RNA was first mixed with
Buffer GE to a total volume of 10 ml for genomic DNA elimination
and incubated at 42uC for 5 m and on ice for 1 m. Reverse-
transcription mix which consist of enzyme reverse transcriptase
and buffer was then added to a volume of 20 ml and subjected to
thermal profile of 42uC for 15 m followed by 95uC for 5 m. 91 ml
of RNase free water was then added to each reaction in
accordance to the manufacturer’s instructions.
For conversion of microRNA to cDNA, 10 ng of the total RNA
was reverse transcripted using the Universal cDNA Synthesis kit
(Exiqon, Denmark) the manufacturer’s instructions. Briefly, 10 ng
of the extracted RNA will be mixed with enzyme reverse
transcriptase and buffer to a volume of 10 ml. The reaction mix
will then subject to thermal profile of 25uC for 5 m, 42uC for 30 m
followed by 85uC for 5 m according to the manufacturer’s
instructions.
Quantitative real time polymerase chain reaction
The EV71 specific primers targeting the conserve VP1 regions
were 59-GCTCTATAGGAGATAGTGTGAGTAGGG-39 and
the reverse primer 59-ATGACTGCTCACCTGCGTGTT-39
[65]. Primers for DGCR8 were 59-ACTTGTGCATGT-
TAGCTGTGTAGA-39 and the reverse primer 59-GCTTAA-
GACTAGTTTACAAGACCAGAGT-39 were designed to span
exon-exon boundaries. The primers for the house keeping gene
actin (b-ACT) used were 59-ACCAACTGGGACGACATGGA-
GAAA-39 and the reverse primer 59-TAGCACAGCCTGGA-
TAGCAACGTA-39. The qPCR was performed using the iTaq
Universal SYBR Green Supermix (Bio-Rad Laboratories, CA,
USA) on the BioRad CFX96 Real-Time PCR system (Bio-Rad
Laboratories, CA, USA). Briefly, 1 ml of cDNA and 1 ml of the
forward and the reverse primers were added iTaq Universal
SYBR Green Supermix. The reaction mix was then subjected to
thermal profile of denaturation at 95uC for 30 s, followed by
amplification and quantification in 40 cycles at 95uC for 5 s
followed by 60uC for 30 s. At the end of amplification cycles,
melting temperature analysis was performed by the BioRad
Figure 7. EV71 is unable to down regulate host antiviral response in miRNA depleted cells during infection. DGCR8 knockdown cells
and control cells (scrambled DsiRNA) were infected with EV71 (MOI of 1). Total intracellular RNA were harvested at 36 hpi, converted to cDNA and
measured by quantitative real time polymerase chain reaction (qPCR) (n = 3, * = p values of ,0.05). A) Relative expression of Toll-like receptor
signalling measured by qPCR. (B) Relative expression of RIG-1 like receptor signalling measured by qPCR. (C) Relative expression of Nod-like receptor
signalling measured by qPCR. (D) Relative expression of Type 1 interferon signalling measured by qPCR.
doi:10.1371/journal.pone.0102997.g007
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CFX96 Real-Time PCR system (Bio-Rad Laboratories, CA,
USA). Relative gene expression was quantified based on 22DDCT
method [66].
For RT2 profiler PCR array, PCR arrays were performed with
customized PCR containing pre-dispensed primers to monitor
Human antiviral response PAHS-122ZD-2 (Qiagen, Hilden,
Germany). qPCR was performed using RT2 SYBR Green qPCR
mastermix (Qiagen, Hilden, Germany). Briefly, a total volume of
25 ml of cDNA and RT2 SYBR Green qPCR mastermix were
added into each well of the Human antiviral response array 96
wells plate PAHS-122ZD-2 (Qiagen, Hilden, Germany) in
accordance to the manufacturer’s instructions. The reaction mix
was then subjected to thermal profile of denaturation at 95uC for
10 m, followed by amplification and quantification in 40 cycles at
95uC for 15 s followed by 60uC for 1 m. At the end of
amplification cycles, melting temperature analysis was performed
by the BioRad CFX96 Real-Time PCR system (Bio-Rad
Laboratories, CA, USA).
For the detection of microRNA, qPCR was performed using the
ExiLENT SYBR Green Master mix (Exiqon, Denmark) on the
BioRad CFX96 Real-Time PCR system (Bio-Rad Laboratories,
CA, USA). Briefly, 2.5 ml of cDNA and 1 ml of the forward and the
reverse primers was added to ExiLENT SYBR Green Master mix
(Exiqon, Denmark) according to the manufacturer’s instructions.
The reaction mix will then subjected to thermal profile of
denaturation at 95uC for 10 m, followed by amplification and
quantification in 40 cycles at 95uC for 10 s, 60uC for 30 s followed
by 50uC for 30 s. At the end of amplification cycles, melting
temperature analysis will be performed by the BioRad CFX96
Real-Time PCR system (Bio-Rad Laboratories, CA, USA).
Primers for microRNA qPCR were designed and purchased from
Exiqon, Denmark. U6snRNA was used as reference RNA for the
normalization of microRNA (miRNA) qPCR data. Relative gene
expression was quantified based on 22DDCT method [66].
Western blot
Total cellular protein for HT29 cells and control cells were
collected using a lysis mix in mammalian cell lysis solution–
CelLytic M (Sigma-Aldrich Pte Ltd, USA) in accordance with
manufacturer’s instructions. Equal protein concentration (20 mg)
from each samples were added onto 10% Mini-PROTEAN TGX
(Bio-Rad Laboratories, CA, USA) and separated by electropho-
resis. Separated proteins were transferred onto nitrocellulose
membrane (Bio-Rad Laboratories, CA, USA). The membranes
were incubated with mouse anti EV71 antibody (AbD serotech,
Oxford, UK) or anti tubulin antibody (Santa Cruz Biotechnology
inc, California, USA) respectively in shaker 4uC overnight. The
membranes were washed three times in Tris-buffered saline with
0.05% tween-20 before and incubating with secondary antibodies
conjugated to horseradish peroxidase (HRP) for 30 m. (Thermo-
Scientific, Waltham, USA). After three wash with Tris-buffered
saline and 0.05% tween-20, membrane was subjected to Clarity
Western ECL Substrate (Bio-Rad Laboratories, CA, USA) in
accordance with manufacturer’s instructions. The membranes
Figure 8. Schematic illustration of the interplay between EV71 and host miRNAs. EV71 altered host miRNAs such as has-miR-548 to
manipulate host antiviral responses such as Toll-like signalling, NOD-like signalling, RIG-1 signalling and Type I interferon pathways to enhance its
survival during pathogenesis.
doi:10.1371/journal.pone.0102997.g008
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were then scanned using the LI-COR C-DiGit Blot Scanner (LI-
COR Biosciences, Lincoln, Nebraska, USA).
Cell viability and counts
Cell count and viability was performed at 0 h, 48 h and 72 h on
the Luna Automated Cell Counter system (Logos Biosystem, USA)
in accordance to the manufacturer’s instructions. Briefly, the cells
were trypsinised and topped up with fresh media to a total volume
of 1000 ml of media and 10 ml of this cell suspension were mixed
with 10 ml of tryphan blue. 10 ml of this diluted cell suspension
were then loaded onto the Luna counting slide for analysis.
Statistical analysis
All statistical analysis was performed on GraphPad Prism
Version 6.0c (GraphPad Software, USA). Student t test was used
to compare two groups. p values of ,0.05 were considered
statistically significant.
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Figure S1 Cell viability assessed 24 h after transfection
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